Compositions and methods for t-cell mediated depletion of cells expressing interleukin-5 receptor
T-cell engaging proteins (TEPs) targeting IL5R-ECs through pMHCs and TCs trigger the immune system to eliminate IL5R-expressing cells, addressing the inadequacies of current therapies and effectively treating eosinophil-related disorders and cancers by reducing eosinophil proliferation and inflammation.
Patent Information
- Application Number
- PCT/US2026/028215
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-15
- Filing Date
- 2026-05-14
- Publication Date
- 2026-11-19
AI Technical Summary
Current therapeutic approaches are inadequate for effectively targeting and depleting IL5R-expressing cells (IL5R-ECs) associated with eosinophil proliferation and inflammation in disorders such as asthma and hematologic malignancies, as well as lymphoid cancers, due to the complexity of IL5R signaling pathways and the need for selective and controlled T-cell activation.
Development of T-cell engaging proteins (TEPs) that bind to IL5R and mediate a T-cell response, utilizing peptide-major histocompatibility complexes (pMHCs), immunoglobulin Fc polypeptides, and targeting components (TCs) to present viral or bacterial antigens, triggering the patient's immune system to eliminate IL5R-ECs, optionally with activating immunomodulatory polypeptides.
The TEPs achieve selective and controlled depletion of IL5R-ECs, reducing eosinophil proliferation and inflammation, while minimizing inflammatory responses, providing off-the-shelf solutions for treating IL5R-associated disorders like asthma, atopic dermatitis, and various cancers.
Smart Images

Figure IMGF000044_0001_TABLE 
Figure IMGF000046_0001_TABLE 
Figure IMGF000047_0001_TABLE
Abstract
Description
COMPOSITIONS AND METHODS FOR T-CELL MEDIATED DEPLETION OF CELLS EXPRESSING INTERLEUKIN-5 RECEPTORCROSS-REFERENCE
[0001] This application claims the benefit of U.S. Provisional Patent Application No. 63 / 806,385 filed May 15, 2025, which application is incorporated herein by reference in its entirety.INCORPORATION BY REFERENCE OF SEQUENCE LISTING PROVIDED AS AN XML FILE
[0002] A Sequence Listing is provided herewith as a Sequence Listing XML, “CUEB-163WO_SeqList.xmf’ created on May 11, 2026 and having a size of 418.766 bytes. The contents of the Sequence Listing XML are incorporated by reference herein in their entirety.INTRODUCTION
[0003] Interleukin-5 (IL-5) is a glycosylated protein cytokine produced predominantly by CD4+ T lymphocytes, and is involved in eosinophilic proliferation and inflammation. In the human body, growth and differentiation of eosinophils takes place primarily through the interaction between IL-5 and its receptor at the cell surface. Tire IL-5 receptor comprises two subunits, IL5Ra and IL5Rp. IL5R is predominantly expressed on eosinophils and basophils, as well as mast cell progenitors (MCPs), and is important in eosinophilic survival, differentiation and activation. It also is found in bone marrow and ly mphoid tissue, in the lungs and airways, and in the gastrointestinal tract. IL5R also is known as CD125, CD125 antigen, CDwl25 and HSIL5R3.
[0004] IL5R binds IL-5 initially with low affinity, but subsequent binding of the P subunit the IL-5 receptor binds with high affinity and can initiate signal transduction, leading to the increase of eosinophils in blood and tissues. In particular, the proline-rich cytoplasmic domain of the IL5R subunit plays a critical role in the proliferative response following IL-5 binding.
[0005] In addition to their involvement in the eosinophilic proliferation and inflammation observed in diseases such as asthma, atopic demiatitis, eosinophilic esophagitis and hypereosinophilic syndrome, IL5R-expressing cells ( TL5R-ECs ) also play a role in the progression of hematologic and lymphoid malignancies such as acute eosinophilic leukemia, and B- and T-cell cancers, which may exhibit a prominent eosinophilic inflammatory response. The IL5R-JAK1 / JAK2 signaling pathway results in the activation of STAT5 and other STAT proteins, which lead to cell proliferation, survival and immune evasion. Other downstream signaling includes the PI3K / AKT and MAPK pathways, which are also involved in cell survival, metabolic activity and anti-apoptotic signals. In addition, other cytokines andgrowth factors such as IL-3 and GM-CSF may work synergistically with IL-5. Once activated, eosinophils can secrete additional molecules that enhance their proliferation and the recruitment of other immune cells, creating a sustained inflammatory loop.
[0006] IL5R is thus a promising therapeutic target for a wide range of IL5R-associated disorders, including those in which eosinophil proliferation is a contributing factor. Thus, new therapeutic approaches are needed for the treatment of IL5R-associated disorders.SUMMARY
[0007] The present disclosure provides T-cell engaging proteins (“TEPs”) that can bind to IL5R and / or IL5RP and mediate a T-cell response that results in a reduction or substantial elimination of IL5R-ECs.
[0008] In certain embodiments, the TEP comprises:i) a peptide-major histocompatibility complex f‘pMHC”) comprising a peptide epitope, a P2-microglobulin (“P2M”) polypeptide, and an MHC class I heavy chain polypeptide;ii) a scaffold component such as an immunoglobulin (“Ig”) Fc polypeptide;iii) at least one targeting component (“TC”) that targets IL5R, e.g., an antibody or antibody fragment (e g. scFv) or other peptide or protein that specifically binds to IL5R (e.g., binds to IL5R; and / or IL5RP); andiv) optionally one or more activating immunomodulatory polypeptides (“MODs”).
[0009] In a manner similar to an antigen-presenting cell (APC), the pMHC of a TEP that is bound to IL5R can present an epitope that is recognized by a T-cell receptor (TCR) of a T-cell in a patient's T-cell repertoire. Because most humans have been exposed to known viral and bacterial pathogens such as cytomegalovirus (CMV), Epstein-Barr virus (EBV), influenza (flu), tetanus, and SARS-CoV-2 (SCV2), or have been vaccinated against viral and bacterial pathogens, most humans already possess a repertoire of T-cells specific for such antigens. Hence, in some embodiments, a TEP that is bound to IL5R and presents an epitope for such a known viral or bacterial antigen will make the IL5R-EC appear to the patient’s immune system as a virus- or bacteria-infected cell. The patient’s existing T-cells will thus bind to the pMHC of the TEP and release their cytotoxic components, resulting in elimination of the IL5R-EC. In this way, the patient’s own immune system accomplishes depletion of the patient’s IL5R-ECs. As discussed herein, pMHCs that present other epitopes to T-cells may be employed in TEPs.
[0010] In some embodiments, the TEP is a dual-targeting TEP that comprises two different TCs, e.g., two different anti-IL5R antibodies or antibody fragments. In some cases, the TCs will be able to separately bind to IL5R and the TEP will be able to bind to both target IL5R epitopes simultaneously. In some embodiments, the TEP is a dual-targeting TEP that comprises two different TCs, e.g.. a TC thattargets IL5R (e.g., an anti-IL5R antibody or antibody fragment) and a TC that binds to a target other than IL5R.
[0011] In some embodiments, the TEP comprises two different pMHCs, e.g., pMHCs that present epitopes to two different viral antigens. In this way, the TEPs can mediate depletion though the action of different anti-viral T-cells in a patient’s T-cell repertoire. Further, in some embodiments, a patient is first immunized with a vaccine that causes the production of T-cells specific for the pMHC of the TEP, thereby increasing the repertoire of T-cells that can bind the TEPs and eliminate the IL5R-ECs. Such vaccines can be, e.g., an influenza (flu) vaccine, CMV vaccine, tetanus vaccine, SARS-CoV-2 vaccine, EBV vaccine, Yellow Fever vaccine, a vaccine of peptides, or other vaccine to a pathogen such as a virus or bacteria, or to any other antigen, e.g.. a cancer antigen. In some embodiment embodiments, the TEP comprises an optional activating MOD. In some embodiment embodiments, the TEP does not comprise an optional activating MOD, i.e., the TEP is “MOD-less.”
[0012] This disclosure thus provides off-the-shelf products that can be used for treating IL5R-associated disorders. Such disorders include eosinophil proliferation and subsequent inflammation in disorders such as asthma, atopic dermatitis, rheumatoid arthritis, inflammatory bowel disease and various hematological, lymphoid and solid tumor cancers mediated by lL5R-ECs. Moreover, T-cell depletion is a highly sensitive process and thus may provide a desired level of depletion of IL5R-ECs, e.g., a substantially complete deletion, or a less-than-complete deletion, if desired, while also only activating a limited population of available T-cclls with the potential for reduced risk of inflammatory' responses such as cytokine release syndrome.BRIEF DESCRIPTION OF THE DRAWINGS
[0013] FIGS. 1A-1I illustrate configurations for TEPs comprising single-chain pMHCs.
[0014] FIGS. 2A-2D illustrate configurations for TEPs comprising single-chain pMHCs, where the pMHCs comprise intrachain disulfide bonds.
[0015] FIGS. 3A-3B illustrate configurations for dimeric TEPs comprising two identical TEPs, each of which comprises a single-chain pMHC.
[0016] FIGS. 4A-4F illustrate configurations for dimeric TEPs comprising two different TEPs, each of which comprises a single-chain pMHC.
[0017] FIGS. 5A-5G illustrate configurations for TEPs comprising heterodimeric pMHCs.
[0018] FIGS. 6A-6P illustrate configurations for dimeric TEPs comprising two TEPs, each of which comprises a heterodimeric pMHC.
[0019] FIGS. 7A-7E provide amino acid sequences of wild-type HLA-A*0201 (FIG. 7A; SEQ ID NO:4) and variants (FIG. 7B-7E; SEQ ID NOs:5-8, respectively).
[0020] FIGS. 8A-8E provide amino acid sequences of wild-type HLA-A* 1101 (FIG. 8 A; SEQ ID NO:9) and variants (FIG. 8B-8E; SEQ ID NOs: 10-13, respectively).
[0021] FIGS. 9A-9E provide amino acid sequences of wild-type EILA-A*2402 (FIG. 9A; SEQ ID NO: 14) and variants (FIG. 9B-9E; SEQ ID NOs: 15-18, respectively).
[0022] FIGS. 10A-10E provide amino acid sequences of wild -type HLA-A* 3303 (FIG. 10 A; SEQ ID NO: 19) and variants (FIG. 10B-10E; SEQ ID NOs:20-23, respectively).
[0023] FIGS. 11A-11E provide amino acid sequences of wild-type HLA-A*0301 (FIG. 11A; SEQ ID NO:24) and variants (FIG. 1 IB-1 IE; SEQ ID NOs:25-28. respectively).
[0024] FIGS. 12A-12D provide an alignment of amino acid sequences of wild-type (FIG. 12A and continued in FIG. 12B; SEQ ID NOs:29-37, respectively) and variant (FIG. 12C and continued in FIG.12D; SEQ ID NOs:38-46, respectively) HLA-A polypeptides.
[0025] FIGS. 13A-13D provide an alignment of amino acid sequences of wild-type (FIG. 13A and continued in FIG. 13B; SEQ ID NOs:47-53, respectively) and variant (FIG. 13C and continued in FIG.13D: SEQ ID NOs:54-60, respectively) HLA-B polypeptides.
[0026] FIGS. 14A-14D provide an alignment of amino acid sequences of wild-type (FIG. 14A and continued in FIG. 14B; SEQ ID NOs:61-69, respectively) and variant (FIG. 14C and continued in FIG.14D; SEQ ID NOs: 70-78. respectively) HLA-C polypeptides.
[0027] FIGS. 15A-15E provide amino acid sequences of wild-type (FIG. 15A; SEQ ID NO:79) HLA-E heavy chains and variants (FIGS. 15B-15E; SEQ ID NOs:80-83; respectively).
[0028] FIGS. 16A-16E provide amino acid sequences of wild-type (FIG. 16A; SEQ ID NO:84) HLA-E heavy chains and variants (FIGS. 16B-16E; SEQ ID NOs:85-88, respectively).
[0029] FIG. 17A provides the amino acid sequence of the light chain variable region of the anti-IL5R antibody, benralizumab (SEQ ID NO:349).
[0030] FIG. 17B provides the amino acid sequence of the light chain of the anti-IL5R antibody, benralizumab (SEQ ID NO:350).
[0031] FIG. 17C provides the amino acid sequence of the heavy chain variable region of the anti-IL5R antibody, benralizumab (SEQ ID NO:351).
[0032] FIG. 17D provides the amino acid sequence of the heavy chain of the anti-IL5R antibody, benralizumab (SEQ ID NO:352).
[0033] FIGS. 17E, 17F and 17G provide the amino acid sequences of the CDR1, CDR2 and CDR3 regions (SEQ ID NOS: 353-355) of the heavy chain of the anti-IL5R antibody benralizumab.
[0034] FIGS. 17H, 171 and 17J provide the amino acid sequences of the CDR1, CDR2 and CDR3 regions (SEQ ID NOS: 356-358) of the light chain of the anti-IL5R antibody benralizumab.
[0035] FIG. 17K provides the amino acid sequence of scFv (vL-vH) of the anti-IL5R antibody, bcnralizumab (SEQ ID NO:359).
[0036] FIG. 17L provides the amino acid sequence of scFv (vH-vL) of the anti-IL5R antibody, benralizumab (SEQ ID NO:360).
[0037] FIG. 17M provides the amino acid sequence of construct 513A comprising an scFv of benralizumab linked to an HLA-A02:01 heavy chain polypeptide and an IgGl Fc polypeptide (SEQ ID NO:361).
[0038] FIG. 17N provides the amino acid sequence of the peptide AF17121 (SEQ ID NO:362).
[0039] FIG. 170 provides the amino acid sequence of construct 513B comprising AF17121 linked to an HLA-A02:01 heavy chain polypeptide and an IgGl Fc polypeptide (SEQ ID NO:363).
[0040] FIGS. 17P-17Q (SEQ ID NOS: 364 and 365, respectively) provide amino acid sequences of the light chains of TEPs described in the Examples.
[0041] FIG. 17R provides the amino acid sequence of construct 513C (SEQ ID NO:366) comprising an scFv of benralizumab linked to an HLA-A02:01 heavy chain polypeptide and a KiH IgGl Fc polypeptide.
[0042] FIG. 17S provides the amino acid sequence of construct 513D (SEQ ID NO:367) comprising AF17121 linked to an HLA-A02:01 heavy chain polypeptide and a KiH IgGl Fc polypeptide.
[0043] FIG. 17T provides the amino acid sequence of construct 3587 (SEQ ID NO:421) comprising an HIV peptide epitope linked to a B2M polypeptide.
[0044] FIGS. 18A-18H provide the amino acid sequences of various constructs (SE ID NOs:422-429) comprising peptide epitopes linked to a B2M polypeptides.
[0045] FIGS. 19A-19I provide the amino acid sequences of exemplary single-chain TEPs (SEQ ID NOs:430-438).
[0046] FIGS. 20A-20B illustrate the results of the experiments described in Example 4.DEFINITIONS
[0047] As used herein, the terms “IL5R-associated disorder” means any condition, disease, illness, or disorder associated with cells that express IL-5R receptor, it’s binding with IL-5, and subsequent cellular events triggered by the binding of IL-5 to IL5R-ECs. Such IL5R-associated disorders, which are discussed below, include but are not limited to disorders characterized by proliferation of eosinophils and / or mast cells, resulting in inflammation and / or the development and progression of certain cancers.
[0048] As used herein, the term “disorder” means any condition, disease, illness, ailment, syndrome, malady, affliction, or other disorder indicative of ill health.
[0049] As used herein, the terms “IL5R binder” means any peptide or polypeptide that specifically binds to IL-5R, including peptides or polypeptides that bind to either or both of IL5R’s two subunits, IL5Ra and IL5Rp. As discussed herein, IL5R binders can include peptides comprising from 4-50 amino acids (e.g., from 14-20 amino acids) that bind to IL5R, including such peptides that bind to IL5Ra. IL5R binders also can include antibodies, including antibody fragments (e.g., scFvs) that bind to IL5R, including antibodies that bind to either or both of IL5Ra and IL5R .
[0050] The terms “peptide,” “polypeptide,” and “protein” are used interchangeably herein, and refer to a polymeric fonn of amino acids of any length, which can include coded and non-coded amino acids, chemically or biochemically modified or derivatized amino acids, and polypeptides having modified peptide backbones. Furthermore, as used herein, a "polypeptide" refers to a protein that includes modifications, such as deletions, additions, and substitutions (generally conservative in nature as would be known to a person in the art) to the native sequence, as long as the protein maintains the desired activity. These modifications can be deliberate, as through site-directed mutagenesis, or can be accidental, such as through mutations of hosts that produce the proteins, or errors due to polymerase chain reaction (PCR) amplification or other recombinant DNA methods. References herein to a specific residue or residue number in a known polypeptide are understood to refer to the amino acid at that position in the wild-type polypeptide. To the extent that the sequence of the wild-type polypeptide is altered, either by addition or deletion of one or more amino acids, one of ordinary skill will understand that a reference to the specific residue or residue number will be correspondingly altered so as to refer to the same specific amino acid in the altered polypeptide, which would be understood to reside at an altered position number. For example, if an MHC class I polypeptide is altered by the addition of one amino acid at the N-terminus, then a reference to position 84 or a specific residue at position 84, will be understood to indicate the amino acids that are at position 85 on the altered polypeptide. Likewise, a reference herein to substitution of a specific amino acid at a specific position, e.g., Y84, is understood to refer to a substitution of an amino acid for the amino acid at position 84 in the w ild-type polypeptide. A Y84C substitution is thus understood to be a substitution of a Cys residue for the Tyr residue that is present in the wild-type sequence. If. e.g., the wild-type polypeptide is altered to change the amino acid at position 84 from its wild-type amino acid to an alternate amino acid, then the substitution for the amino acid at position 84 will be understood to refer to the substitution for the alternate amino acid. If in such case the polypeptide is also altered by the addition or deletion of one or more amino acids, then the reference to the substitution will be understood to refer to the substitution for the alternate amino acid at the altered position number. A reference to a “non-naturally occurring Cys residue” in a polypeptide, e.g., an MHC class I polypeptide, means that the polypeptide comprises a Cys residue in a location where there is no Cys in the corresponding wild-type polypeptide. This can be accomplished throughroutine protein engineering in which a cysteine is substituted for the amino acid that occurs in the wildtype sequence.
[0051] A polypeptide has a certain percent "sequence identity" to another polypeptide, meaning that, when aligned, that percentage of amino acids are the same, and in the same relative position, when comparing the two sequences. Sequence identity can be detennined in a number of different ways. To determine sequence identity, sequences can be aligned using various convenient methods and computer programs (e.g., BLAST (Basic Local Alignment Search Tool), T-COFFEE, MUSCLE, MAFFT, etc.), available over the world wide web at sites including ncbi.nlm.nili.gov / BLAST, ebi.ac.uk / Tools / msa / tcoffee / , ebi.ac.uk / Tools / msa / muscle / , mafft.cbrc.jp / alignment / software / . See, e.g.. Altschul et al. (1990). J. Mol. Biol. 215:403-10. Unless otherwise stated, “sequence identity” as referred to herein is determined by BLAST+2.10.0 using default parameters, which is available over the world wide web at sites including https: / / ncbiinsights.ncbi.nlm.nih.gov / 2019 / 12 / 18 / blast-2-10-0 / .
[0052] “T-cell” includes all types of immune cells expressing CD3, including T-helper cells (CD4+cells), cytotoxic T-cells (CD8+cells), T-regulatory cells (Treg), and NK-T-cells. Unless otherwise indicated, the term “T-cell” as used herein refers to a CD8+ T-cell.
[0053] The term “activating immunomodulatory polypeptide” (also referred to herein as an “activating MOD”) means a polypeptide that specifically binds a cognate costimulatory polypeptide on a T-cell, thereby providing a signal which mediates a T-cell response, including, but not limited to, proliferation, activation, differentiation, and the like. As discussed herein, an activating MOD can include, but is not limited to wild-type or variants of wild-type polypeptides such as a cytokine (e.g., IL-2), CD7, B7-1 (CD80), B7-2 (CD86). and 4-1BBL.
[0054] As used herein the term “zw viva" refers to any process or procedure occurring inside of the body.
[0055] As used herein, "in vitro" refers to any process or procedure occurring outside of the body.
[0056] Tire terms “antibody” and “antibodies” include antibodies or immunoglobulins of any isotype, fragments of antibodies that retain specific binding to one or more target antigens, including, but not limited to, Fab, Fv, scFv, and Fd fragments, chimeric antibodies, humanized antibodies, single-chain antibodies (scAb), single domain antibodies (dAb), single domain heavy chain antibodies, a single domain light chain antibodies, nanobodies, bi-specific antibodies, multi-specific antibodies, and fusion proteins comprising an antigen-binding (also referred to herein as antigen binding) portion of an antibody and a non-antibody protein. The antibodies can be detectably labeled, e.g., with a radioisotope, an enzyme that generates a detectable product, a fluorescent protein, and the like. The antibodies can be further conjugated to other moieties, such as members of specific binding pairs, e.g., biotin (member of biotin-avidin specific binding pair), and the like. Also encompassed by the term are Fab’, Fv, F(ab’)2,and / or other antibody fragments that retain specific binding to an antigen, and monoclonal antibodies. As used herein, a monoclonal antibody is an antibody produced by a group of identical cells, all of which were produced from a single cell by repetitive cellular replication. That is, the clone of cells only produces a single antibody species. While a monoclonal antibody can be produced using hybridoma production technology, other production methods known to those skilled in the art can also be used (e.g., antibodies derived from antibody phage display libraries). An antibody can be monovalent or bivalent. An antibody can be an Ig monomer, which is a “Y -shaped” molecule that consists of four polypeptide chains: two heavy chains and two light chains connected by disulfide bonds.
[0057] Hie term “nanobody” (Nb), as used herein, refers to the smallest antigen binding fragment or single variable domain (VHH) derived from a naturally occurring heavy chain antibody and is known to the person skilled in the art. They are derived from heavy chain only antibodies, seen in camelids (Hamers-Casterman et al. (1993) Nature 363:446; Desmyter et al. (1996) Nature Structural Biol. 3:803: and Desmyter et al. (2015) Curr. Opin. Struct. Biol. 32: 1). In the family of "camelids", immunoglobulins devoid of light polypeptide chains are found. "Camelids" comprise old world camelids (Camelus bactrianus and Camelus dromedarius) and new world camelids (for example. Llama paccos, Llama glama. Llama guanicoe and Llama vicugna). A single variable domain heavy chain antibody is referred to herein as a nanobody or a VHH antibody.
[0058] “Antibody fragments” comprise a portion of an antibody, for example, the antigen binding or variable region of the intact antibody. Examples of antibody fragments include Fab, Fab', F(ab')2, and Fv fragments; diabodies; linear antibodies (Zapata et al., Protein Eng. 8(10): 1057-1062 (1995)); domain antibodies (dAb; Holt et al. (2003) Trends Biotechnol. 21:484); single-chain antibody molecules; and multi-specific antibodies formed from antibody fragments. Papain digestion of antibodies produces two identical antigen-binding fragments, called “Fab” fragments, each with a single antigen-binding site, and a residual “Fc” fragment, a designation reflecting the ability to crystallize readily. Pepsin treatment yields an F(ab')2 fragment that has two antigen binding sites and is still capable of cross-linking antigen.
[0059] “Fv” is the minimum antibody fragment that contains a complete antigen-recognition and -binding site. This region consists of a dimer of one heavy- and one light-chain variable domain in tight, non-covalent association. It is in this configuration that the three CDRs of each variable domain interact to define an antigen-binding site on the surface of the VH-VL dimer. Collectively, the six CDRs confer antigen-binding specificity to the antibody. However, even a single variable domain (or half of an Fv comprising only three CDRs specific for an antigen) has the ability to recognize and bind antigen, although at a lower affinity than the entire binding site.
[0060] “Single-chain Fv” or “sFv” or “scFv” antibody fragments comprise the VH and VL domains of antibody, wherein these domains are present in a single polypeptide chain. In some embodiments, the Fv polypeptide further comprises a polypeptide linker between the VHand VL domains, which enables thesFv to form the desired structure for antigen binding. For a review of sFv, see Pluckthun in The Pharmacology of Monoclonal Antibodies, vol. 113, Rosenburg and Moore eds., Springer-Verlag, New York, pp. 269-315 (1994).
[0061] Tire term ‘diabodies’ refers to small antibody fragments with two antigen-binding sites, which fragments comprise a heavy-chain variable domain (VH) connected to a light-chain variable domain (VL) in the same polypeptide chain (VH-VL). By using a linker that is too short to allow pairing between the two domains on the same chain, the domains are forced to pair with the complementary domains of another chain and create two antigen-binding sites. Diabodies arc described more fully in, for example, EP 404,097; WO 93 / 11161; and Hollinger et al. (1993) Proc. Natl. Acad. Set. USA 90:6444-6448.
[0062] Tire terms “treatment7’, “treating” and the like are used herein to generally mean obtaining a desired pharmacologic and / or physiologic effect. The effect may be prophylactic in terms of completely or partially preventing a disorder or symptom thereof and / or may be therapeutic in terms of a partial or complete cure for a disorder and / or adverse effect attributable to the disorder. “Treatment” as used herein covers any treatment of a disorder or symptom in a mammal, and includes: (a) preventing the disorder or symptom from occurring in a subject which may or may not be predisposed to acquiring the disorder or symptom but has not yet been diagnosed as having it; (b) inhibiting the disorder or one or more symptoms associated with the disorder, e.g., arresting its development; and / or (c) relieving the disorder, i.e., causing regression of the disorder. The therapeutic agent may be administered before, during and / or after the onset of disorder or injury’. The treatment of ongoing disorder, where the treatment stabilizes or reduces the undesirable clinical sy mptoms of the patient, is of particular interest. Such treatment is desirably performed prior to complete loss of function in the affected tissues. Hie subject therapy will desirably be administered during the symptomatic stage of the disorder, and in some cases after the symptomatic stage of the disorder.
[0063] The terms “individual,” “subject,” “host,” and “patient,” are used interchangeably herein and refer to any mammalian subject for whom diagnosis, treatment, or therapy is desired. Mammals include, e.g., humans, non-human primates, rodents (e.g., rats; mice), lagomorphs (e.g., rabbits), ungulates (e.g., cows, sheep, pigs, horses, goats, and the like), etc. Unless otherwise indicated, the terms “individual,” “subject,” “host,” and “patient,” refer to a human.
[0064] Unless indicated otherwise, the term “substantially” is intended to encompass both “wholly ” and “largely but not wholly”. For example, an 1g Fc that “substantially does not induce ADCC” (i.e., antibody-dependenT-cell cytotoxicity) means an Ig Fc that induces no ADCC at all or that largely does not induce ADCC.
[0065] As used herein, the term “about” used in connection with an amount indicates that the amount can vary' by 10% of the stated amount. For example, “about 100” means an amount of from 90-110.Where about is used in the context of a range, the “about” used in reference to the lower amount of the range means that the lower amount includes an amount that is 10% lower than the lower amount of the range, and “about” used in reference to the higher amount of the range means that the higher amount includes an amount 10% higher than the higher amount of the range. For example, from about 100 to about 1000 means that the range extends from 90 to 1100.
[0066] Before the present disclosure is further described, it is to be understood that this disclosure is not limited to particular embodiments described, as such may, of course, vary. It is also to be understood that the terminology' used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting, since the scope of the present disclosure will be limited only by the appended claims.
[0067] Where a range of values is provided, it is understood that each intervening value, to the tenth of the unit of the lower limit unless the context clearly dictates otherwise, between the upper and lower limit of that range and any other stated or intervening value in that stated range, is encompassed within the disclosure. The upper and lower limits of these smaller ranges may independently be included in the smaller ranges, and are also encompassed within the disclosure, subject to any specifically excluded limit in the stated range. Where tire stated range includes one or both of the limits, ranges excluding either or both of those included limits are also included in the disclosure.
[0068] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs. Although any methods and materials similar or equivalent to those described herein can also be used in the practice or testing of the present disclosure, acceptable and / or preferred methods and materials are now described. All publications mentioned herein are incorporated herein by reference to disclose and describe the methods and / or materials in connection with which the publications are cited.
[0069] As used herein and in tire appended claims, the singular forms “a.” “an,” and “the” include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to a “T-cell modulatory protein” includes a plurality of such proteins and reference to “the immunomodulatory polypeptide” includes reference to one or more immunomodulatory polypeptides and equivalents thereof known to those skilled in the art, and so forth. It is further noted that the claims may be drafted to exclude any optional element. As such, this statement is intended to serve as antecedent basis for use of such exclusive terminology as “solely,” “only” and the like in connection with the recitation of claim elements, or use of a “negative” limitation.
[0070] The terms “comprising,” “having,” “including,” and “containing” are to be construed as open-ended terms (i.e., meaning “including, but not limited to,”) unless otherwise noted. Recitation of ranges of values herein are merely intended to serve as a shorthand method of referring individually to eachseparate value falling within the range, unless otherwise indicated herein, and each separate value is incorporated into the specification as if it were individually recited herein. For example, if the range 10-15 is disclosed, then 11, 12, 13, and 14 are also disclosed. All methods described herein can be perfonned in any suitable order unless otherwise indicated herein or otherwise clearly contradicted by context. The use of any and all examples, or exemplary language (e.g., “such as”) provided herein, is intended merely to better illuminate the embodiments of the disclosure and does not pose a limitation on the scope of the disclosure unless otherwise claimed.
[0071] The term “and / or” as used herein a phrase such as “A and / or B” is intended to include both A and B; A or B; A (alone); and B (alone). Likewise, the term “and / or” as used herein a phrase such as “A, B, and / or C” is intended to encompass each of the following embodiments: A, B, and C; A. B, or C; A or C; A or B; B or C; A and C; A and B; B and C; A (alone); B (alone); and C (alone).
[0072] It is understood that aspects and embodiments of the present disclosure described herein include “comprising,” “consisting of,” and “consisting essentially of’ aspects and embodiments. Unless stated otherwise, the disclosure of an embodiment or aspect, and / or recitation of a claim, that uses the open-ended term “comprising” to describe its features and / or components is also intended to disclose / recite the same embodiment, aspect or claim as “consisting” and “consisting essentially of’ the same features and / or components.
[0073] It is appreciated that certain features of the disclosure, which are, for clarity, described in the context of separate embodiments, may also be provided in combination in a single embodiment.Conversely, various features of the disclosure, which are, for brevity, described in the context of a single embodiment, may also be provided separately or in any suitable sub-combination. All combinations of the embodiments pertaining to the disclosure are specifically embraced by the present disclosure and are disclosed herein just as if each and every combination was individually and explicitly disclosed. In addition, all sub-combinations of the various embodiments and elements thereof are also specifically embraced by the present disclosure and are disclosed herein just as if each and every such subcombination was individually and explicitly disclosed herein.
[0074] The publications discussed herein are provided solely for their disclosure prior to the filing date of the present application. Nothing herein is to be construed as an admission that the present disclosure is not entitled to antedate such publication. Further, the dates of publication provided may be different from the actual publication dates, which may need to be independently confirmed.DETAILED DESCRIPTION
[0075] Hie present disclosure provides, among other things, methods and compositions of matter (TEPs) for treating an individual who has a IL5R-associated disorder. The methods compriseadministering to the individual a therapeutic amount of a TEP that can bind to IL5R and mediate a T-cell response that results in a reduction or substantial elimination of the patient’s IL5R-ECs.
[0076] In certain embodiments, the TEP comprises:i) a peptide-major histocompatibility complex (“pMHC”) comprising a peptide epitope, a 02-microglobulin (“02M”) polypeptide, and an MHC class I heavy chain polypeptide;ii) a scaffold component, e.g., an immunoglobulin C‘Ig”) Fc polypeptide;iii) at least one targeting component (“TC”) that is an IL5R binder; andiv) optionally one or more activating immunomodulatory polypeptides.
[0077] As used herein, the term "‘peptide epitope” means a peptide that can be bound to MHC polypeptides (i.e., a p2-microglobulin (“02M”) polypeptide, and an MHC class I heavy chain polypeptide) and form a pMHC complex, such that the pMHC presents an epitope that can be specifically bound to a T-cell receptor (TCR) of a T-cell.
[0078] As described below, a TEP can be provided in many configurations.T-CELL ENGAGING PROTEINS (TEPS)
[0079] As noted above, TEPs of this disclosure include: i) a peptide-major histocompatibility complex (“pMHC”) comprising a peptide epitope, a [32 -microglobulin (“02M”) polypeptide, and an MHC class I heavy chain polypeptide; ii) a scaffold component, e.g., an immunoglobulin (“Ig”) Fc polypeptide, iii) at least one TC, and iv) optionally one or more activating immunomodulatory polypeptides or “MODs”. Tire TEP presents a peptide-MHC complex (pMHC) that can be specifically bound to a T-cell receptor (TCR) of a T-cell. Tire pMHC is formed by the combination of the peptide epitope, 02M polypeptide and the MHC class I heavy chain polypeptide. An “MHC class I heavy chain polypeptide” is sometimes referred to herein as a human leukocyte antigen (HLA) class I heavy chain polypeptide.
[0080] The scaffold component can be, e.g., an immunoglobulin (Ig) Fc polypeptide or a non-Ig Fc polypeptide, but often will be an Ig Fc polypeptide, which can help provide good manufacturability and prolonged half-life of the TEP. Tire TEP may comprise one or more independently selected peptide linkers between any two of the components of the TEP, e.g., between one or more of: i) the peptide epitope and the 02M polypeptide (in TEPs in which the peptide is part of a fusion protein with the 02M polypeptide); ii) the MHC class I heavy chain polypeptide and the TC; iii) the MHC class I heavy chain polypeptide and an Ig Fc polypeptide; iv) an Ig Fc polypeptide and the TC; v) an Ig Fc polypeptide and an optional activating MOD; vi) the TC and an activating MOD; vii) where the TEP comprises two or more TCs in tandem, between the TCs, and viii) where the TEP comprises two or more activating MODs in tandem, between the activating MODs.
[0081] As discussed below, there are multiple possible constructs for the pMHC of a TEP. Generally speaking, either (i) the peptide epitope of the pMHC will be part of a single-chain or heterodimericfusion polypeptide, in which case the peptide epitope typically will be joined to the N-tenninus of the P2M polypeptide via a peptide linker, or (ii) the peptide epitope of the pMHC will be chemically conjugated to a conjugation site in either the P2M polypeptide or MHC heavy chain polypeptide. These possible constructs are discussed below.
[0082] As discussed in more detail below, where a TEP comprises more than one TC, the TCs may be the same or different. As noted above, for example, in some embodiments, a TEP that comprises more than one TC could be a dual -targeting TEP that comprises first and second TCs that are IL5R binders, including first and second TCs that bind to different epitopes or subunits of IL5R such that both TCs can bind simultaneously to IL5R. In other embodiments, a dual-targeting TEP can comprise a first TC that is an IL5R binder and a second TC that binds to a different target, e.g., a target other than IL5R that is also associated with an IL5R-associated disorder, or a target that is associated with another condition or disorder, e g., a primary disorder or condition that can lead to an IL5R-associated disorder characterized by eosinophil proliferation and / or activation, and / or inflammation. Alternatively, or additionally, tire TEP can be a dimer of two TEPs, in which case each TEP can comprise the (i) the same or different TCs, and / or (ii) the same or different peptide epitopes such that the dimeric TEP presents two different pMHCs (e.g., a CMV pMHC and a SARS-CoV-2 pMHC) that engage two different subsets of a patient's T-cell repertoire. Additionally, where a TEP comprises more than one activating MOD, the multiple activating MODs can be the same or different.A. TEPs in which the peptide epitope of the pMHC is part of a fusion protein
[0083] As noted above, in some cases, the peptide epitope will be part of a fusion protein. In such cases, the pMHC may comprise either a single polypeptide chain or a heterodimer of two polypeptide chains. Both configurations are discussed below.(i) Single-chain pMHCs
[0084] Schematic examples of TEPs in which the pMHC is a single-chain polypeptide are provided in FIGS. 1 A-1I. These figures illustrate some of the many possible combinations of the pMHC, the MHC class I heavy chain polypeptide (comprising, e.g., the al, a2 and a3 subunits), an Ig Fc polypeptide, the at least one TC, one or more optional activating MODs, and linkers (denoted by the lines between the components). The dashed line between the P2M polypeptide and the al subunit of the MHC heavy chain polypeptide represents a peptide linker. Although the Ig Fc polypeptide typically will be connected to the C-terminus of the MHC heavy chain polypeptide, it is possible that a TC and / or MOD could be interposed between the MHC heavy chain polypeptide and Ig Fc polypeptide, as illustrated in FIGS. 1D-1H.
[0085] Examples of single-chain pMHCs are described in WO 2022 / 197970 (“WO ‘970”) to Cue Biopharma, Inc., the disclosure of which is expressly incorporated herein by reference. As disclosed inWO ‘970, single-chain pMHCs can comprise one or two disulfide bonds that spontaneously form between Cys residues that can be provided in the components of the pMHC. One such disulfide bond can join a Cys residue in the 02M polypeptide to a Cys residue in the MHC heavy chain polypeptide. For example, the pMHC can comprise a disulfide bond between a Cys at amino acid 12 of the 02M polypeptide and a Cys at amino acid 236 of the MHC heavy chain polypeptide. Such disulfide bonds that join a Cys in the 02M polypeptide to a Cys in the MHC heavy chain polypeptide are referred to herein as “body disulfides”. A second disulfide bond can join a Cys that is provided in the linker between the peptide epitope and the 02M polypeptide to a Cys in the MHC heavy chain polypeptide. Such disulfide bonds between (i) a Cys in the linker that joins the peptide epitope and (32M polypeptide and (ii) a Cys in the MHC heavy chain polypeptide, are referred to herein as “linker disulfides”. As disclosed in WO ‘970, a Cys in the linker may be joined to a Cys at position 84 of the MHC heavy chain polypeptide, which is located in the al subunit of the MHC heavy chain polypeptide. It has also been found that a linker disulfide may be formed between (i) a Cys in the linker between the peptide epitope and the 02M polypeptide and (ii) a Cys at any one of positions 135-143 of the a2 subunit of the MHC heavy chain polypeptide (e.g., a Cys at any one of positions 138-140 of the al subunit, or a Cys at position 139 of the al subunit). pMHCs with such linker disulfide bonds have been found to enable proper presentation of the peptide epitope to achieve selective binding to target TCRs. See WO 2024 / 264004 and WO 2024 / 264007 to Cue Biopharma, Inc ., the disclosures of which as they pertain to single-chain T-cell modulatory polypeptides comprising a linker between (i) the peptide epitope and the 02M polypeptide and (ii) a Cys at any one of positions 135-143 of the al subunit of the MHC heavy chain polypeptide is expressly incorporated herein by reference.
[0086] Schematic examples of TEPs in which the pMHC is a single-chain polypeptide that comprises one or two of the above-described disulfide bonds are provided in FIGS. 2A-D. Many other configurations are possible. For example, the optional activating MOD and / or TC may be interposed between the MHC heavy chain polypeptide and the Ig Fc (not shown).
[0087] In some embodiments, two TEPs comprising single-chain TEPs will form dimers through the spontaneous formation of one or more disulfide bonds between Cys residues in the Ig Fc polypeptides of each TEP. The dimers can comprise two identical TEPs, in which case the dimeric TEP is a homodimer. See, e.g., FIGS 3A and 3B. In such cases, as illustrated in FIGS. 3A and 3B, the two identical singlechain TEPs typically will form dimers through the spontaneous formation of two disulfide bonds betw een Cys residues in the Ig Fc polypeptides of each TEP.
[0088] In some embodiments, the dimeric TEP comprises non-identical TEPs, in which case the dimeric TEP is a heterodimer. In such cases, the two TEPs of the dimeric TEP typically will have interspecific dimerization sequences, e.g., Knob-in-Hole dimerization sequences, that facilitate the selective dimerization of the two different single-chain TEPs. See, e.g., FIGS. 4A-4F, which illustrate afew of the many possible combinations of two different TEPs. In FIG. 4A, the dimeric TEP is a dualtargeting TEP that comprises two single-chain TEPs that have different TCs, for example, two different IL5R binders, e.g., two different antibodies (e.g., scFvs) that target IL5R, or alternatively a first TC that binds to IL5R and a second TC that binds to a target other than IL5R. In FIG. 4B, the dimeric TEP comprises two single-chain TEPs that have different TCs as discussed above, and one of the single-chain TEPs further comprises an activating MOD. In FIG. 4C, the dimeric TEP comprises two single-chain TEPs that have the same TCs, but different peptide epitopes. For example, combinations of different viral peptide epitopes from common viruses such as CMV, EBV and SARS-CoV-2 can be employed to increase the potential response by an individual’s existing T-cell repertoire. In FIG. 4D, the dimeric TEP comprises two single-chain TEPs that have different TCs and different peptide epitopes, and one of the single-chain TEPs further comprises an activating MOD. In FIG. 4E. the dimeric TEP comprises two single-chain TEPs that have different TCs as discussed above, and also different peptide epitopes, e.g., an EBV peptide epitope and a SARS-CoV-2 peptide epitope. In FIG. 4F, the dimeric TEP comprises two single-chain TEPs that have the same TCs and the same activating MODs, but different peptide epitopes, e.g.. a CMV peptide epitope and an EBV peptide epitope. The dimeric TEPs in FIGS. 4A-4F are illustrated with Knob-in-Hole interspecific binding sequences, but other interspecific binding sequences are well known and could be used instead. Such interspecific dimerization sequences are disclosed in WO 2022 / 197970 to Cue Biopharma, Inc ., the disclosure of which as it pertains to interspecific dimerization sequences is expressly incorporated herein by reference. See, e.g., paragraph
[0210] , the disclosure of which is expressly incorporated herein by reference. As illustrated in FIGS. 1D-1H, it also is possible to position the TC and / or optional activating MOD N-tenninal to the Ig Fc polypeptide in any of the homodimeric or heterodimeric configurations of single-chain TEPs.(ii) Heterodimeric pMHCs
[0089] In some cases, the pMHC of the TEP is a heterodimer formed by first and second polypeptides, where the first polypeptide comprises the peptide epitope, 2M polypeptide and connecting linker, and the second polypeptide comprises the MHC heavy chain polypeptide. The Ig Fc and TC are also positioned on the second polypeptide. Tire optional activating MODs, if present, typically will be a component of the second polypeptide chain, but also may be linked to the C-terminus of the P2M polypeptide on the first polypeptide. The pMHC may further comprise a body disulfide bond and also a linker disulfide bond as discussed above. Heterodimeric pMHCs comprising body disulfide bonds and linker disulfide bonds are described in WO 2020 / 132138 (to Cue Biopharma, Inc ), the disclosure of which as it pertains to multimeric T-cell modulatory polypeptides comprising such heterodimeric pMHCs is expressly incorporated by reference.
[0090] Examples of TEPs in which the pMHC is heterodimeric are provided in FIGS. 5A-5G, which illustrate a few of the many possible combinations of TC(s) and optional activating MOD(s) on the second polypeptide chain, as well as some of the possible body disulfide bond and linker disulfide bond combinations that may be employed. Tire TCs may be positioned C-tenninal to the MHC heavy chain polypeptide, as shown in FIGS. 5A, B and E, in which the TC is positioned C-terminal to the Ig Fc. Alternatively, the TC may be positioned N-terminal to the MHC heavy chain polypeptide, as shown in FIGS. 5C and D. Alternatively, TCs may be positioned both N-terminal to the MHC heavy chain polypeptide and C-tcrminal to heavy chain as shown in FIGS. 5F and G. In FIG. 5F, the TCs arc the same, and in FIG. 5G they are different. The TCs also may be interposed between the MHC heavy chain polypeptide and the Ig Fc, or between the optional activating MOD(s) and another component of the second polypeptide (not shown). The optional activating MOD(s) likewise may be located at any position along the second polypeptide that is N-terminal or C-terminal to the MHC heavy chain polypeptide. For example, the optional activating MOD may be interposed between the MHC heavy chain polypeptide and the Ig Fc, between the MHC heavy chain polypeptide and a TC, or between the Ig Fc and TC (all not shown).
[0091] TEPs comprising a heterodimeric pMHC also may form dimeric TEPs through the spontaneous formation of one or more disulfide bonds between Cys residues in the Ig Fc polypeptides of each TEP. FIGS. 6A-L illustrate some of the many possible configurations for such dimeric TEPs comprising the TEPs having heterodimeric pMHCs described above.
[0092] In embodiments where the two TEPs are identical in structure, the two identical single-chain TEPs typically will form dimers through the spontaneous formation of disulfide bonds (typically two disulfide bonds) between Cys residues in the Ig Fc polypeptides of each TEP. FIGS. 6A-6F illustrate some of the many possible configurations of dimeric TEPs that are homodimers of two identical TEPs. FIGS. 6A and B illustrate dimeric TEPs comprising C-terminal TCs. FIG. 6A illustrates a dimeric TEP with a body disulfide, and FIG. 6B illustrates a dimeric TEP with both a body disulfide and a linker disulfide.
[0093] FIGS. 6C, D and E illustrate dimeric TEPs comprising N-terminal TCs. FIG. 6C illustrates a dimeric TEP with both a body disulfide and a linker disulfide. FIG. 6D illustrates a dimeric TEP with both a body disulfide and a linker disulfide, as well as optional activating MODs positioned at the C-tenninus of the Ig Fc. FIG. 6E illustrates a dimeric TEP having TCs that are N-tenninal to the MHC heavy chain polypeptide and optional activating MODs that are N-tenninal to the TCs. Tire dimeric TEP of FIG. 6E comprises a body disulfide but not a linker disulfide.
[0094] FIG. 6F illustrates a dimeric TEP comprising TEPs that have a TC that is C-terminal to the Ig Fc and a different TC that is N-terminal to the MHC heavy chain polypeptide. Alternatively, all fourTCs could be the same. The dimeric TEP of FIG. 6F comprises both a body disulfide and a linker disulfide.
[0095] In some embodiments, the dimeric TEP comprises non-identical TEPs. In such cases, the two TEPs of the dimeric TEP typically will have interspecific dimerization sequences, e.g., Knob-in-Hole dimerization sequences, that facilitate the selective dimerization of the two different TEPs. FIGS. 6G- 60 illustrate a few of the many possible configurations in which the dimeric TEP comprises two different TEPs. In FIGS. 6G and 6H, the dimeric TEP comprises two TEPs that have different TCs that arc positioned C-tcrminal to the Ig Fc polypeptides of the two TEPs. As discussed above, such dualtargeting TEPs can, e.g., comprise two different IL5R binders, including e.g., two antibodies that bind to different epitopes of IL5R or one antibody and one peptide that bind to IL5R. or alternatively a first scFv that targets IL5R and a second scFv that binds to a protein other than IL5R. The dimeric TEP illustrated in FIG. 6G comprises a body disulfide (FIG. 6G), whereas the dimeric TEP illustrated in FIG. 6H comprises both a body disulfide and a linker disulfide. In FIG. 61, the dimeric TEP comprises two N-temiinal TEPs that are positioned N-tenninal to the MHC heavy chain polypeptide and comprise different TCs as discussed above. In FIG. 6J, the dimeric TEP comprises two TEPs that comprise the same TCs positioned N -terminal to the MHC heavy chain polypeptide, but one of the TEPs additionally comprises an activating MOD positioned C-terminal to the Ig Fc polypeptide. The dimeric TEP in FIGS.61 and 6J comprise both a body disulfide and a linker disulfide. In FIG. 6K, the dimeric TEP comprises two TEPs that comprise different TCs positioned C-terminal to the Ig Fc polypeptide. In the dimeric TEP of FIG. 6K, each TEP comprises a body disulfide. The dimeric TEP in FIG. 6K also comprises an activating MOD N-terminal to tire MHC heavy chain polypeptide on one of the TEPs. In FIG. 6L, the dimeric TEP comprises two TEPs that have the same TCs C-terminal to the MHC heavy chain and comprises both a body disulfide and a linker disulfide. The dimeric TEP in FIG. 6K also comprises an activating MOD C-terminal to the MHC heavy chain polypeptide on one of the TEPs. FIGS. 6M-6O illustrate the same dimers as illustrated in FIGS. 6I-6L, except that the two TEPs that comprise the dimers of 6M-6O each have different peptide epitopes. As noted above, combinations of different viral peptide epitopes from common viruses such as CMV. EBV and SARS-CoV-2 can be employed to increase the potential response by an individual’s existing T-cell repertoire. Many other configurations for such dimeric TEPs are possible. Moreover, although the dimeric TEPs in FIGS. 6G to 6L are illustrated with Knob-in-Hole interspecific binding sequences, other interspecific binding sequences are well known to persons of skill in the art and could be used instead.
[0096] Further, although the dimeric TEPs comprising two different TEPs discussed above (FIGS. 4A-F and 6A-P) have been illustrated as having the same body disulfides and linker disulfides in each TEP, the two different TEPs could have different body disulfides and / or linker disulfides. For example, a dimeric TEP could comprise a first TEP that has a body disulfide and a second TEP that has both abody disulfide and a linker disulfide. As another example, a dimeric TEP could comprise two TEPs that have both a body disulfide and a linker disulfide, where the linker disulfide of one TEP comprises a disulfide bond linking a Cys in the 02m-peptide epitope linker to a Cys at position 84 in its MHC heavy chain and the other TEP comprises a disulfide bond linking a Cys in the 02m-peptide epitope linker to a Cys at position 139 in its MHC heavy chain.(iii) pMHCs presented by multimeric antigen-presenting polypeptides (MAPPs)
[0097] In some cases, where the pMHC of a TEP is a single-chain polypeptide or a heterodimeric complex as described above, the pMHC may be provided as a component, i.e., as a presenting sequence or presenting complex, of a multimeric antigen-presenting polypeptide (MAPP) as described in WO 2021 / 242935 (Cue Biopharma, Inc.) or WO 2022 / 099157 (Cue Biopharma, Inc ), tire disclosures of which are expressly incorporated by reference. Such MAPPs thus would comprise the pMHC, an Ig Fc and a TC. The MAPPs optionally may also comprise one or more activating MODs, and as noted above, combinations of different TCs can be employed to bind to different targets, and / or different viral peptide epitopes from common viruses such as CMV, EBV and SARS-CoV-2 can be employed to increase the potential response by an individual’s existing T-cell repertoire.B. TEPs in which the peptide epitope is chemically conjugated to the pMHC
[0098] Unlike the above TEPs in which the peptide epitope of the pMHC is part of a fusion protein with (i) the 02M polypeptide in the case of heterodimeric TEPs, or (ii) both the 02M polypeptide and the MHC class I polypeptide in the case of single-chain TEPs, in some cases the TEP may comprise a peptide epitope that is chemically conjugated to either the 02 M polypeptide or the MHC class I polypeptide.
[0099] In some cases, TEPs comprising chemically conjugated peptide epitopes comprise a heterodimer of MHC polypeptides, i.e., the 02M polypeptide is on tire first polypeptide and the MHC heavy chain polypeptide is on the second polypeptide chain. In such cases, the peptide epitope is chemically conjugated to either the 02M polypeptide or MHC heavy chain polypeptide. See, e.g., WO 2019 / 051127, WO 2020 / 132365, WO 2020 / 132366, and WO 2020 / 132368 (Cue Biopharma, Inc.), the disclosures of which as they pertain to pMHCs comprising a chemically conjugated peptide epitope are expressly incorporated by reference. Like the heterodimeric TEPs illustrated in FIGS. 5A-G above, the TC, MHC heavy chain polypeptide, Ig Fc and optional MOD can be positioned anywhere along the second polypeptide in such heterodimeric TEPs comprising chemically conjugated peptide epitopes. In such embodiments, the unconjugated scaffold of the TEP is first prepared and then the peptide epitope is then chemically conjugated. Accordingly, such unconjugated heterodimeric TEP scaffolds comprising a first polypeptide comprising a 02M polypeptide, and a second polypeptide comprising the TC, MHC heavy chain polypeptide, Ig Fc and optional MOD, are expressly contemplated and disclosed herein.
[0100] In some cases, TEPs comprising chemically conjugated peptide epitopes comprise single-chain MHC polypeptides, i.c., the 02M polypeptide and MHC heavy chain polypeptide arc in the same polypeptide chain. In such cases, the peptide epitope is chemically conjugated to either the 02M polypeptide orthe MHC heavy chain polypeptide. See. e.g., WO 2022 / 015880, WO 2022 / 099156 and WO 2022 / 137158 (Cue Biopharma, Inc.), the disclosures of which as they pertain to single-chain pMHCs comprising a chemically conjugated peptide epitope are expressly incorporated by reference. In such embodiments, the unconjugated single-chain scaffold of the TEP is first prepared and then the peptide epitope is then chemically conjugated. Accordingly, such unconjugatcd single chain TEP scaffolds comprising a P2M polypeptide, TC, MHC heavy chain polypeptide, Ig Fc and optional MOD are expressly contemplated and disclosed herein.
[0101] Dimeric TEPs comprising two TEPs comprising chemically conjugated peptide epitopes as described above (either two identical TEPs or two different TEPs) also may be formed. In such embodiments, the unconjugated dimeric scaffold of the TEP is first prepared and then the peptide epitopes are then chemically conjugated. Accordingly, such unconjugated dimeric TEP scaffolds comprising a 02 M polypeptide, TC. MHC heavy chain polypeptide, Ig Fc and optional MOD are expressly contemplated and disclosed herein. As described above, Ig Fc polypeptides comprising interspecific binding sequences typically will be used in embodiments where a dimeric TEP comprises two different TEPs, and Ig Fc polypeptides comprising non-interspecific binding sequences typically will be used in embodiments where a dimeric TEP comprises two identical TEPs. And as noted above, combinations of different viral peptide epitopes from common viruses such as CMV, EBV and SARS-CoV-2 can be employed to increase the potential response by an individual's existing T-cell repertoire. Embodiments comprising different peptide epitopes could be prepared using the same or different linking conjugation methods.MHC POLYPEPTIDESA. p2M polypeptides
[0102] The 02M polypeptide present in the TEP can comprise an amino acid sequence having at least 90%, at least 95%, at least 98%, at least 99%, or 100%, amino acid sequence identity to the following 02M amino acid sequence: IQRTPKIQVY SRHPAENGKS NFLNCYVSGF HPSDIEVDLLKNGERIEKVE HSDLSFSKDW SFYLLYYTEF TPTEKDEYAC RVNHVTLSQP KTVKWDRDM (SEQ ID NO: 1) In some cases, a 02M polypeptide comprises an amino acid sequence having at least 90%, at least 95%, at least 98%, at least 99%, or 100%, amino acid sequence identity to the following 02 M amino acid sequence: IQRTPKIQVY SCHPAENGKS NFLNCYVSGF HPSDIEVDLLKNGERIEKVE HSDLSFSKDW SFYLLYYTEF TPTEKDEYAC RVNHVTLSQP KIVKWDRDM (SEQ ID NO:2), where amino acid 12 is a Cys. In some cases, a 02M polypeptidecomprises the amino acid sequence IQRTPKIQVY SCHPAENGKS NFLNCYVSGF HPSDIEVDLLKNGERIEKVE HSDLSFSKDW SFYLLYYTEF TPTEKDEYAC RVNHVTLSQP KIVKWDRDM (SEQ ID NO:2).B. MHC class I heavy chain polypeptides
[0103] As noted above, the pMHC of a TEP comprises an MHC class I heavy chain polypeptide. Suitable MHC class I heavy chain polypeptides include a human MHC class I heavy chain polypeptide, where human MHC polypeptides are also referred to as '‘human leukocyte antigen” f'HLA”) polypeptides. Class I HLA heavy chain polypeptides include HLA-A heavy chain polypeptides, HLA-B heavy chain polypeptides, HLA-C heavy chain polypeptides, HLA-E heavy chain polypeptides, HLA-F heavy chain polypeptides, and HLA-G heavy chain polypeptides.
[0104] Unless otherwise specified below, the amino acid numbering of an MHC class I heavy chain polypeptide present in a pMHC polypeptide is based on the amino acid numbering of the MHC class I heavy chain polypeptide depicted in FIG. 7A. It should be noted that the amino acid numbering of the MHC class I heavy chain polypeptide depicted in FIG. 7A applies equally to the amino acid numbering of the MHC class I heavy chain polypeptides depicted in FIGS. 12A-12B (alignment of amino acid sequences of wild-type HLA-A heavy chain polypeptides), FIGS. 13A-13B (alignment of amino acid sequences of wild-type HLA-B heavy chain polypeptides), FIGS. 14A-14B (alignment of amino acid sequences of wild-type HLA-C heavy chain polypeptides), and FIGS. 15A and FIG. 16A (amino acid sequences of wild-type HLA-E heavy chain polypeptides).
[0105] In some cases, the MHC class I heavy chain is a heavy chain from an HLA-A, -B, -C, -E, -F, or -G allele. In some cases, the MHC class I heavy chain is a heavy chain from HLA-A* 0101, A* 0201, A*0301, A* 1101. A*230I, A*2402, A*2407. A*3303, and / or A*3401. In some cases, the MHC class I heavy chain is a heavy chain from HLA-B*0702, B*0801, B*1502, B*3802, B*4001, B*4601, and / or B*5301. In some cases, the MHC class I heavy chain is a heavy chain from HLA-C*0102, C*0303, C*0304, C*040I, C*0602, C*0701, C*702, C*0801, and / or C*I502. In some cases, the MHC class I heavy chain is a heavy chain from HLA-E*0101 (HLA-E* 01:01:01:01), HLA-E*01:03(HLA-E*01:03:01:01), HLA-E*01:04. HLA-E*0I:05, HLA-E*01:06, HLA-E*01:07, HLA-E*01:09, and HLA-E*01:10. Two HLA-E alleles that have a significant prevalence in humans are HLA-E*0101 (HLA-E*01:01:01:01) and HLA-E*01:03(HLA-E*01:03:01:01), and both have identical peptide -binding grooves.
[0106] Unless expressly stated otherwise, a pMHC polypeptide does not include membrane anchoring domains (transmembrane regions) of an MHC class I heavy chain, or a part of MHC class I heavy chain sufficient to anchor the resulting pMHC to a cell (e.g., eukaryotic cell such as a mammalian cell) in which it is expressed. In some cases, the MHC class I heavy chain present in a pMHC does not include asignal peptide, a transmembrane domain, or an intracellular domain (cytoplasmic tail) associated with a native MHC class I heavy chain. Thus, e.g., in some cases, the MHC class I heavy chain present in a pMHC polypeptide includes only the al, a2, and a3 domains of an MHC class I heavy chain. In some cases, the MHC class I heavy chain present in a pMHC has a length of from about 270 amino acids (aa) to about 290 aa. In some cases, the MHC class I heavy chain present in a pMHC has a length of 270 aa.271 aa, 272 aa, 273 aa, 274 aa, 275 aa, 276 aa, 277 aa, 278 aa, 279 aa, 280 aa, 281 aa, 282 aa, 283 aa, 284 aa, 285 aa, 286 aa, 287 aa, 288 aa, 289 aa, or 290 aa.
[0107] In some cases, an MHC class I heavy chain polypeptide present in a pMHC polypeptide comprises an amino acid sequence having at least 85%, at least 90%, at least 95%, at least 97%, at least 98%, at least 99%, or 100%, amino acid sequence identity to all or part (e.g., 50, 75, 100. 150, 200. or 250 contiguous amino acids) of the amino acid sequence of any of the human HLA heavy chain polypeptides depicted in FIGS. 7-16, where the MHC class I heavy chain polypeptide comprises a Cys at amino acid 84 or at any one of amino acids 135-143 (e.g., at amino acid 139). Where the MHC class I heavy chain polypeptide comprises a Cys at any one of amino acids 135-143 (e.g., a Cys at amino acid 139), an amino acid other than Cys is at position 84. Conversely, where the MHC class I heavy chain polypeptide comprises a Cys at position 84. amino acids 135-143 are other than Cys. In some cases, the MHC class I heavy chain has a length of 270 aa, 271 aa, 272 aa, 273 aa, 274 aa, 275 aa, 276 aa, 277 aa, 278 aa, 279 aa, 280 aa, 281 aa, 282 aa, 283 aa, 284 aa, 285 aa, 286 aa, 287 aa, 288 aa, 289 aa, or 290 aa.
[0108] In some cases, a pMHC polypeptide comprises an HLA-A heavy chain polypeptide with the above-noted amino acid substitution(s). Hie HLA-A heavy chain polypeptides, or portions thereof, that may be that may be incorporated into a pMHC polypeptide include, but are not limited to, the alleles: A*0101, A*0201, A*0301, A* 1101, A*2301, A*2402, A*2407, A*3303, and A*3401. In some cases, a pMHC polypeptide comprises an HLA-B heavy chain polypeptide with the above-noted amino acid substitution(s). In some cases, a pMHC polypeptide comprises an HLA-C heavy chain polypeptide with the above-noted amino acid substitution(s). In some cases, a pMHC polypeptide comprises an HLA-E heavy chain polypeptide with the above-noted amino acid substitution(s).C. Intrachain disulfide bonds
[0109] As discussed above, a pMHC of this disclosure may be a single-chain or heterodimeric polypeptide (or dimer thereof) that may comprise one or more disulfide bonds. As also discussed above, a pMHC may comprises a linker disulfide bond formed between: i) a Cys at amino acid 84 in the al subunit of tire MHC heavy chain polypeptide or any one of amino acids 135-143 (e.g., amino acid 139) in the a2 subunit of tire MHC heavy chain polypeptide, based on the numbering of the MHC class I heavy chain polypeptide depicted in FIG. 7A; and a Cys present in the first peptide linker, where the first peptide linker is interposed between the peptide epitope and the P2M polypeptide. In some cases, theMHC class I heavy chain polypeptide in a pMHC polypeptide comprises a Cys at position 84. In some cases, the MHC class I heavy chain polypeptide in a pMHC polypeptide comprises a Cys at any one of positions 135-143, e.g., a Cys at position 139.
[0110] Thus, for example, in some cases, amino acids 135-143 of the MHC class I heavy chain of a pMHC polypeptide comprises the amino acid sequence CADMAAQTT (SEQ ID NO: 100). As another example, in some cases, amino acids 135-143 of the MHC class I heavy chain of a pMHC polypeptide comprises the amino acid sequence ACDMAAQTT (SEQ ID NO: 101). As another example, in some cases, amino acids 135-143 of the MHC class I heavy chain of a pMHC polypeptide comprises tire amino acid sequence AACMAAQTT (SEQ ID NO: 102). As another example, in some cases, amino acids 135-143 of the MHC class I heavy chain of a pMHC polypeptide comprises the amino acid sequence AADCAAQTT (SEQ ID NO: 103). As another example, in some cases, amino acids 135-143 of the MHC class I heavy chain of a pMHC polypeptide comprises the amino acid sequence AADMCAQTT (SEQ ID NO:104). As another example, in some cases, amino acids 135-143 ofthe MHC class I heavy chain of a pMHC polypeptide comprises the amino acid sequence AADMACQTT (SEQ ID NO: 105). As another example, in some cases, amino acids 135-143 of the MHC class I heavy chain of a pMHC polypeptide comprises the amino acid sequence AADMAACTT (SEQ ID NO: 106). As another example, in some cases, amino acids 135-143 of the MHC class I heavy chain of a pMHC polypeptide comprises the amino acid sequence AADMAAQCT (SEQ ID NO: 107). As another example, in some cases, amino acids 135-143 of the MHC class I heavy chain of a pMHC polypeptide comprises the amino acid sequence AADMAAQTC (SEQ ID NO: 108).
[0111] As another example, in some cases, amino acids 135-143 of the MHC class I heavy chain of a pMHC polypeptide comprises the amino acid sequence CADMAAQIT (SEQ ID NO: 109). As another example, in some cases, amino acids 135-143 of the MHC class I heavy chain of a pMHC polypeptide comprises the amino acid sequence ACDMAAQIT (SEQ ID NO: 110). As another example, in some cases, amino acids 135-143 of the MHC class I heavy chain of a pMHC polypeptide comprises tire amino acid sequence AACMAAQIT (SEQ ID NO: 111). As another example, in some cases, amino acids 135-143 of the MHC class I heavy chain of a pMHC polypeptide comprises the amino acid sequence AADCAAQIT (SEQ ID NO: 112). As another example, in some cases, amino acids 135-143 of the MHC class I heavy chain of a pMHC polypeptide comprises the amino acid sequence AADMCAQIT (SEQ ID NO: 113). As another example, in some cases, amino acids 135-143 of the MHC class I heavy chain of a pMHC polypeptide comprises the amino acid sequence AADMACQIT (SEQ ID NO: 114). As another example, in some cases, amino acids 135-143 of tire MHC class I heavy chain of a pMHC polypeptide comprises the amino acid sequence AADMAACIT (SEQ ID NO: 115). As another example, in some cases, amino acids 135-143 of the MHC class I heavy chain of a pMHC polypeptide comprises the amino acid sequence AADMAAQCT (SEQ ID NO: 116). As another example, in some cases, amino acids 135-143 of the MHC class I heavy chain of a pMHC polypeptide comprises the amino acid sequence AADMAAQIC (SEQ ID NO: 117).
[0112] As another example, in some cases, amino acids 135-143 of the MHC class I heavy chain of a pMHC polypeptide comprises the amino acid sequence CADTAAQIT (SEQ ID NO: 118). As another example, in some cases, amino acids 135-143 of the MHC class I heavy chain of a pMHC polypeptide comprises the amino acid sequence ACDTAAQIT (SEQ ID NO: 119). As another example, in some cases, amino acids 135-143 of the MHC class I heavy chain of a pMHC polypeptide comprises the amino acid sequence AACTAAQIT (SEQ ID NO: 120). As another example, in some cases, amino acids 135-143 of the MHC class I heavy chain of a pMHC polypeptide comprises the amino acid sequence AADCAAQIT (SEQ ID NO: 121). As another example, in some cases, amino acids 135-143 of the MHC class I heavy chain of a pMHC polypeptide comprises the amino acid sequence AADTCAQIT (SEQ ID NO: 122). As another example, in some cases, amino acids 135-143 of the MHC class I heavy chain of a pMHC polypeptide comprises the amino acid sequence AADTACQIT (SEQ ID NO: 123). As another example, in some cases, amino acids 135-143 of the MHC class I heavy chain of a pMHC polypeptide comprises the amino acid sequence AADTAACIT (SEQ ID NO: 124). As another example, in some cases, amino acids 135-143 of the MHC class I heavy chain of a pMHC polypeptide comprises the amino acid sequence AADTAAQCT (SEQ ID NO: 125). As another example, in some cases, amino acids 135-143 of the MHC class I heavy chain of a pMHC polypeptide comprises the amino acid sequence AADTAAQIC (SEQ ID NO: 126).
[0113] As another example, in some cases, amino acids 135-143 of the MHC class I heavy chain of a pMHC polypeptide comprises the amino acid sequence CVDTAAQIS (SEQ ID NO: 127). As another example, in some cases, amino acids 135-143 of the MHC class I heavy chain of a pMHC polypeptide comprises the amino acid sequence ACDTAAQIS (SEQ ID NO: 128). As another example, in some cases, amino acids 135-143 of the MHC class I heavy chain of a pMHC polypeptide comprises the amino acid sequence AVCTAAQIS (SEQ ID NO: 129). As another example, in some cases, amino acids 135-143 of the MHC class I heavy chain of a pMHC polypeptide comprises the amino acid sequence AVDCAAQIS (SEQ ID NO: 130). As another example, in some cases, amino acids 135-143 of the MHC class I heavy chain of a pMHC polypeptide comprises the amino acid sequence AVDTCAQIS (SEQ ID NO: 131). As another example, in some cases, amino acids 135-143 of the MHC class I heavy chain of a pMHC polypeptide comprises the amino acid sequence AVDTACQIS (SEQ ID NO: 132). As another example, in some cases, amino acids 135-143 of the MHC class I heavy chain of a pMHC polypeptide comprises the amino acid sequence AVDTAACIS (SEQ ID NO: 133). As another example, in some cases, amino acids 135-143 of the MHC class I heavy chain of a pMHC polypeptide comprises the amino acid sequence AVDTAAQCS (SEQ ID NO: 134). As another example, in some cases, amino acids 135-143 of the MHC class I heavy chain of a pMHC polypeptide comprises the amino acid sequence AVDTAAQIC (SEQ ID NO: 135).
[0114] In some cases, the MHC class I heavy chain polypeptide in a pMHC polypeptide comprises an amino acid sequence having at least 85%. at least 90%, at least 95%, at least 97%, at least 98%. or at least 99%, amino acid sequence identity to any one of the HLA-A amino acid sequences depicted in FIGS. 8C-8D, where either (i) amino acid 84 is Cys, and where amino acid 139 is other than a Cys, or (ii) amino acid 139 is Cys, and amino acid 84 is otherthan a Cys (e.g., where amino acid 84 is Ala, Gly, or Vai). In some cases, the MHC class I heavy chain polypeptide in a pMHC polypeptide comprises an amino acid sequence having at least 85%, at least 90%, at least 95%, at least 97%, at least 98%. or at least 99%, amino acid sequence identity to any one of the HLA-A amino acid sequences depicted in FIG.8C-8D, where either (i) amino acid 84 is Cys and amino acid 139 is otherthan a Cys, or (ii) amino acid 139 is Cys and amino acid 84 is otherthan a Cys (e g., where amino acid 84 is Tyr) such that amino acid 84 is unable to form a disulfide bond with the Cys in the linker that is interposed between the peptide epitope and the P2M polypeptide. In some cases, the MHC class I heavy chain polypeptide in a pMHC polypeptide comprises an amino acid sequence having at least 85%, at least 90%, at least 95%, at least 97%, at least 98%, or at least 99%, amino acid sequence identity to any one of the HLA-A amino acid sequences depicted in FIG. 8C-8D, where either (i) amino acid 84 is Cys and amino acid 139 is other than a Cys, or (ii) amino acid 139 is Cys and amino acid 84 is Tyr, and where amino acid 236 is Ala. In some cases, the MHC class I heavy chain polypeptide in a pMHC polypeptide comprises an amino acid sequence having at least 85%, at least 90%, at least 95%, at least 97%, at least 98%, or at least 99%, amino acid sequence identity to any one of the HLA-A amino acid sequences depicted in FIG. 8C-8D, where either (i) amino acid 84 is Cys and amino acid 139 is otherthan a Cys, or (ii) amino acid 139 is Cys and amino acid 84 is Tyr, and where amino acid 236 is Cys. In some cases, the MHC class I heavy chain polypeptide in a pMHC polypeptide comprises an amino acid sequence having at least 85%, at least 90%, at least 95%, at least 97%, at least 98%, or at least 99%, amino acid sequence identity to any¬ one of the HLA-A amino acid sequences depicted in FIG. 8C-8D, where either (i) amino acid 84 is Cys and amino acid 139 is other than a Cys, or (ii) amino acid 139 is Cys, where amino acid 84 is Ala, and where amino acid 236 is Ala. In some cases, the MHC class I heavy chain polypeptide in a pMHC polypeptide comprises an amino acid sequence having at least 85%, at least 90%, at least 95%, at least 97%, at least 98%, or at least 99%, amino acid sequence identity to any? one of the HLA-A amino acid sequences depicted in FIG. 8C-8D, where amino acid 139 is Cys, where amino acid 84 is Ala, and where amino acid 236 is Cys. In some cases, the MHC class I heavy chain polypeptide in a pMHC polypeptide comprises an amino acid having at least 85%. at least 90%, at least 95%, at least 97%, at least 98%. at least 99%, or 100%, amino acid sequence identity to any one of the HLA-A amino acid sequence depicted in FIG. 7B-7E, FIG. 8B-8E, FIG. 9B-9E, FIG. 10B-10E, and FIG. 1 IB-1 IE.
[0115] In some cases, the MHC class I heavy chain polypeptide in a pMHC polypeptide comprises an amino acid sequence having at least 85%, at least 90%, at least 95%, at least 97%, at least 98%, or at least 99%, amino acid sequence identity to any one of the HLA-B amino acid sequences depicted in FIGS. 13C-13D, where either (i) amino acid 84 is Cys and amino acid 139 is other than a Cys, or (ii) amino acid 139 is Cys and amino acid 84 is other than a Cys (e.g., where amino acid 84 is Ala, Gly, or Vai). In some cases, the MHC class I heavy chain polypeptide in a pMHC polypeptide comprises an amino acid sequence having at least 85%, at least 90%, at least 95%, at least 97%, at least 98%, or at least 99%, amino acid sequence identity to any one of the HLA-B amino acid sequences depicted in FIGS. 13C-13D, where either (i) amino acid 84 is Cys and amino acid 139 is other than a Cys, or (ii) amino acid 139 is Cys and amino acid 84 is other than a Cys (e.g., where amino acid 84 is Tyr. In some cases, the MHC class I heavy chain polypeptide in a pMHC polypeptide comprises an amino acid sequence having at least 85%, at least 90%, at least 95%, at least 97%, at least 98%, or at least 99%, amino acid sequence identity to any one of the HLA-B amino acid sequences depicted in FIGS. 13C-13D, where either (i) amino acid 84 is Cys and amino acid 139 is other than a Cys, or (ii) amino acid 139 is Cys and amino acid 84 is Tyr, and where amino acid 236 is Ala. In some cases, the MHC class I heavy chain polypeptide in a pMHC polypeptide comprises an amino acid sequence having at least 85%, at least 90%, at least 95%, at least 97%, at least 98%, or at least 99%, amino acid sequence identity to any one of the HLA-B amino acid sequences depicted in FIGS. 13C-13D, where either (i) amino acid 84 is Cys and amino acid 139 is other than a Cys, or (ii) amino acid 139 is Cys and amino acid 84 is Tyr, and where amino acid 236 is Cys. In some cases, the MHC class I heavy chain polypeptide in a pMHC polypeptide comprises an amino acid sequence having at least 85%, at least 90%, at least 95%, at least 97%, at least 98%, or at least 99%, amino acid sequence identity to any one of the HLA-B amino acid sequences depicted in FIGS. 13C-13D, where either (i) amino acid 84 is Cys and amino acid 139 is other than a Cys, or (ii) amino acid 139 is Cys and amino acid 84 is Ala, and where amino acid 236 is Ala. In some cases, the MHC class I heavy chain polypeptide in a pMHC polypeptide comprises an amino acid sequence having at least 85%, at least 90%, at least 95%, at least 97%, at least 98%, or at least 99%, amino acid sequence identity to any one of the HLA-B amino acid sequences depicted in FIGS. 13C-13D, where either (i) amino acid 84 is Cys and amino acid 139 is other than a Cys, or (ii) amino acid 139 is Cys and where amino acid 84 is Ala, and where amino acid 236 is Cys.
[0116] In some cases, the MHC class I heavy chain polypeptide in a pMHC polypeptide comprises an amino acid sequence having at least 85%, at least 90%, at least 95%, at least 97%, at least 98%, or at least 99%, amino acid sequence identity to any one of the HLA-C amino acid sequences depicted in FIGS. 14C-14D, where either (i) amino acid 84 is Cys and amino acid 139 is other than a Cys, or (ii) amino acid 139 is Cys and amino acid 84 is other than a Cys (e.g., where amino acid 84 is Ala, Gly, or Vai). In some cases, the MHC class I heavy chain polypeptide in a pMHC polypeptide comprises anamino acid sequence having at least 85%, at least 90%, at least 95%, at least 97%, at least 98%, or at least 99%, amino acid sequence identity to any one of the HLA-C amino acid sequences depicted in FIGS. 14C-14D, where either (i) amino acid 84 is Cys and amino acid 139 is other than a Cys, or (ii) amino acid 139 is Cys and amino acid 84 is other than a Cys (e.g., where amino acid 84 is Tyr. In some cases, the MHC class I heavy chain polypeptide in a pMHC polypeptide comprises an amino acid sequence having at least 85%, at least 90%, at least 95%, at least 97%, at least 98%, or at least 99%, amino acid sequence identity to any one of the HLA-C amino acid sequences depicted in FIGS. 14C-14D, where either (i) amino acid 84 is Cys and amino acid 139 is other than a Cys, or (ii) amino acid 139 is Cys and amino acid 84 is Tyr, and where amino acid 236 is Ala. In some cases, the MHC class I heavy chain polypeptide in a pMHC polypeptide comprises an amino acid sequence having at least 85%, at least 90%, at least 95%. at least 97%, at least 98%, or at least 99%, amino acid sequence identity to any one of the HLA-C amino acid sequences depicted in FIGS. 14C-14D, where either (i) amino acid 84 is Cys and amino acid 139 is other than a Cys, or (ii) amino acid 139 is Cys and amino acid 84 is Tyr, and where amino acid 236 is Cys. In some cases, the MHC class I heavy chain polypeptide in a pMHC polypeptide comprises an amino acid sequence having at least 85%, at least 90%, at least 95%, at least 97%, at least 98%, or at least 99%, amino acid sequence identity to any one of the HLA-C amino acid sequences depicted in FIGS. 14C-I4D, where either (i) amino acid 84 is Cys and amino acid 139 is other than a Cys, or (ii) amino acid 139 is Cys and amino acid 84 is Ala, and where amino acid 236 is Ala. In some cases, the MHC class I heavy chain polypeptide in a pMHC polypeptide comprises an amino acid sequence having at least 85%, at least 90%, at least 95%, at least 97%, at least 98%, or at least 99%, amino acid sequence identity to any one of the HLA-C amino acid sequences depicted in FIGS. 14C-14D, where either (i) amino acid 84 is Cys and amino acid 139 is other than a Cys, or (ii) amino acid 139 is Cys and amino acid 84 is Ala, and where amino acid 236 is Cys.
[0117] In some cases, the MHC class I heavy chain polypeptide in a pMHC polypeptide comprises an amino acid sequence having at least 85%, at least 90%, at least 95%, at least 97%, at least 98%, at least 99%, or 100%, amino acid sequence identity to any one of the HLA-E amino acid sequences depicted in FIGS. 15B-15E and 16B-16E, where either (i) amino acid 84 is Cys and amino acid 139 is other than a Cys, or (ii) amino acid 139 is Cys and amino acid 84 is other than a Cys (e.g.. where amino acid 84 is Ala, Gly, or Vai). In some cases, the MHC class I heavy chain polypeptide in a pMHC polypeptide comprises an amino acid sequence having at least 85%, at least 90%, at least 95%, at least 97%, at least 98%, at least 99%, or 100%, amino acid sequence identity to any one of the HLA-E amino acid sequences depicted in FIGS. 15B-15E and 16B-16E, where either (i) amino acid 84 is Cys and amino acid 139 is other than a Cys, or (ii) amino acid 139 is Cys and where amino acid 84 is other than a Cys (e.g., where amino acid 84 is Tyr. In some cases, the MHC class I heavy chain polypeptide in a pMHC polypeptide comprises an amino acid sequence having at least 85%, at least 90%, at least 95%, at least97%, at least 98%, at least 99%, or 100%, amino acid sequence identity to any one of the HLA-E amino acid sequences depicted in FIGS. 15B-15E and 16B-16E, where either (i) amino acid 84 is Cys and amino acid 139 is other than a Cys, or (ii) amino acid 139 is Cys and amino acid 84 is Tyr, and where amino acid 236 is Ala. In some cases, the MHC class I heavy chain polypeptide in a pMHC polypeptide comprises an amino acid sequence having at least 85%. at least 90%, at least 95%, at least 97%, at least 98%, at least 99%, or 100%, amino acid sequence identity to any one of the HLA-E amino acid sequences depicted in FIGS. 15B-15E and 16B-16E, where either (i) amino acid 84 is Cys and amino acid 139 is other than a Cys, or (ii) amino acid 139 is Cys and amino acid 84 is Tyr, and where amino acid 236 is Cys. In some cases, the MHC class I heavy chain polypeptide in a pMHC polypeptide comprises an amino acid sequence having at least 85%, at least 90%, at least 95%, at least 97%, at least 98%, at least 99%, or 100%, amino acid sequence identity to any one of the HLA-E amino acid sequences depicted in FIGS. 15B-15E and 16B-16E, where either (i) amino acid 84 is Cys and amino acid 139 is other than a Cys, or (ii) amino acid 139 is Cys and amino acid 84 is Ala, and where amino acid 236 is Ala. In some cases, the MHC class I heavy chain polypeptide in a pMHC polypeptide comprises an amino acid having at least 85%, at least 90%, at least 95%, at least 97%, at least 98%, at least 99%, or 100%, amino acid sequence identity to any one of the HLA-E amino acid sequences depicted in FIGS. 15B-15E and 16B-16E, where either (i) amino acid 84 is Cys and amino acid 139 is other than a Cys, or (ii) amino acid 139 is Cys and amino acid 84 is Ala, and where amino acid 236 is Cys.
[0118] In some cases, the TEP comprises an MHC class I HLA-A allele heavy chain. In some cases, the MHC class I heavy chain polypeptide comprises an amino acid sequence having at least 80%. at least 85%, at least 90%, at least 95%, at least 98%. at least 99%, or 100%, amino acid sequence identity to the following HLA-A heavy chain amino acid sequence:
[0119] GSHSMRYFFTSVSRPGRGEPRFIAVGYVDDTQFVRFDSDAASQRMEPRAPWIEQEGPE YWDGETRKVKAHSQTHRVDLGTLRGYYNQSEAGSHTVQRMYGCDVGSDWRFLRGYHQYAY DGKDYIALKEDLRSWTAADMAAQTTKHKWEAAHVAEQLRAYLEGTCVEWLRRYLENGKETL QRTDAPKTHMTHHAVSDHEATLRCWALSFYPAEITLTWQRDGEDQTQDTELVETRPAGDGTFQ KWAAVVVPSGQEQRYTCHVQHEGLPKPLTLRWE (SEQ ID NO: 136).
[0120] In some cases, the MHC class I heavy chain polypeptide comprises an Ala at position 84 and a Cys at position 236. Thus, c.g., in some cases, the MHC class I heavy chain polypeptide comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 98%. at least 99%, or 100%, amino acid sequence identity to the following HLA-A heavy chain amino acid sequence:
[0121] GSHSMRYFFTSVSRPGRGEPRFIAVGYVDDTQFVRFDSDAASQRMEPRAPWIEQEGPE YWDGETRKVKAHSQTHRVDLGTLRGAYNQSEAGSHTVQRMYGCDVGSDWRFLRGYHQYAY DGKDYIALKEDLRSWTAADMAAQTTKHKWEAAHVAEQLRAYLEGTCVEWLRRYLENGKETLQRTDAPKTHMTHHAVSDHEATLRCWALSFYPAEITLTWQRDGEDQTQDTELVETRPCGDGTFQ KWAAVVVPSGQEQRYTCHVQHEGLPKPLTLRWE (SEQ ID NO: 137), where amino acid 84 is an Ala and amino acid 236 is a Cys.
[0122] In some cases, the MHC class I heavy chain polypeptide comprises a Cys at position 84 and a Cys at position 236. Thus, e.g., in some cases, the MHC class I heavy chain polypeptide comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100%, amino acid sequence identity to the following HLA-A heavy chain amino acid sequence:
[0123] GSHSMRYFFTSVSRPGRGEPRFIAVGYVDDTQFVRFDSDAASQRMEPRAPWIEQEGPE YWDGETRKVKAHSQTHRVDLGTLRGCYNQSEAGSHTVQRMYGCDVGSDWRFLRGYHQYAY DGKDYIALKEDLRSWTAADMAAQTTKHKWEAAHVAEQLRAYLEGTCVEWLRRYLENGKETL QRTDAPKTHMTHHAVSDHEATLRCWALSFYPAEITLTWQRDGEDQTQDTELVETRPCGDGTFQ KWAAVVVPSGQEQRYTCHVQHEGLPKPLTLRWE (SEQ ID NO: 138), where amino acid 84 is a Cys and amino acid 236 is a Cys.
[0124] In some cases, the MHC class I heavy chain polypeptide comprises an Ala at position 84. a Cys at any one of positions 135-143 (e.g., at position 139), and a Cys at position 236. Thus, e.g., in some cases, the MHC class I heavy chain polypeptide comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100%, amino acid sequence identity to the following HLA-A heavy chain amino acid sequence:
[0125] GSHSMRYFFTSVSRPGRGEPRFIAVGYVDDTQFVRFDSDAASQRMEPRAPWIEQEGPE YWDGETRKVKAHSQTHRVDLGTLRGAYNQSEAGSHTVQRMYGCDVGSDWRFLRGYHQYAY DGKDYIALKEDLRSWTAADMCAQTTKHKWEAAHVAEQLRAYLEGTCVEWLRRYLENGKETL QRTDAPKTHMTHHAVSDHEATLRCWALSFYPAEITLTWQRDGEDQTQDTELVETRPCGDGTFQ KWAAVVVPSGQEQRYTCHVQHEGLPKPLTLRWE (SEQ ID NO: 139), where amino acid 84 is an Ala, amino acid 139 is a Cys, and amino acid 236 is a Cys.PEPTIDE EPITOPES
[0126] As noted above a peptide epitope is a peptide that can be presented by the MHC polypeptides (in one of the manners described above), such that the pMHC presents an epitope that can be specifically recognized and bound by a TCR of a target T-cell.
[0127] A peptide epitope present in a pMHC polypeptide can have a length of at least 4 amino acids, e.g., from 4-25 aa (e.g., 4 amino acids (aa), 5 aa, 6 aa, 7 aa, 8 aa, 9 aa, 10 aa, 11 aa, 12 aa, 13 aa, 14 aa, 15 aa, 16 aa, 17 aa, 18 aa, 19 aa or 20 aa), including a range of from 6-15 aa, 8-12 aa, 8-16 aa, 8-10 aa, 9-11 aa. 5-10 aa, 10-15 aa, 15-20 and 20-25 aa in length. In some cases, the peptide epitope is 8, 9. 10, 11 or 12 amino acids in length.
[0128] Suitable epitopes presented by a pMHC include, but are not limited to, epitopes present in an infectious disease agent, e.g., a viral infectious disease agent or other infectious agent such as a bacteria or other pathogen. Alternatively, a pMHC may present an epitope to any other antigen that are found in a human, e.g.. a cancer antigen (e.g., a melanoma-associated or MAGE antigen), or may be induced in a human through vaccination. In some embodiments, the epitope will be one for which a patient has or is likely to have a preexisting T-cell repertoire due to a prior infection and / or vaccination.
[0129] Examples of viral infectious disease agents include, e.g., Adenoviruses, Adeno-associated virus, Alphaviruses (Togaviruses), Eastern equine encephalitis virus, Eastern equine encephalomyelitis virus, Venezuelan equine encephalomyelitis vaccine strain TC-83, Western equine encephalomyelitis virus. Arenaviruses. Lymphocytic choriomeningitis virus (non-neurotropic strains), Tacaribe virus complex, Bunyaviruses, Bunyamwera virus. Rift Valley fever virus vaccine strain MP- 12, Chikungunya virus, Calciviruses, Coronaviruses, Cowpox virus, Flaviviruses (Togaviruses), Group B Arboviruses, Dengue virus serotypes 1, 2, 3, and 4, Yellow fever virus vaccine strain 17D, Hepatitis A, B, C, D, and E viruses, the Cytomegalovirus, Epstein Barr virus (EBV), Eastern Equine encephalitis virus, Herpes simplex types 1 and 2, Herpes zoster, Human herpesvirus types 6 and 7, hepatitis C virus (HVC). hepatitis B virus (HBV), Influenza viruses types A, B, and C, Papovaviruses, Newcastle disease virus, Measles virus. Mumps virus, Parainfluenza viruses types 1, 2, 3, and 4, polyomaviruses (JC virus, BK virus), Respiratory syncytial virus, Human parvovirus (B 19), Coxsackie viruses types A and B, Echoviruscs, Polioviruses, Rbinoviruscs. Alastrim (Variola minor virus), Smallpox (Variola major virus), Whitepox Reoviruses, Coltivirus, human Rotavirus, and Orbivirus (Colorado tick fever virus), Rabies virus, Vesicular stomatitis virus, measles, virus, Rubivirus (rubella). Semliki Forest virus, St. Louis encephalitis virus, Venezuelan equine encephalitis virus, Venezuelan equine encephalomyelitis vims, Arenaviruses (a.k.a. South American Hemorrhagic Fever vims), Flexal, Lymphocytic choriomeningitis vims (LCM) (neurotropic strains), Hantaviruses including Hantaan vims, Rift Valley fever vims, Japanese encephalitis vims, Yellow fever vims, Monkeypox vims, Human immunodeficiency vims (HIV) types 1 and 2, Human T-cell lymphotropic vims (HTLV) types 1 and 2, Simian immunodeficiency vims (SIV), Vesicular stomatitis vims, Guanarito vims, Lassa fever vims, Junin vims, Machupo vims, Sabia, Crimean-Congo hemorrhagic fever vims, Ebola viruses, Marburg vims, Tick-borne encephalitis vims complex (flavi) including Central European tick-home encephalitis. Far Eastern tick-borne encephalitis, Hanzalova, Hypr, Kumlinge, Kyasanur Forest disease, Omsk hemorrhagic fever, and Russian Spring Summer encephalitis vimses, Herpesvirus simiae (Herpes B or Monkey B vims), Cercopithecine herpesvirus 1 (Herpes B vims), Equine morbillivims (Hendra and Hendra-like vimses), Nipah vims, Variola major vims (Smallpox vims), Variola minor vims (Alastrim), African swine fever vims, African horse sickness vims, Akabane vims, Avian influenza vims (highly pathogenic), Blue tongue vims, Camel pox vims, Classical swine fever vims, Cowdria ruminantium(heartwater), Foot and mouth disease virus, Goat pox virus, Japanese encephalitis virus, Lumpy skin disease virus, Malignant catarrhal fever virus, Menangle virus, Newcastle disease virus (VVND), Vesicular stomatitis virus (exotic), and Zika virus. Antigens encoded by such viruses are known in the art; a peptide epitope suitable for use in a TEP of the present disclosure can include a peptide from any known viral antigen.
[0130] Examples of bacterial infectious disease agents include, e.g., Clostridium tetani (responsible for tetanus), corynebacterium diphtherias (responsible for diphtheria), bordetella pertussis (responsible for whooping cough), streptococcus pneumoniae (responsible for pneumonia, meningitis, and other serious illnesses), mycobacterium tuberculosis (responsible for TB), pneumococcal bacteria, Neisseria meningitidis (responsible for meningococcal infections), Haemophilus influenzae type b (Hib) (responsible for meningitis and pneumonia), Vibrio cholerae (responsible for cholera), and anthrax. Notably, vaccines are commonly available for many of these agents, and thus patients already may have received such vaccines and thus have a pre-existing repertoire of T-cells that will recognize a pMHC that presents an epitope of the virus. Alternatively, as discussed below, patients can be given such vaccines prior to treatment with a TEP.
[0131] In some cases, an epitope presented by a pMHC is an epitope present in an antigen encoded by a virus or bacteria that infects a majority of the human population and / or for which a majority of the humans have been vaccinated or can be vaccinated. Exemplary viruses include, e.g., flu, measles, cytomegalovirus (CMV), Epstein-Barr virus (EBV), HPV, tetanus, bordetella pertussis, adenovirus, coronaviruses such as the SARS-CoV-2, smallpox, yellow fever, and the like. Exemplary bacterial agents for which vaccines are widely administered include, e.g., Clostridium tetani (responsible for tetanus), corynebacterium diphtherias (responsible for diphtheria), bordetella pertussis (responsible for whooping cough), and Haemophilus influenzae type b (Hib) (responsible for meningitis and pneumonia). Vaccines are commonly available for many of these viral and bacterial agents and are known to elicit a strong immunodominant response, and thus patients already may have received such vaccines and have a pre-existing repertoire of T-cells that will recognize a pMHC that presents an epitope of the virus or bacteria. Alternatively, as discussed below, patients can be given such vaccines prior to treatment with a TEP.
[0132] In some cases, the epitope presented by a pMHC of a TEP is an epitope specific to an HLA-A, -B, -C, -E, -F, or -G allele. In an embodiment, the epitope peptide present in a TEP presents an epitope restricted to HLA-A*0101, A*0201, A*0301, A* 1101, A*2301, A*2402, A*2407, A*3303, and / or A* 3401. In an embodiment, the epitope peptide present in a TEP presents an epitope restricted to HLA-B*0702, B*0801, B* 1502, B*3802, B*4001, B*4601, and / or B*5301. In an embodiment, the epitope peptide present in a TEP presents an epitope restricted to HLA-C*0102, C*0303, C*0304, C*0401, C*0602, C*0701, C*702, C*0801, and / or C* 1502. In an embodiment, the epitope peptide present in aTEP presents an epitope restricted to HLA-E, e.g., highly prevalent HLA-E alleles such as HLA-E*0101 and HLA-E* 01.03. A few exemplary peptide epitopes are discussed below.A. CMV Peptide Epitopes
[0133] In some cases, a TEP of the present disclosure comprises a CMV peptide epitope, i.e., a peptide that when in an MHC / peptide complex (e g., an HLA / peptide complex), presents a CMV epitope (i.e., an epitope present in a CMV antigen) to a T-cell. As with other peptide epitopes of this disclosure, a CMV peptide epitope has a length of at least 4 amino acids, e.g., from 4 amino acids to about 25 amino acids (e.g., 4 amino acids (aa), 5 aa, 6 aa, 7 aa, 8 aa, 9 aa, 10 aa, 11 aa, 12 aa, 13 aa, 14 aa, 15 aa, 16 aa, 17 aa, 18 aa, 19 aa, 20 aa, 21 aa, 22 aa, 23 aa, 24 aa, or 25 aa, including within a range of from 4 to 20 aa., from 6 to 18 aa., from 8 to 15 aa. from 8 to 12 aa., from 5 to 10 aa., from 10 to 15 aa., from 15 to 20 aa., from 10 to 20 aa., or from 15 to 25 aa. in length).
[0134] A given CMV epitope-specific T-cell binds an epitope having a reference amino acid sequence of a given CMV epitope but does not substantially bind an epitope that differs from the reference amino acid sequence. For example, a given CMV epitope -specific T-cell binds a CMV epitope having a reference amino acid sequence, and binds an epitope that differs from the reference amino acid sequence, if at all, with an affinity that is less than 10 ° M, less than 10’5M, or less than 10’4M. A given CMV epitope -specific T-cell can bind an epitope for which it is specific with an affinity of at least 10'7M, at least 10'8M, at least 10‘9M, or at least 1010M.
[0135] In some cases, a CMV peptide epitope present in a TEP of the present disclosure is a peptide from CMV pp65. In some cases, a CMV peptide epitope present in a TEP of the present disclosure is a peptide from CMV gB (glycoprotein B).
[0136] For example, in some cases, a CMV peptide epitope present in a TEP of the present disclosure is a peptide of a CMV polypeptide having a length of at least 4 amino acids, e.g., from 4 amino acids to about 25 amino acids (e.g., 4 amino acids (aa), 5 aa, 6 aa, 7 aa, 8 aa, 9 aa, 10 aa, 11 aa, 12 aa, 13 aa, 14 aa, 15 aa, 16 aa, 17 aa, 18 aa, 19 aa, 20 aa, 21 aa, 22 aa, 23 aa, 24 aa, or 25 aa, including within a range of from 4 to 20 aa., from 6 to 18 aa., from 8 to 15 aa. from 8 to 12 aa., from 5 to 10 aa., from 10 to 15 aa., from 15 to 20 aa.. from 10 to 20 aa., or from 15 to 25 aa. in length), and comprising an amino acid sequence having at least 80%, at least 85%. at least 90%, at least 95%, at least 98%, at least 99%. or 100%, amino acid sequence identity to the following CMV pp65 amino acid sequence:
[0137] MESRGRRCPE MISVLGPISG HVLKAVFSRG DTPVLPHETR LLQTGIHVRV SQPSLILVSQ YTPDSTPCHRGDNQLQVQHT YFTGSEVENV SVNVHNPTGR SICPSQEPMS IYVYALPLKM LNIPSINVHH YPSAAERKHR HLPVADAVIH ASGKQMWQAR LTVSGLAWTR QQNQWKEPDV YYTSAFVFPT KDVALRHVVC AHELVCSMEN TRATKMQVIG DQYVKVYLES FCEDVPSGKL FMHVTLGSDV EEDLTMTRNP QPFMRPHERN GFTVLCPKNM IIKPGKISHIMLDVAFTSHE HFGLLCPKSI PGLSISGNLL MNGQQIFLEV QAIRETVELR QYDPVAALFF FDIDLLLQRG PQYSEHPTFT SQYRIQGKLE YRHTWDRHDE GAAQGDDDVW TSGSDSDEEL VTTERKTPRV TGGGAMAGAS TSAGRKRKSA SSATACTSGV MTRGRLKAES TVAPEEDTDE DSDNEIHNPA VFTWPPWQAG ILARNLVPMV ATVQGQNLKY QEFFWDANDI YRIFAELEGV WQPAAQPKRR RHRQDALPGP CIASTPKKHR G (SEQ ID NO: 140).
[0138] As one non-limiting example, a CMV peptide epitope present in a TEP of the present disclosure has the amino acid sequence NLVPMVATV (SEQ ID NO: 141) and has a length of 9 amino acids.
[0139] In some cases, a CMV peptide epitope present in a TEP of the present disclosure is a peptide having a length of at least 4 amino acids, e.g., from 4 amino acids to about 25 amino acids (e.g., 4 amino acids (aa), 5 aa, 6 aa, 7 aa, 8 aa, 9 aa, 10 aa, 11 aa, 12 aa, 13 aa, 14 aa, 15 aa, 16 aa, 17 aa, 18 aa, 19 aa, 20 aa, 21 aa, 22 aa, 23 aa, 24 aa, or 25 aa, including within a range of from 4 to 20 aa., from 6 to 18 aa., from 8 to 15 aa. from 8 to 12 aa., from 5 to 10 aa., from 10 to 15 aa., from 15 to 20 aa., from 10 to 20 aa., or from 15 to 25 aa. in length) of a CMV polypeptide comprising an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%. at least 98%, at least 99%, or 100%, amino acid sequence identity to the following CMV gB amino acid sequence:
[0140] MESRIWCLVVCVNLCIVCLGAAVSSSSTSHATSSTHNGSHTSRTTSAQTRSVYSQHVT SSEAVSHRANETIYNTTLKYGDVVGVNTTKYPYRVCSMAQGTDLIRFERNIICTSMKPINEDLDE GIMVVYKRNIVAHTFKVRVYQKVLTFRRSYAYIYTTYLLGSNTEYVAPPMWEIHHINKFAQCYS SYSRVIGGTVFVAYHRDSYENKTMQLIPDDYSNTHSTRYVTVKDQWHSRGSTWLYRETCNLNC MLTITTARSKYPYHFFATSTGDVVYISPFYNGTNRNASYFGENADKFFIFPNYTIVSDFGRPNAAP ETHRLVAFLERADSVISWDIQDEKNVTCQLTFWEASERTIRSEAEDSYHFSSAKMTATFLSKKQE VNMSDSALDCVRDEAINKLQQIFNTSYNQTYEKYGNVSVFETSGGLVVFWQGIKQKSLVELER LANRSSLNITHRTRRSTSDNNTTHLSSMESVHNLVYAQLQFTYDTLRGYINRALAQIAEAWCVD QRRTLEVFKELSKINPSAILSAIYNKPIAARFMGDVLGLASCVTINQTSVKVLRDMNVKESPGRC YSRPVVIFNFANSSYVQYGQLGEDNEILLGNHRTEECQLPSLKIFIAGNSAYEYVDYLFKRMIDL SS1STVDSMIALDIDPLENTDFRVLELYSQKELRSSNVFDLEE1MREFNSYKQRVKYVEDKVVDP LPPYLKGLDDLMSGLGAAGKAVGVAIGAVGGAVASVVEGVATFLKNPFGAFTIILVAIAVVIIT YLIYTRQRRLCTQPLQNLFPYLVSADGTTVTSGSTKDTSLQAPPSYEESVYNSGRKGPGPPSSDA STAAPPYTNEQAYQMLLALARLDAEQRAQQNGTDSLDGQTGTQDKGQKPNLLDRLRHRKNGY RHLKDSDEEENV (SEQ ID NO: 142).
[0141] In some cases, the CMV epitope present in a TEP of the present disclosure presents an epitope specific to an HLA-A, -B, -C, -E, -F, or -G allele. In some cases, the epitope peptide present in a TEP presents an epitope restricted to HLA-A*0101, A*0201, A*0301, A* 1101, A*2301, A*2402, A*2407, A*3303, and / or A*3401. In some cases, the CMV epitope present in a TEP of the present disclosurepresents an epitope restricted to HLA- B*0702, B*0801, B* 1502, B*3802, B*4001, B*4601, and / or B*5301. In some cases, the CMV epitope present in a TEP of the present disclosure presents an epitope restricted to C*0102, C*0303, C*0304, C*0401, C*0602, C*0701, C*702, C*0801, and / or C* 1502. As one example, in some cases, a TEP of the present disclosure comprises: a) a CMV peptide epitope having amino acid sequence NLVPMVATV (SEQ ID NO: 141) and having a length of 9 amino acids; b) an HLA-A*0201 class I heavy chain polypeptide; and c) a P2M polypeptide.
[0142] In some cases, a TEP of the present disclosure comprises, as the TC, a peptide or an scFv or a nanobody specific for IL5R and comprises as tire peptide epitope a CMV peptide epitope. In some cases, the CMV peptide epitope is a peptide of a CMV pp65 polypeptide. In some cases, the CMV peptide epitope is a peptide of a CMV gB polypeptide. In some cases, the CMV peptide epitope has the amino acid sequence NLVPMVATV (SEQ ID NO: 141) and has a length of 9 amino acids.
[0143] In some cases, a TEP of the present disclosure comprises, as the TC, a peptide or an scFv or a nanobody specific for IL5R and comprises, as the peptide epitope a CMV peptide epitope. In some cases, the CMV peptide epitope is a peptide of a CMV pp65 polypeptide. In some cases, the CMV peptide epitope is a peptide of a CMV gB polypeptide. In some cases, the CMV peptide epitope has the amino acid sequence NLVPMVATV (SEQ ID NO: 141) and has a length of 9 amino acids.
[0144] In some cases, a TEP of the present disclosure is a dual-targeting TEP that comprises two different TCs, e.g., two different IL5R binders, e.g., two different scFvs or nanobodies specific for IL5R, including for different epitopes of IL5R, or a peptide and an scFv that bind to IL5R, and comprises, as the peptide epitope a CMV peptide epitope. In some cases, the CMV peptide epitope is a peptide of a CMV pp65 polypeptide. In some cases, the CMV peptide epitope is a peptide of a CMV gB polypeptide. In some cases, the CMV peptide epitope has the amino acid sequence NLVPMVATV (SEQ ID NO: 141) and has a length of 9 amino acids.
[0145] In some cases, a TEP of the present disclosure comprises, as the TC, a peptide or an scFv or a nanobody specific for IL5R, and comprises, as the peptide epitope a CMV peptide epitope. In some cases, the CMV peptide epitope is a peptide of a CMV pp65 polypeptide. In some cases, the CMV peptide epitope is a peptide of a CMV gB polypeptide. In some cases, the CMV peptide epitope has the amino acid sequence NLVPMVATV (SEQ ID NO: 141) and has a length of 9 amino acids.
[0146] In some cases, the CMV peptide epitope can be TPRVTGGGAM (SEQ ID NO: 439). In some cases, the CMV peptide epitope can be VTEHDTLLY (SEQ ID NO: 440).B. SARS-CoV-2 Peptide Epitopes
[0147] In some cases, a TEP can comprise a peptide epitope of a Betacoronavirus (e.g., SARS-CoV-2). Such peptide epitopes are typically at least about 4 amino acids in length and present a SARS-CoV-2 epitope to a T-cell when in an MHC / peptide complex (e.g., an HLA / peptide complex).
[0148] A SARS-CoV-2 peptide epitope present in a TEP can have a length of at least 4 amino acids, c.g., from 4 amino acids to about 25 amino acids in length (c.g., 4 amino acids (aa), 5 aa, 6 aa, 7 aa, 8 aa, 9 aa, 10 aa, 11 aa, 12 aa, 13 aa, 14 aa, 15 aa, 16 aa, 17 aa, 18 aa, 19 aa, 20 aa, 21 aa, 22 aa, 23 aa, 24 aa, or 25 aa, including within a range of from 4 to 20 amino acids, from 6 to 18 amino acids, from 8 to 15 amino acids, from 8 to 12 amino acids, from 9-11 amino acids, from 9-10 amino acids, from 5 to 10 amino acids, from 10-15 amino acids, from 10 to 20 amino acids, and from 15 to 25 amino acids in length), for example, lengths of 9, 10, 11, 12, 13 or 14 amino acids.
[0149] A SARS-CoV-2 peptide epitope present in a TEP is a peptide specifically bound by a T-cell, i.e., the epitope is specifically bound by an epitope-specific T-cell. An epitope -specific T-cell binds an epitope having a reference amino acid sequence but does not substantially bind an epitope that differs from the reference amino acid sequence. For example, an epitope-specific T-cell binds an epitope having a reference amino acid sequence, and binds an epitope that differs from the reference amino acid sequence, if at all, with an affinity that is less than 10'6M, less than 10-5M, or less than 10-4M. An epitope -specific T-cell can bind an epitope for which it is specific with an affinity of at least 10'7M, at least 10'8M, at least 10‘9M. or at least IO10M.
[0150] In certain embodiments, the peptide epitope present in a TEP is a peptide of a Betacoranrmzra.’-encoded polypeptide. In some cases, the peptide epitope is a SARS-CoV-2 peptide (i.e., a peptide of a SARS-CoV-2 -encoded polypeptide). In some cases, the peptide epitope is a SARS-CoV-2 peptide from a SARS-CoV-2 -encoded surface glycoprotein. In some cases, the peptide epitope is a SARS-CoV-2 peptide from a SARS-CoV-2 -encoded membrane glycoprotein. In some cases, the peptide epitope is a SARS-CoV-2 peptide from a SARS-CoV-2 -encoded nucleocapsid phosphoprotein.
[0151] In some cases, a peptide present in a TEP is a SARS-CoV-2 peptide from a SARS-CoV-2 -encoded surface glycoprotein. Examples of such peptide epitopes are: NLTTRTQL (SEQ ID NO: 143), LPPAYTNSF (SEQ ID NO: 144), KVFRSSVLH (SEQ ID NO: 145), LPFFSNVTW (SEQ ID NO: 146), PFFSNVTWF (SEQ ID NO: 147), RFDNPVLPF (SEQ ID NO: 148), LPFNDGVYF (SEQ ID NO: 149), GVYFASTEK (SEQ ID NO: 150), TEKSNIIRGW (SEQ ID NO: 151), TLDSKTQSL (SEQ ID NO: 152), GVYYHKNNK (SEQ ID NO: 153), YYHKNNKSW (SEQ ID NO: 154), VYSSANNCTF (SEQ ID NO: 155), FEYVSQPFL (SEQ ID NO: 156), EYVSQPFLM (SEQ ID NO: 157), FVFKNIDGY (SEQ ID NO: 158), TPINLVRDL (SEQ ID NO: 159), LPQGFSAL (SEQ ID NO: 160), LPIGINITRF (SEQ ID NO: 161), INITRFQTL (SEQ ID NO: 162), LLALHRSYL (SEQ ID NO: 163), WTAGAAAYY (SEQ ID NO: 164), YYVGYLQPRTF (SEQ ID NO: 165), YLQPRTFLL (SEQ ID NO: 166), YLQPRTFL (SEQ ID NO: 167), SETKCTLKSF (SEQ ID NO: 168), TLKSFTVEK (SEQ ID NO: 169), QPTESIVRF (SEQ ID NO: 170), RFPNITNLCPF (SEQ ID NO: 171), GEVFNATRF (SEQ ID NO: 172), NATRFASVY (SEQ ID NO: 173), LYNSASFSTF (SEQ ID NO: 174), NSASFSTFK (SEQ ID NO: 175), RQIAPGQTGK (SEQ ID NO: 176), KIADYNYKL (SEQ ID NO: 177), NYNYLYRLF (SEQ ID NO: 178), RLFRKSNLK(SEQ ID NO: 179), KPFERDISTEI (SEQ ID NO: 180), YFPLQSYGF (SEQ ID NO: 181), QPYRVVVL (SEQ ID NO: 182), PYRVVVLSF (SEQ ID NO: 183), GPKKSTNLV (SEQ ID NO: 184), TSNQVAVLY (SEQ ID NO: 185), VYSTGSNVF (SEQ ID NO: 186), AEHVNNSY (SEQ ID NO: 187), IPIGAGICASY (SEQ ID NO: 188), SPRRARSVA (SEQ ID NO: 189). VASQSIIAY (SEQ ID NO: 190), SIIAYTMSL (SEQ ID NO: 191), LGAENSVAY (SEQ ID NO: 192), AYSNNSIAIPTNF (SEQ ID NO: 193), IPTNFTISV (SEQ ID NO: 194), TEILPVSMTK (SEQ ID NO: 195), QEVFAQVKQIY (SEQ ID NO: 196), KQIYKTPPIK (SEQ ID NO: 197), IYKTPPIKDF (SEQ ID NO: 198), LLFNKVTLA (SEQ ID NO: 199), TLADAGFIK (SEQ ID N0:200), LADAGFIKQY (SEQ ID NO:201), ADAGFIKQY (SEQ ID NO:202), VLPPLLTDEMIAQY (SEQ ID NO:203), IPFAMQMAY (SEQ ID NO:204), SSTASALGK (SEQ ID NO:205), VLNDILSRL (SEQ ID NO:206), RLDKVEAEV (SEQ ID NO:207). VEAEVQIDRL (SEQ ID NO:208). AEVQIDRLI (SEQ ID NO:209). LITGRLQSL (SEQ ID NO:210). RLQSLQTYV (SEQ ID NO:211), AEIRASANL (SEQ ID NO:212), ASANLAATK (SEQ ID NO:213), HLMSFPQSA (SEQ ID NO:214), FPQSAPHGVVF (SEQ ID NO:215), APHGVVFL (SEQ ID NO:216), VTYVPAQEK (SEQ ID NO:217), TYVPAQEKNF (SEQ ID NO:218), REGVFVSNGTHW (SEQ ID NO:219), GTHWFVTQR (SEQ ID NO:220), TVYDPLQPELDSFK (SEQ ID NO:221).KEIDRLNEV (SEQ ID NO:222). QELGKYEQYIKW (SEQ ID NO:223), YEQYIKWPW (SEQ ID NO:224), QYIKWPWYI (SEQ ID NO:225), FIAGLIAIV (SEQ ID NO:226). and SEPVLKGVKL (SEQ ID NO:227).
[0152] In some cases, a peptide present in a TEP is a SARS-CoV-2 peptide from a SARS-CoV-2 -encoded membrane glycoprotein. Examples of such peptide epitopes are:: GTITVEELK (SEQ ID NO:228), EELKKLLEQW (SEQ ID NO:229), KLLEQWNLV (SEQ ID NO:230), FAYANRNRF (SEQ ID NO:231), YANRNRFLY (SEQ ID NO:232), SYFIASFRLF (SEQ ID NO:233), RLFARTRSM (SEQ ID NO:234), VPLHGTIL (SEQ ID NO:235), SELVIGAVIL (SEQ ID NO:236), HLRIAGHHL (SEQ ID NO:237), RIAGHHLGR (SEQ ID NO:238), KEITVATSRTL (SEQ ID NO:239), ATSRTLSYYK (SEQ ID NO:240), ASQRVAGDSGFAAY (SEQ ID NO:241), and VAGDSGFAAY (SEQ ID NO:242).
[0153] In some cases, the peptide epitope is a SARS-CoV-2 peptide from a SARS-CoV-2 -encoded nucleocapsid phosphoprotein. Examples of such peptide epitopes are: LPNNTASWF (SEQ ID NO:243). KFPRGQGVPI (SEQ ID NO:244), NTNSSPDDQIGYY (SEQ ID NO:245), SPRWYFYYL (SEQ ID NO:246), LLLDRLNQL (SEQ ID NO 247), KAYNVTQAF (SEQ ID NO 248), QELIRQGTDYKHW (SEQ ID NO:249), ASAFFGMSR (SEQ ID NO:250), SRIGMEVTPSGTW (SEQ ID NO:251), GMEVTPSGTWL (SEQ ID NO:252), TPSGTWLTY (SEQ ID NO:253), AYKTFPPTEPK (SEQ ID NO:254), and LPAADLDDF (SEQ ID NO:255).
[0154] In some cases, the peptide epitope is RLQSLQTYV (SEQ ID NO:256). In some cases, the peptide epitope is YLQPRTFLL (SEQ ID NO:257). In some cases, a TEP comprises an HLA-A*02:01 heavy chain polypeptide and comprises the peptide epitope YLQPRTFLL (SEQ ID NO:257).
[0155] In some cases, the peptide epitope is one that can be presented in a complex with a P2M polypeptide and an HLA-E polypeptide. As one non-limiting example, in some cases, the peptide epitope is a peptide of a SARS-CoV-2 Nspl3 polypeptide. In some cases, the peptide epitope is VMPLSAPTL (SEQ ID NO:258). In some cases, a TEP comprises an HLA-E heavy chain polypeptide and comprises the peptide epitope VMPLSAPTL (SEQ ID NO:258).
[0156] In some cases, a TEP of the present disclosure comprises, as the TC, a peptide or an scFv or a nanobody specific for IL5R, and comprises, as the peptide epitope a SARS-CoV-2 peptide epitope.
[0157] In some cases, a TEP of the present disclosure is a dual-targeting TEP that comprises two different TCs. e.g., two different scFvs or nanobodies specific for IL5R, including for different epitopes of IL5R, and comprises, as the peptide epitope a SARS-CoV-2 peptide epitope.
[0158] Numerous additional SARS-CoV-2 peptide epitopes are disclosed in WO 2023 / 137156 to Cue Biopharma, tire disclosure of which as it relates to SARS-CoV-2 peptide epitopes is expressly incorporated herein by reference.C. HPV Peptide Epitopes
[0159] As noted above, a TEP can comprise an HPV peptide epitope.
[0160] In some cases, an HPV peptide suitable for inclusion in a pMHC polypeptide can be a peptide of an HPV E6 polypeptide or an HPV E7 polypeptide. The HPV epitope can be an epitope of HPV of any of a variety of genotypes, including, e.g., HPV16, HPV18, HPV31, HPV33, HPV35, HPV39, HPV45. HPV51, HPV52, HPV56, HPV58, HPV59. HPV68, HPV73, or HPV82. In some cases, the peptide is an HPV E6 peptide. In some cases, the peptide is an HPV E7 peptide. An amino acid sequence of an HPV16 E6 polypeptide is SEQ ID NO:259. An amino acid sequence of an HPV16 E7 polypeptide is SEQ ID NO:260. In some cases, an HPV peptide is a peptide of from 4-20 aa, e g., 6-15 aa, 8-12 aa, 8-10 aa, 9-11 aa, 5-10 aa, 10-15 aa, or 15-20 aa in length of an amino acid sequence having at least 90%, at least 95%, at least 97%, at least 98%, at least 99%, or 100%, amino acid sequence identity to the HPV E6 amino acid sequence set forth in SEQ ID NO:259 or the HPV E7 amino acid sequence set forth in SEQ ID NO:260.
[0161] Examples of HPV E6 peptides suitable for inclusion in a TEP include, but are not limited to, E6 18-26 (KLPQLCTEL; SEQ ID NO:261); E626-34 (LQTTIHDII; SEQ ID NO:262); E649-57 (VYDFAFRDL; SEQ ID NO:263); E652-60 (FAFRDLCIV; SEQ ID NO:264); E675-83 (KFYSKISEY; SEQ ID NO:265); and E680-88 (ISEYRHYCY; SEQ ID NO:266).
[0162] Examples of HPV E7 peptides suitable for inclusion in a TEP include, but are not limited to, E7 7-15 (TLHEYMLDL; SEQ ID NO:267); E7 11-19 (YMLDLQPET; SEQ ID NO:268); E7 11-20 (YMLDLQPETT; SEQ ID NO:269); E744-52 (QAEPDRAHY; SEQ ID NO:270); E749-57 (RAHYNIVTF (SEQ ID NO:271); E761-69 (CDSTLRLCV; SEQ ID NO:272); and E7 67-76(LCVQSTHVDI; SEQ ID NO:273); E7 82-90 (LLMGTLGIV; SEQ ID NO:274); E786-93 (TLGIVCPI; SEQ ID NO:275); and E792-93 (LLMGTLGIVCPI; SEQ ID NO:276).
[0163] In some cases, a suitable HPV peptide for inclusion in a TEP is an HPV E6 peptide that binds HLA-A24 (e.g.. is an HLA-A2401 -restricted epitope). Non-limiting examples include: VYDFAFRDL (SEQ ID NO:277) CYSLYGTTL (SEQ ID NO:278); EYRHYCYSL (SEQ ID NO:279); KLPQLCTEL (SEQ ID NO:280); DPQERPRKL (SEQ ID NO:281); HYCYSLYGT (SEQ ID NO:282); DFAFRDLCI (SEQ ID NO:283); LYGTTLEQQY (SEQ ID NO:284); HYCYSLYGTT (SEQ ID NO:285);EVYDFAFRDL (SEQ ID NO:286); EYRHYCYSLY SEQ ID NO:287); VYDFAFRDLC (SEQ ID NO:288); YCYSIYGTTL (SEQ ID NO 289); VYCKTVLEL (SEQ ID NO:290); VYGDTLEKL (SEQ ID NO:291); and LTNTGLYNLL (SEQ ID NO:292).
[0164] In some cases, a suitable HPV peptide for inclusion in a TEP is selected from the group consisting of: DLQPETTDL (SEQ ID NO:293); TLHEYMLDL (SEQ ID NO:294); TPTLHEYML (SEQ ID NO:295); RAHYNIVTF (SEQ ID NO:296); GTLGIVCPI (SEQ ID NO:297); EPDRAHYNI (SEQ ID NO:298); QLFLNTLSF (SEQ ID NO:299); FQQLFLNTL (SEQ ID NO:300); and AFQQLFLNTL (SEQ ID NO:301).
[0165] In some cases, a suitable HPV peptide presents an HLA-A* 2401 -restricted epitope. Nonlimiting examples of HPV peptides presenting an HLA-A* 2401 -restricted epitope include:VYDFAFRDL (SEQ ID NO:302); RAHYNIVTF (SEQ ID NO:303); CDSTLRLCV (SEQ ID NO:304); and LCVQSTHVDI (SEQ ID NO:305).
[0166] In some cases, a TEP of the present disclosure comprises, as the TC, a peptide or an scFv or a nanobody specific for IL5R, and comprises, as the peptide epitope an HPV peptide epitope.
[0167] In some cases, a TEP of the present disclosure is a dual-targeting TEP that comprises two different TCs, e.g., two different scFvs or nanobodies specific for IL5R, including for different epitopes of IL5R, and comprises, as the peptide epitope an HPV peptide epitope.D. Influenza Peptide Epitopes
[0168] Numerous publications have reported HLA-restricted peptides associated with influenza virus. See, e.g., Nicholas, et al., Immunopeptidomic analysis of influenza A virus infected human tissues identifies internal proteins as a rich source of HLA ligands, PLOS Pathogens, 2022; Jan, 18(1), Pederson, et aL, Immunogenicity of HLA Class I and II Double Restricted Influenza A-Derived Peptides, PLOS ONE, 2016; (11)1, Habel, et al., and HLA-A* 11:01 -restricted CD8+ T-cell immunity against influenza A and influenza B viruses in Indigenous and non-Indigenous people, PLOS Pathogens, 2022 Mar.; 18(3), and Hogan, et al., Cryptic MHC-E epitope from influenza elicits a potent cytolytic T-cell response. Nature Immunology, 12 October 2023, published online at https: / / doi.org / IO.1038 / s41590-023-01644-5, which describes the HLA-E restricted peptide SLQGRTLIL (SEQ ID NO:3) and mRNAvaccine capable of eliciting T-cells that recognize that peptide presented by nonclassical MHC-Ib, in particular MHC-E (HLA-E in humans).
[0169] Additional HLA-restricted peptides associated with influenza virus include ILGFVFTLTV (SEQ ID NO:368), ILRGSVAHK (SEQ ID NO:369). KSMREEYRK (SEQ ID NO:370).RMVLASTTAK (SEQ ID NO:371), QPEWFRNVL (SEQ ID NO:372), SPIVPSFDM (SEQ ID NO:373), CTELKLSDY (SEQ ID NO:374), VSDGGPNLY (SEQ ID NO:375), FMYSDFHFI (SEQ ID NO:376), GILGFVFTL (SEQ ID NO:377), RVLSFIKGTK (SEQ ID NO:378), SIIPSGPLK (SEQ ID NO:379), KTGGPIYKR (SEQ ID NO:380), ASCMGLIY (SEQ ID NO:381), SRYWAIRTR (SEQ ID NO:382), LPFDKTTVM (SEQ ID NO:383), ELRSRYWAI (SEQ ID NO:384), and LPRRSGAAGA (SEQ ID NO:385). See www.immuneepitope.org.
[0170] In some cases, a TEP of the present disclosure comprises, as the TC, a peptide or an scFv or a nanobody specific for IL5R, and comprises, as the peptide epitope an influenza peptide epitope.
[0171] In some cases, a TEP of the present disclosure is a dual-targeting TEP that comprises two different TCs. e.g., two different scFvs or nanobodies specific for IL5R, including for different epitopes of IL5R, and comprises, as the peptide epitope an influenza peptide epitope.E. Epstein-Barr Virus Peptide Epitopes
[0172] Numerous publications have reported HLA-restricted peptides associated with Epstein-Barr Virus (EBV). See, e.g., Vietzen, et al., HLA-E-restricted immune responses are crucial for the control of EBV infections and the prevention of PTLD, Blood, March 30, 2023, 141(13): 1560-1573, reporting that EBV strains encoding for tire specific LMP-1 peptide variants GGDPHLPTL (SEQ ID NO:386) or GGDPPLPTL (SEQ ID NO:387), presented by HLA-E. elicit strong inhibitory NKG2A+ NK and CD8+T-cell responses. See also: Huisman, et aL. Identification of Functional HLA-A*01:01-Restricted Epstein-Barr Latent Membrane Protein 2- Specific T-Cell Receptors, J. Infect Dis, 2022 Sep 1:226(5):833-842, reporting HLA-A*01:01 restricted peptide for EBV; Jilek, et aL, HLA-B7-Restricted EBV-Specific CD8+ T-cells Are Dysregulated in Multiple Sclerosis, J. Immunol (2012) 188 (9):4671-4680; and Zheng, et al., Human Leukocyte Antigen (HLA) A* 1101-Restricted Epstein-Barr Virus-Specific T-cell Receptor Gene Transfer to Target Nasopharyngeal Carcinoma, Cancer Immunology Research (2015) 3 (10): 1138-1147. One example of an HLA-A*1101 restricted EBV epitope is IVTDFSVIK (SEQ ID NQ:306). Examples of an HLA-A*02 restricted EBV epitopes are FLDKGTYTL(SEQ ID NO:307) and YLLEMLWRL(SEQ ID NO:308).Additional HLA-restncted peptides for EBV include YVLDHLIVV (SEQ ID NO: 388), LLWAARPRL (SEQ ID NO:389), ALIDEFMSV (SEQ ID NO:390), SLGGLLTMV (SEQ ID NO:391), FLDKGTYTL (SEQ ID NO:392), FLYALALLL (SEQ ID NO:393), YLLEMLWRL (SEQ ID NO:394). RVRAYTYSK (SEQ ID NO:395), RLRAEAQVK (SEQ ID NO:396), ATIGTAMYK (SEQ IDNO:397), AVFDRKSDAK (SEQ ID NO:398), IVTDFSVIK (SEQ ID NO:399), SSCSSCPLSK (SEQ ID NOAOO), DYCNVLNKEF (SEQ ID NOAOl), PYLFWLAAI (SEQ ID NO:402), TYGPVFMCL (SEQ ID NO A03), TYGPVFMSL (SEQ ID NO:404), RPPIFIRRL (SEQ ID NO:405), QPRAPIRPI (SEQ ID NOA06), FLRGRAYGL (SEQ ID NO:407), RAKFKQLL (SEQ ID NO:408), RRIYDLIEL (SEQ ID NOA09), YPLHEQHGM (SEQ ID NOAIO), EPLPQGQLTAY (SEQ ID NOAH). HPVGEADYFEY (SEQ ID NOA12), IEDPPFNSL (SEQ ID NO:413), EENLLDFVRF (SEQ ID NOAM), QAKWRLQTL (SEQ ID NOAM). See www.immuneepitope.org. Among them, the HLA-A*02-restricted BRLFI109-117 epitope YVLDHLIVV (SEQ ID NO:388) has a high prevalence among human population and a high percentage of antigen-specific CD8+T cells. See van der Wulp, W.; et al. Cancer Gene Ther. 2024, 31, 58-68; Kristensen, N, P.; et al. Set. Adv. 2024, 10. eadm8951. In addition, the BCLF11341-1349 ALIDEFMSV (SEQ ID NO:390), BARF0356-364 LLWAARPRL (SEQ ID NO:389), LMP2A426-434 SLGGLLTMV (SEQ ID NO:391) as a mutant to CLGGLLTMV (SEQ ID NOAM) and LMP2 FLYALALLL (SEQ ID NO:393) have been identified as anotherthree HLA-A*02-restricted immunodominant EBV epitope with high prevalence among healthy donorsand some autoimmune patients. See Forrest C.; et al. PLoS Pathog. 2018, 14, el007110; Lee, S. P.; et al. J. Virol. 1993, 67, 7428-7435; Lautscham. G.; et al. J. Virol. 2003, 77, 2757-2761; Klatt, T.; et al. J. Rheumatol. 2005, 32,. 239-251.BcLFliog-iigRPSKQRTFIVV (SEQ ID NOA17) has been identified as an immunodominant B*07:02-restricted EBV epitope. See Forrest C.; et al. PLoS Pathog. 2018, 14, e!007110.
[0173] In some cases, a TEP of the present disclosure comprises, as the TC, a peptide or an scFv or a nanobody specific for IL5R, and comprises, as the peptide epitope an EBV peptide epitope.
[0174] In some cases, a TEP of the present disclosure is a dual-targeting TEP that comprises two different TCs, e.g., two different scFvs or nanobodies specific for IL5R, including for different epitopes of IL5R, and comprises, as the peptide epitope an EBV peptide epitope.F. Cancer Peptide Epitopes
[0175] As noted above, a pMHC can present an epitope of a cancer antigen such as a melanoma-associated antigen such as any one of the MAGE antigens, e.g.. MAGE-A1, MAGE-A2, MAGE-A3 and MAGE-A4. For example, ELAGIGILTV ( SEQ ID NO : 331 ) is associated with MART- 1.
[0176] In some cases, a TEP of the present disclosure comprises, as the TC, a peptide or an scFv or a nanobody specific for IL5R, and comprises, as the peptide epitope a cancer-associated peptide epitope.
[0177] In some cases, a TEP of the present disclosure is a dual-targeting TEP that comprises two different TCs. e.g., two different scFvs or nanobodies specific for IL5R, including for different epitopes of IL5R, and comprises, as the peptide epitope a cancer-associated peptide epitope.G. Varicella Zoster Virus (VZV)
[0178] A pMHC can present an epitope of Varicella Zoster Virus (VZV), c.g., ILIEGIFFV (SEQ ID NO:418). See Chiu, C.; et al. PLoS Pathog. 2014, 10, el004008; Sullivan, N. L. et al. Clin. Infect. Dis. 2019, 69, 348-351.H. Other Peptide Epitopes
[0179] As also noted above, a pMHC can present an epitope of any other target antigen, including antigens that can be provided via vaccination, e g., in a vaccine that provides antigenic peptides.
[0180] For example, systematic studies of CD8+ T cell epitopes of Yellow Fever Vaccines have discovered a wide range of immunodominant epitopes with different HLA restrictions, including KSEYMTSWFY (SEQ ID NO:419), LLWNGPMAV (SEQ ID NO:420), KLAQRRVFH (SEQ ID NO:313), RVKLSALTLK (SEQ ID NO:314), VLWDIPTPK (SEQ ID NO:315), IYGIFQSTF (SEQ ID NO:316), KTWGKNLVF (SEQ ID NO 317), DVILPIGTR (SEQ ID NO:318), RPIDDRFGL (SEQ ID NO:319), SPRERLVLTL (SEQ ID NO:320), SVKEDLVAY (SEQ ID NO:321), QEVEFIGY (SEQ ID NO:322), HAVPFGLVSM (SEQ ID NO:323), HPFALLLVL (SEQ ID NO:324). FHERGYVKL (SEQ ID NO:325), YEKKLALYL (SEQ ID NO:326), TESWIVDRQW (SEQ ID NO:327), HESHLVRSW (SEQ ID NO:328), KTWGKNLVF (SEQ ID NO:329), TRRFLPQIL (SEQ ID NO:330). See Stryhn A.; et al. Front. Immunol. 2020, 11, 1836. . Among them, the most immunodominant HLA*02-restricted epitope is NS4B214-222 LLWNGPMAV (SEQ ID NO:420). See Akondy, R. S.; et al. J. Immunol. 2009, 183, 7919-7930; Akondy. R. S.; et al. Nature. 2017, 552, 362-367.FIGS. 18A-H provide examples of a few of the peptide epitopes described above linked to B2M sequences comprising R12C substitutions. Such peptide epitope-B2M sequences can be combined with an MHC class I heavy chain, an Ig Fc polypeptide, and optionally one or more MODs, to construct TEPs as described herein.I. Exemplary Dual-Epitope Combinations
[0181] TEPs comprising two different viral epitopes can be prepared using knob-in-hole interspecific dimerization sequences to prepare heterodimers comprising two single-chain TEPs as illustrated in FIG.4C (MOD-less) and 4D (comprising a single MOD), or heterodimers comprising two heterodimers as illustrated in FIG. 6M (MOD-less) or FIGS. 6N-6P (comprising a single MOD). For example, TEPs can comprise viral epitopes that redirect the cytotoxicity of the existing cellular immunity against both CMV and EBV, both of which are highly prevalent in human populations. Other examples include CMV and HPV, both of which are highly prevalent in human populations, EBV and HPV, CMV (or EBV or HPV) and yellow fever, with the potential for priming and / or boosting by yellow fever vaccine. CMV (or EBV or HPV) and Influenza A, with the potential for priming and / or boosting through the immunization.and CMV (or EBV or HPV) and chickenpox, again with the potential for priming and / or boosting through the immunization with varicella zoster virus vaccines.
[0182] Such dual-epitope single-chain TEPs can be prepared, for example, using two-chain transfections in which one single-chain TEP having a “knob” mutation, e.g., a MOD-less single-chain TEP having an amino acid sequence shown in FIG. 19A (SEQ ID NO:430) comprising a CMV peptide epitope, is prepared along with a single-chain having a “hole” mutation, e.g., a MOD-less single-chain TEP having an amino acid sequence shown in any one of FIGS. 19B-19I (SEQ ID NOs:431-438) comprising an EBV, yellow fever virus, Influenza, or Varicella Zoster Virus, in ExpiCHO cells and cultured for product expression. (Each of the HLA-A*02:01 sequences in FIGS. 19A-19I (SEQ ID NOs:430-438) comprises A139C and A236C mutations.) Upon harvest and media clarification, TEPs are purified, e.g., through a standard two-step chromatography process and dialyzed into final product buffer prior to use.SCAFFOLD POLYPEPTIDES
[0183] Suitable scaffold polypeptides include antibody-based scaffold polypeptides and non-antibody-based scaffolds. Non-antibody-bascd scaffolds include, e.g., albumin, an XTEN (extended recombinant) polypeptide, transferrin, an Fc receptor polypeptide, an elastin-like polypeptide (see, e.g., Hassouneh et al. (2012) Methods Enzymol. 502:215; e.g., a polypeptide comprising a pentapeptide repeat unit of (Val-Pro-Gly-X-Gly; SEQ ID NO:935), where X is any amino acid other than proline), an albumin-binding polypeptide, a silk-like polypeptide (see, e.g., Valluzzi et al. (2002) Philos Trans R Soc Lond B Biol Sci.357: 165), a silk -elastin-like polypeptide (SELP; see, e.g., Megeed et al. (2002) Adv Drug Deliv Rev. 54: 1075), and the like. Suitable XTEN polypeptides include, e.g., those disclosed in WO 2009 / 023270, WO 2010 / 091122, WO 2007 / 103515. US 2010 / 0189682, and US 2009 / 0092582; see also Schellenberger et al. (2009) Nat Biotechnol. 27: 1186). Suitable albumin polypeptides include, e.g.. human serum albumin.
[0184] Suitable scaffold polypeptides will in some cases be a half-life extending polypeptides. Thus, in some cases, a suitable scaffold poly peptide increases the in vivo half-life (e.g., the serum half-life) of the TEP, compared to a control TEP lacking the scaffold polypeptide. For example, in some cases, a scaffold polypeptide increases the in vivo half-life (e.g.. the serum half-life) of the TEP. compared to a control TEP lacking the scaffold polypeptide, by at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 50%, at least about 2-fold, at least about 2.5-fold, at least about 5-fold, at least about 10-fold, at least about 25 -fold, at least about 50-fold, at least about 100-fold, or more than 100-fold. As an example, in some cases, an Fc polypeptide increases the in vivo half-life (e.g., the serum half-life) of the TEP, compared to a control TEP lacking the Fc polypeptide, by at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 50%, at least about 2-fold,at least about 2.5-fold, at least about 5-fold, at least about 10-fold, at least about 25-fold, at least about 50-fold, at least about 100-fold, or more than 100-fold.
[0185] An Ig Fc polypeptide of a TEP can be a human IgGl Fc, a human IgG2 Fc, a human IgG3 Fc, a human IgG4 Fc. etc., or a variant of a wild-type Ig Fc polypeptide. Variants include naturally occurring variants, non-naturally occurring variants, and combinations thereof. In some cases, for example, the Ig Fc can be a variant of a Fc polypeptide such as a human IgGl Fc, which variant has a reduced or substantially eliminated Fc-mediated effector function such as complement-dependent cytotoxicity (CDC), antibody-dcpcndcnT-ccll-mcdiatcd cytotoxicity (ADCC), and / or antibody-dcpcndcnT-ccllular phagocytosis (ADCP).
[0186] In some cases, e.g., where TEP comprises a heterodimer of first and second polypeptides, the Ig Fc may be at the C-terminus of the second polypeptide. In such cases, the Ig Fc polypeptide optionally does not comprise a C-terminal Lys.
[0187] In some cases, the Fc poly peptide present in a TEP is an IgG 1 Fc polypeptide, or a variant of an IgGl Fc polypeptide. For example, in some cases, the IgGl Fc polypeptide present in a TEP comprises an amino acid sequence having at least 80%. at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100%, amino acid sequence identity to the following human IgGl Fc polypeptide amino acid sequence: DKTHTCPPCP APELLGGPSV FLFPPKPKDT LMISRTPEVT CVVVDVSHED PEVKFNWYVD GVEVHNAKTK PREEQYNSTY RVVSVLTVLH QDWLNGKEYK CKVSNKALPA PIEKTISKAK GQPREPQVYT LPPSRDELTK NQVSLTCLVK GFYPSDIAVE WESNGQPENN YKTTPPVLDS DGSFFLYSKL TVDKSRWQQG NVFSCSVMHE ALHNHYTQKS LSLSPG (SEQ ID NO:309). Such IgGl Fc polypeptides may or may not comprise a C-terminal lysine.
[0188] In some cases, the Fc polypeptide present in a TEP comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100%, amino acid sequence identity to the following human IgGl Fc polypeptide amino acid sequence: DKTHTCPPCP APELLGGPSV FLFPPKPKDT LMISRTPEVT CVVVDVSHED PEVKFNWYVD GVEVHNAKTK PREEQYNSTY RVVSVLTVLH QDWLNGKEYK CKVSNKALPA PIEKTISKAK GQPREPQVYT LPPSRDELTK NQVSLTCLVK GFYPSDIAVE WESNGQPENN YKTTPPVLDS DGSFFLYSKL TVDKSRWQQG NVFSCSVMHE ALHNHYTQKS LSLSPGK (SEQ ID NQ:310).
[0189] In some cases, the Ig Fc polypeptide present in a TEP comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%. or 100%, amino acid sequence identity to the Ig Fc polypeptide amino acid sequence set forth in SEQ ID NO: / / or SEQ ID NO: / / , where amino acid 14 is an Ala and amino acid 15 is an Ala. (As discussed below, substitutions of Ala for Leu at amino acids 14 and 15 are known as the “LALA” mutations.) Thus, in some cases, the Ig Fc polypeptide present in a TEP comprises an amino acid sequence having at least 80%, at least 85%,at least 90%, at least 95%, at least 98%, at least 99%, or 100%, amino acid sequence identity to the following Ig Fc amino acid sequence:DKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEV HNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQ VYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLT VDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG (SEQ ID NO:311), where ammo acid 14 is an Ala and amino acid 15 is an Ala, and where the Ig Fc omits a C-terminal Lys.
[0190] In some cases, the Ig Fc polypeptide present in a TEP comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%. or 100%, amino acid sequence identity to the following Ig Fc amino acid sequence:DKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEV HNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQ VYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLT VDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO:312), where ammo acid 14 is an Ala and amino acid 15 is an Ala, and where the Ig Fc comprises a C-terminal Lys.IMMUNOMODULATORY POLYPEPTIDES
[0191] As noted above, a TEP optionally comprises one or more activating immunomodulatory polypeptides (“MODs”). In some cases, a MOD present in the TEP is a wild-type (“wt”) MOD. In other cases, a MOD present in a TEP is a variant of a wt MOD that has reduced affinity for a binding partner on a T-cell (a “co-MOD”), including e.g., reduced binding to one or more chains or domains of the co-MOD compared to the affinity of a corresponding wild-type MOD for the co-MOD. Suitable MODs that exhibit reduced affinity for a co-MOD can have from 1 amino acid (aa) to 20 aa differences from a wildtype MOD. For example, in some cases, a variant MOD present in a TEP differs in amino acid sequence by 1 aa, 2 aa, 3 aa, 4 aa, 5 aa, 6 aa, 7 aa, 8 aa, 9 aa, or 10 aa, from a corresponding wild-type MOD. As another example, in some cases, a variant MOD present in a TEP differs in amino acid sequence by 11 aa, 12 aa, 13 aa, 14 aa, 15 aa, 16 aa, 17 aa, 18 aa, 19 aa, or 20 aa, from a corresponding wild-type MOD. For example, a variant MOD present in a TEP may bind its co-MOD with an affinity that it at least 10% less, at least 15% less, at least 20% less, at least 25% less, at least 30% less, at least 35% less, at least 40% less, at least 45% less, at least 50% less, at least 55% less, at least 60% less, at least 65% less, at least 70% less, at least 75% less, at least 80% less, at least 85% less, at least 90% less, at least 95% less, or more than 95% less, than the affinity of a corresponding wild-type MOD for the co-MOD.
[0192] Exemplary’ pairs of activating MODs and their co-MODs include, but arc not limited to those set out in Table 1, below :Table 1Immunomodulatory Co-MODPolypeptide (MOD)4-1BBL 4-1BBIL-2 IL-2 receptorIL-7 IL-7 receptorIL- 12 IL- 12 receptorIL- 15 IL- 15 receptorIL-23 IL-23 receptorIL-31 IL-31 receptorCD80 CD28CD86 CD28OX40L (CD252) 0X40 (CD 134)Fas ligand FasICOS-L ICOSICAM LFA-1CD30L CD30CD40 CD40LCD83 CD83LHVEM (CD270) CD 160JAG1 (CD339) NotchJAG1 CD46CD80 CTLA4CD86 CTLA4CD70 CD27TGFp TGFp receptor
[0193] Wild-type activating immunomodulatory polypeptides and variants, including reduced affinity variants, such as CD80, CD86, 4-1BBL and IL-2 are described in the published literature, e.g., published PCT application WO2020132138A1 and W02019 / 051091 (Cue Biopharma, Inc.), the disclosures of which as they pertain to MODs and specific variant MODs of CD80, CD86, 4-1BBL. IL-2 are expressly incorporated herein by reference, including specifically paragraphs [00260J-
[0455] of WO2020132I38A1 and paragraphs
[0157] -
[0352] of WO2019 / 051091.
[0194] Of interest are MODs that are variants of the cytokine IL-2. Wild-type IL-2 binds to IL-2 receptor (IL-2R) on the surface of a T-cell. Wild-type IL-2 has a strong affinity for IL-2R and will bind to activate most or substantially all CD8+ T-cells. For this reason, synthetic fonns of wild type IL-2 such as the drug Aldesleukin (trade name Proleukin®) are known to have severe side-effects when administered to humans for the treatment of cancer because the IL-2 indiscriminately activates both target and non-target T-cells.
[0195] An IL-2 receptor is in some cases a heterotrimeric polypeptide comprising an alpha chain (IL-2Ra; also referred to as CD25), a beta chain (IL-2RP; also referred to as CD 122: and a gamma chain (IL-2Ry; also referred to as CD 132). Amino acid sequences of human IL-2, human IL-2Ra. IL2R0, and IL-2Ry are known. See, e.g., published PCT applications WO2020132138A1 and W02019 / 051091, discussed above.
[0196] In some cases, an IL-2 variant MOD of this disclosure exhibits decreased binding to IL-2Ra, thereby minimizing or substantially reducing the activation of Tregs by tire IL-2 variant. Alternatively, or additionally, in some cases, an IL-2 variant MOD of this disclosure exhibits decreased binding to IL-2R and / or IL-2Ry such that the IL-2 variant MOD exhibits an overall reduced affinity for IL-2R. In some cases, an IL-2 variant MOD of this disclosure exhibits both properties, i.e., it exhibits decreased or substantially no binding to IL-2Ra, and also exhibits decreased binding to IL-2R0 and / or IL-2Ry such that the IL-2 variant polypeptide exhibits an overall reduced affinity for IL-2R. For example, IL-2 variants having substitutions at H16 and F42 have shown decreased binding to IL-2Ra and IL-2Rp. See, Quayle et al., Clin Cancer Res; 26(8) April 15, 2020, which discloses that the binding affinity of an IL-2 polypeptide with H16A and F42A substitutions for human IL-2Ra and IL-2RP was decreased 110- and 3-fold, respectively, compared with wild-type IL2 binding, predominantly due to a faster off-rate for each of these interactions. TEPs comprising such variants, including variants that exhibit decreased binding to IL-2Ra and IL-2RB, can thus preferentially bind to and activate IL-2 receptors on T-cells that contain the target TCR that is specific for the epitope presented by the pMHC of the TEP, and are thus less likely to deliver IL-2 to non-target T-cells, i.e., T-cells that do not contain a TCR that specifically binds the epitope presented by the pMHC of the TEP. That is, the binding of the IL-2 variant MOD to its costimulatory polypeptide on the T-cell achieves greater selectivity because the binding of the TEP is substantially driven by the binding of the MHC -epitope moiety rather than by the binding of the variant IL-2 polypeptide to IL-2R receptors on the T-cell.
[0197] Suitable IL-2 variant MODs thus include a polypeptide that comprises an amino acid sequence having at least 90%, at least 95%. at least 97%, at least 98%, or at least 99% amino acid sequence identity to the wild-type IL-2 amino acid sequence:APTSSSTKKT QLQLEHLLLD LQMILNGINN YKNPKLTRML TFKFYMPKKA TELKHLQCLEEELKPLEEVL NLAQSKNFHL RPRDLISNIN VIVLELKGSE TTFMCEYADE TATIVEFLNRWITFCQSIIS TLT (SEQ ID NO:341)and that have one or more amino acid differences from the above wild-type IL-2 amino acid sequence. In some cases, such a variant IL-2 polypeptide of this disclosure exhibits reduced binding affinity to IL-2R, compared to the binding affinity of an IL-2 polypeptide comprising the wild-type IL-2 amino acid sequence when assayed under the same conditions. For example, in some cases, a variant IL-2 polypeptide binds IL-2R with a binding affinity that Is at least 10% less, at least 15% less, at least 20% less, at least 25%, at least 30% less, at least 35% less, at least 40% less, at least 45% less, at least 50% less, at least 55% less, at least 60% less, at least 65% less, at least 70% less, at least 75% less, at least 80% less, at least 85% less, at least 90% less, at least 95% less, or more than 95% less, than tire binding affinity of an IL-2 polypeptide comprising the wild-type IL-2 amino acid sequence:
[0198] Some exemplary combinations of mutations that reduce binding of an IL-2 variant polypeptide to IL-2Ra and IL-2R|3 include the following from Table 2:Table 2Mutation(s) to Mutation(s) todecrease binding decrease binding Exemplary combinationsto IL-2Ra to IL-2R0R38 with any E15 with any El 5 A with R38A, R38D or R38Eamino acid other amino acid otherthan Arg, e.g., Ala, than GluAsp. GluR38 with any Hl 6, with any H16A with R38A, R38D or R38Eamino acid other amino acid other H16T with R38A, R38D or R38Ethan Arg, e.g., Ala, than His, e.g., Ala,H16E with R38A, R38D or R38EAsp, Glu Glu, Thr, or Asp,H16D with R38A, R38D or R38ER38 with any D84, with any D84H with R38A, R38D or R38Eamino acid other amino acid otherthan Arg, e.g., Ala, than Asp, e.g., His, D84K with R38A, R38D or R38EAsp. Glu Lys or Arg D84R with R38A, R38D or R38ER38 with any N88, with any R38a with N88S, N88A, N88G, N88R, N88T, or N88D amino acid other amino acid other R38D with N88S, N88A, N88G, N88R, N88T, or N88D than Arg, e.g., Ala, than Asn, e.g., Ser,R38E with N88S, N88A, N88G, N88R, N88T, or N88D Asp. Glu Ala. Gly, Arg, Thror AspMutation(s) to Mutation(s) todecrease binding decrease binding Exemplary combinationsto IL-2Ra to IL-2R0R38 with any V91 with any R38A with V91E, V91A or V91Tamino acid other amino acid otherthan Arg, e.g., Ala, than Vai, e.g., Glu, R38D with V91E, V91A or V91TAsp. Glu Ala or Thr R38E with V91E, V91A or V91TR38 with any 192 with any amino R38A, I92Aamino acid other acid other than lie,than Arg, e.g., Ala, e.g., Ala R38D, I92AAsp. Glu R38E, I92AF42, with any E15 with any El 5 A, F42Aamino acid other amino acid other El 5 A, F42Kthan Phe, e.g., Ala than Gluor Lys, , as well asMet, Pro, Ser, Thr,Trp, Tyr, and VaiF42, with any Hl 6, with any H16A, F42A; H16T, F42A;amino acid other amino acid other H16E, F42A; H16D, F42Athan Phe, e.g., Ala than His, e.g., Ala,or Lys, as well as Glu, Thr, or Asp,Met, Pro, Ser, Thr, H16A, F42K; H16T, F42K;Trp, Tyr, and VaiH16E, F42K; H16D, F42KF42, with any D84, with any F42A with D84H, D84K or D84Ramino acid other amino acid otherthan Phe, e.g., Ala than Asp, e.g., His, F42K with D84H, D84K or D84Ror Lys, as well as Lys or ArgMet, Pro, Ser, Thr,Trp, Tyr, and VaiF42, with any N88, with any F42A with N88S, N88A, N88G, N88R, N88T, or N88D amino acid other amino acid other F42K with N88S, N88A, N88G, N88R, N88T, or N88D than Phe, e.g., Ala than Asn, e.g., Ser,or Lys, as well as Ala. Gly, Arg, ThrMet, Pro, Ser, Thr, or AspTrp, Tyr, and VaiF42, with any V91 with any F42A with V91E, V91A, or V91Tamino acid other amino acid otherthan Phe, e.g., Ala than Vai, e.g., Glu, F42K with V91 E, V91 A, or V91 Tor Lys, as well as Ala or ThrMet, Pro, Ser, Thr,Trp, Tyr, and VaiMutation(s) to Mutation(s) todecrease binding decrease binding Exemplary combinationsto IL-2Ra to IL-2R0F42, with any 192 with any amino F42A with I92Aamino acid other acid other than lie,than Phe, e.g., Ala e.g., Ala F42K with I92Aor Lys, as well asMet, Pro, Ser, Thr,Trp, Tyr, and VaiK43, with any E15 with any E15A, K43Eamino acid other amino acid otherthan Lys, e.g., Glu than GluK43, with any Hl 6, with any H16A, K43E; H16T, K43E;amino acid other amino acid other H16E, K43E: H16D, K43Ethan Lys, e.g., Glu than His, e.g., Ala,Glu, Thr, or Asp,K43, with any D84, with any K43E with D84H, D84K or D84Ramino acid other amino acid otherthan Lys, e.g., Glu than Asp, e.g., His,Lys or ArgK43, with any N88, with any K43E with N88S, N88A, N88G, N88R, N88T, or N88D amino acid other amino acid otherthan Lys, e.g., Glu than Asn, e.g., Ser,Ala, Gly, Arg, Thror AspK43, with any V91 with any K43E with V91E, V91A, or V91Tamino acid other amino acid otherthan Lys, e.g., Glu than Vai, e.g., Glu,Ala or ThrK43, with any 192 with any amino K43E, I92Aamino acid other acid other than He,than Lys, e.g., Glu e.g.. AlaE62, with any E15 with any E15A, E62Qamino acid other amino acid otherthan Glu, e.g., Gin than GluE62, with any Hl 6, with any H16A, E62Q; H16T, E62Q;amino acid other amino acid other H16E, E62Q: H16D, E62Qthan Glu, e.g., Gin than His, e.g., Ala,Glu, Thr, or Asp,Mutation(s) to Mutation(s) todecrease binding decrease binding Exemplary combinationsto IL-2Ra to IL-2R0E62, with any D84, with any E62Q with D84H, D84K or D84Ramino acid other amino acid otherthan Glu, e.g., Gin than Asp, e.g., His,Lys or ArgE62, with any N88, with any E62Q with N88S, N88A, N88G, N88R, N88T, or N88D amino acid other amino acid otherthan Glu, e.g., Gin than Asn, e.g., Ser,Ala, Gly, Arg, Thror AspE62, with any V91 with any E62Q with V91E, V91A. or V91Tamino acid other amino acid otherthan Glu, e g., Gin than Vai, e.g., Glu,Ala or ThrE62, with any 192 with any amino E62Q, I92Aamino acid other acid other than lie,than Glu, e.g., Gin e.g., AlaF42, with any E15 with any E15A, F42A with D84H. D84K or D84Ramino acid other amino acid other ELSA, F42K with D84H, D84K or D84Rthan Phe, e.g., Ala than Gluor Lys, as well asMet, Pro, Ser, Thr, D84, with anyTrp, Tyr, and Vai amino acid otherthan Asp, e.g., His,Lys and ArgF42, with any E15 with any ELSA, F42A with N88S, N88A, N88G. N88R, N88T, or amino acid other amino acid other N88Dthan Phe, e.g., Ala than Glu E15A, F42K with N88S, N88A, N88G, N88R, N88T, or or Lys, as well as N88DMet, Pro, Ser, Thr, N88, with anyTrp, Tyr, and Vai amino acid otherthan Asn, e.g., Ser,Ala, Gly, Arg, Thr,and AspF42, with any E15 with any E15A, F42A with V91E, V91A, or V91Tamino acid other amino acid other E15A, F42K with V91E, V91A, or V91Tthan Phe, e.g., Ala than Gluor Lys, as well asV91 with anyamino acid otherMutation(s) to Mutation(s) todecrease binding decrease binding Exemplary combinationsto IL-2Ra to IL-2R0Met. Pro, Ser, Thr, than Vai, e.g.. Glu,Trp, Tyr, and Vai Ala or ThrF42, with any El 5 with any ELSA, F42A with I92Aamino acid other amino acid otherthan Phe, e.g., Ala than Glu El 5 A, F42K with I92Aor Lys, as well asMet, Pro, Ser, Thr, 192 with any aminoTrp, Tyr, and Vai acid other than He,e.g.. AlaF42, with any Hl 6, with any H16A, F42A with D84H, D84K or D84Ramino acid other amino acid other H16A, F42K with D84H, D84K or D84Rthan Phe, e.g., Ala than His, e.g., Ala,or Lys, as well as Glu, Thr, or Asp H16T, F42A with D84H, D84K or D84RMet, Pro, Ser, Thr, H16T, F42K with D84H, D84K or D84RTrp, Tyr, and Vai D84, with anyamino acid other H16E, F42A with D84H. D84K or D84Rthan Asp, e.g., His, H16E, F42K with D84H. D84K or D84RLys and ArgH16D, F42A with D84H, D84K or D84RH16D, F42K with D84H, D84K or D84RF42, with any Hl 6, with any H16A, F42A with N88S, N88A, N88G, N88R, N88T, or amino acid other amino acid other N88Dthan Phe, e.g., Ala than His, e.g., Ala, H16A, F42K with N88S. N88A, N88G, N88R. N88T, or or Lys, as well as Glu, Thr, or Asp N88DMet, Pro, Ser, Thr,Trp, Tyr, and Vai N88, with any H16T, F42A with N88S, N88A, N88G, N88R, N88T, or amino acid other N88Dthan Asn, e.g., Ser, Hl 6T, F42K with N88S, N88A, N88G, N88R, N88T, or Ala, Gly, Arg, Thr, N88Dand AspH16E, F42A with N88S, N88A, N88G. N88R, N88T, or N88DH16E, F42K with N88S, N88A, N88G, N88R, N88T, or N88DH16D, F42A with N88S. N88A, N88G, N88R. N88T, or N88DH16D, F42K with N88S, N88A, N88G, N88R, N88T, or N88DF42, with any Hl 6, with any H16A, F42A with V91E, V91A, or V91Tamino acid other amino acid other H16A, F42K with V91E, V91A, or V91Tthan Phe, e.g., Ala than His, e.g., Ala,or Lys, as well as Glu, Thr, or Asp H16T, F42A with V91E, V91A, or V91TMutation(s) to Mutation(s) todecrease binding decrease binding Exemplary combinationsto IL-2Ra to IL-2R0Met. Pro, Ser, Thr, H16T, F42K with V91E, V91A, or V91TTrp, Tyr, and VaiV91 with any H16E, F42A with V91E, V91A, or V91Tamino acid other H16E, F42K with V91E, V91A, or V91Tthan Vai, e.g., Glu,Ala or Thr H16D, F42A with V91E, V91A, or V91TH16D, F42K with V91E, V91A, or V91TF42, with any Hl 6, with any H16A, F42A with 192 Aamino acid other amino acid other H16A, F42Kwith I92Athan Phe, e.g., Ala than His, e g., Ala,or Lys, as well as Glu. Thr, or Asp H16T, F42A with 192 AMet, Pro, Ser, Thr, H16T, F42K with 192 ATrp, Tyr, and VaiH16E, F42A with 192 A192 with any aminoacid other than He, H16E, F42K with 192 Ae.g., Ala H16D, F42A with I92AH16D, F42K with I92A
[0199] In some cases, a suitable variant IL-2 polypeptide comprises an amino acid sequence having at least 90%, at least 95%, at least 97%, at least 98%, at least 99%, or 100% amino acid sequence identity to the amino acid sequence: APTSSSTKKT QLQLEXiLLLD LQMILNGINN YKNPKLTRML TX2KFYMPKKA TELKHLQCLEEELKPLEEVL NLAQSKNFHL RPRDLISNIN VIVLELKGSE TTFMCEYADE TATIVEFLNRWITFCQSIIS TLT (SEQ ID NO: 342). where Xi is an amino acid other than His, and where X2is an amino acid other than Phe. In some cases, a suitable variant IL-2 polypeptide comprises an amino acid sequence having at least 90%, at least 95%, at least 97%, at least 98%, at least 99%, or 100% amino acid sequence identity to the amino acid sequence: APTSSSTKKT QLQLEXiLLLD LQMILNGINN YKNPKLTRML TX2KFYMPKKA TELKHLQCLEEELKPLEEVL NLAQSKNFHL RPRDLISNIN VIVLELKGSE TTFMCEYADE TATIVEFLNRWITFCQSIIS TLT(SEQ ID NO:343), where: i) Xi is Ala, Arg, Asn, Asp, Cys, Gin, Glu. Gly, He, Leu, Lys, Met, Phe, Pro, Ser. Thr, Trp, Tyr, or Vai; and ii) X2is Ala. Arg, Asn, Asp, Cys, Gin. Glu, Gly. His, lie, Leu, Lys, Met. Pro, Ser, Thr, Trp, Tyr, or Vai. In some cases, Xi is Ala and X2is Ala. In some cases, Xi is Thr and X2is Ala. In some cases, Xi is Asp and X2is Ala. In some cases, Xi is Glu and X2is Ala.
[0200] In some cases, a suitable variant IL-2 polypeptide comprises an amino acid sequence having at least 90%, at least 95%, at least 97%, at least 98%, at least 99%, or 100% amino acid sequence identity to the amino acid sequence: APTSSSTKKT QLQLEALLLD LQMILNGINN YKNPKLTRML TAKFYMPKKA TELKHLQCLEEELKPLEEVL NLAQSKNFHL RPRDLISNIN VIVLELKGSETTFMCEYADE TATIVEFLNRWITFCQSIIS TLT (SEQ ID NO: 344), i.e, the variant IL-2 polypeptide has the amino acid sequence of wild-type IL-2 but with H16A and F42A substitutions (shown in bold). Alternatively, the foregoing sequence, but with substitutions other than Ala at H16 and / or F42 may be employed, e.g., H16T may be employed instead of H16A. In some cases, a variant IL-2 polypeptide present in a TEP comprises the amino acid sequence: APTSSSTKKT QLQLEALLLD LQMILNGINN YKNPKLTRML TAKFYMPKKA TELKHLQCLEEELKPLEEVL NLAQSKNFHL RPRDLISNIN VIVLELKGSE TTFMCEYADE TATIVEFLNRWITFCQSIIS TLT (SEQ ID NO:345). In some cases, a variant IL-2 polypeptide present in a TEP comprises the amino acid sequence: APTSSSTKKT QLQLETLLLD LQMILNGINN YKNPKLTRML TAKFYMPKKA TELKHLQCLEEELKPLEEVL NLAQSKNFHL RPRDLISNIN VIVLELKGSE TTFMCEYADE TATIVEFLNRWITFCQSIIS TLT(SEQ ID NO:346). In some cases, a TEP comprises two copies of such a variant IL-2 polypeptide. Where a TEP comprises two copies of a variant IL-2 polypeptide, in some cases, the two copies are in tandem. Where a TEP comprises two copies of a variant IL-2 polypeptide, and where the two copies are in tandem, in some cases, the TEP comprises a peptide linker between the two copies.LINKERS
[0201] A TEP of the present disclosure can include one or more peptide linkers interposed between any two components of the TEP. For example, one or more linkers may be interposed between one or more of: i) a peptide epitope and a P2M polypeptide; ii) an MHC class I heavy chain polypeptide and an Ig Fc polypeptide; iii) an MHC class I heavy chain polypeptide and a TC; iv) an MHC class I heavy chain polypeptide and a MOD; v) an Ig Fc polypeptide and a MOD; vi) an Ig Fc polypeptide and a TC; vii) a TC and a MOD; and vii) where a TEP comprises two or more TCs and / or MODs in tandem, between the TCs and / or MODs. As used herein, the phrase “an optional peptide linker between any two of the components of a TEP” refers to a peptide linker between any two adjacent polypeptides in a polypeptide chain of the TEP.
[0202] Suitable linkers (also referred to as “spacers”) can be readily selected and can be of any of a number of suitable lengths, such as from 1 amino acid to 25 amino acids, from 3 amino acids to 20 amino acids, from 2 amino acids to 15 amino acids, from 3 amino acids to 12 amino acids, including 4 amino acids to 10 amino acids, 5 amino acids to 9 amino acids, 6 amino acids to 8 amino acids, or 7 amino acids to 8 amino acids. A suitable linker can be 1, 2, 3. 4, 5, 6, 7. 8, 9, 10, 11, 12, 13. 14. 15. 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 amino acids in length. In some cases, a linker has a length of from 25 amino acids to 50 amino acids, e.g., from 25 to 30, from 30 to 35, from 35 to 40, from 40 to 45, or from 45 to 50 amino acids in length.
[0203] Linkers may be a flexible peptide linker, including a short flexible peptide linker, or a rigid peptide linker. Rigid linkers and short flexible peptide linkers may be used in TEPs when it is desired tominimize the interaction of different polypeptides of the TEP. The use of rigid linkers and / or short flexible peptide linkers can help maintain spatial separation between the polypeptides and thereby possibly impart improved stability and / or manufacturability to the TEP. Such linkers are disclosed in WO 2022 / 197970 (Cue Biopharma. Inc.), the disclosure of which as it pertains to such linkers is expressly incorporated herein by reference, including specifically, but not limited to, paragraphs
[0188] -
[0196] .
[0204] As noted above, the linker between a peptide epitope and a P2M polypeptide may comprise a single Cys residue that can fomi a linker disulfide bond with a Cys in the MHC class I heavy chain polypeptide. Such Cys-containing linkers are disclosed in WO 2022 / 197970 (Cue Biophamia, Inc.), the disclosure of which as it pertains to such peptide linkers is expressly incorporated herein by reference, including specifically, but not limited to, paragraphs
[0202] -
[0207] . See also WO 2023 / 097188, the disclosure of which as it pertains to such linkers is expressly incorporated herein by reference, including specifically, but not limited to, paragraphs
[0224] -
[0237] ,
[0205] In some cases, the Cys-containing peptide linker between the peptide and the P2M polypeptide comprises the amino acid sequence GCGGS (SEQ ID NO:89). In some cases, the Cys-containing peptide linker between the peptide and the P2M polypeptide comprises the amino acid sequence GCGGS(GGGGS)n (SEQ ID NO:90), where n is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10: e.g., 1, 2, or3. In some cases, the Cys-containing peptide linker between the peptide and the P2M polypeptide comprises the amino acid sequence GCGGS(GGGGS)n (SEQ ID NO:91), where n is 2.
[0206] In some cases, the Cys-containing peptide linker between the peptide and the P2M polypeptide comprises the amino acid sequence CGGGS (SEQ ID NO:92). In some cases, the Cys-containing peptide linker comprises the amino acid sequence CGGGS(GGGGS)n (SEQ ID NO:93), where n is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10; e.g., 1, 2, or 3.
[0207] In some cases, the Cys-containing peptide linker between the peptide and the P2M polypeptide comprises the amino acid sequence GGCGS (SEQ ID NO:94). In some cases, the Cys-containing peptide linker comprises the amino acid sequence GGCGS(GGGGS)n (SEQ ID NO:95), where n is 1, 2, 3. 4. 5, 6, 7, 8, 9 or 10, e.g., 1, 2, or 3.
[0208] In some cases, the Cys-containing peptide linker between the peptide and the P2M polypeptide comprises the amino acid sequence GGGCS (SEQ ID NO:96). In some cases, the Cys-containing peptide linker comprises the amino acid sequence GGGCS(GGGGS)n (SEQ ID NO: 97), where n is 1, 2, 3, 4. 5, 6. 7, 8, 9, or 10. e.g., 1, 2. or 3.
[0209] In some cases, the Cys-containing peptide linker between the peptide and the P2M polypeptide comprises the amino acid sequence GGGGC (SEQ ID NO: 98). In some cases, the Cys-containingpeptide linker comprises the amino acid sequence GGGGC(GGGGS)n (SEQ ID NO:99), where n is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, e.g., 1, 2, or 3.
[0210] Where tire TEP comprises a heterodimer, the Cys in the linker can form a disulfide bond with a Cys in the MHC class I heavy chain polypeptide in the second polypeptide. Where the TEP comprises a single-chain polypeptide, the Cys in the linker can form an intrachain disulfide bond with a Cys in the MHC class I heavy chain polypeptide, e.g., with a Cys at position 84 or a Cys at one of positions 135-143, e.g., at position 139.
[0211] It has been found that the cytotoxic effect of TEPs comprising a heterodimeric pMHC is greater when a TC is positioned N-tenninal to the MHC heavy chain polypeptide and the linker between them is no more than about 12 amino acids in length, e.g., no more than 10 amino acids in length (e.g., a (GGGGS)? (SEQ ID NO:347) linker), no more than 8 amino acids in length, no more than 7 amino acids in length, no more than 6 amino acids in length, or no more than 5 amino acids in length, (e.g., a GGGGS (SEQ ID NO:348) linker. See also WO 2023 / 097188, the disclosure of which as it pertains to such linkers is expressly incorporated herein by reference, including specifically, paragraph
[0237] , TARGETING COMPONENTS (TCS)
[0212] As noted above, TEPs comprise at least one TC that is an IL5R binder, and when a TEP comprises more than one TC. the TCs may be the same or different. As noted above, for example, a TEP that comprises more than one TC can comprise two different IL5R binders, e.g., (i) a first TC that is a peptide or an antibody or fragment that binds to IL5R, and (ii) a second TC that binds differently to IL5R. In this way, the TEP potentially can more effectively effect depletion of a patient’s IL5R-ECs. Alternatively, for example, a TEP that comprises more than one TC can comprise (i) a first TC that is a peptide or an antibody or fragment that binds to IL5R, and (ii) a second TC that binds to a different target that can be any protein or antigen other than 1L5R. Examples of such non-lL5R targets include, but are not limited to, a protein or antigen other than IL5R that is (i) associated with an IL5R-associated disorder, e.g., another protein that is commonly present in IL5R-associated disorder, e.g., a protein that is commonly present in IL5R-associated disorders, e.g. inflammatory’ disorders or cancers, (ii) associated with a condition or disorder that is not an IL5R-associated disorder, including disorders that commonly occur concurrently with IL5R-associated disorders, (iii) associated with a primary condition or disorder that can lead to an IL5R-associated disorder such as eosinophilic asthma, or (iv) also found on IL5R-ECs.A. Antibodies that bind to IL5R
[0213] Antibodies that bind to IL5R are known in the art. To date, one anti-IL5R antibody has been approved by the FDA. Benralizumab (marketed as Fasenra®) binds directly to IL5Ra on eosinophils and basophils and is used primarily for the treatment of severe eosinophilic asthma. Benralizumab bindingprevents IL-5 signaling and leads to eosinophilic apoptosis, resulting in depletion of eosinophils and a reduction of inflammation.
[0214] Benralizumab is described in published PCT Applications WO 2008 / 143878 (Medimmune, LLC). The amino acid sequences of the variable region of the light chain, variable region of the heavy chain, the constant region of the light chain and the constant region of the heavy chain, are provided in SEQ ID NOS: 1, 3, 2 and 4 of WO 2021 / 059221, respectively. The amino acid sequences of the variable region of the light chain, and variable region of the heavy chain are also provided herein in FIGS. 17A (SEQ ID NO:349) and 17B (SEQ ID NO:350), respectively. Tire amino acid sequence for the light chain of benralizumab is provided as FIG. 17C (SEQ ID NO:351) and the heavy chain is provided as FIG. 17D (SEQ ID NO:352). Tire amino acid sequences for the heavy chain variable regions CDR1, CDR2 and CDR3 are provided herein as FIGS. 17E (SEQ ID NO:353), 17F (SEQ ID NO:354) and 17G (SEQ ID NO:355), respectively. The amino acid sequences for the light chain variable regions CDR1, CDR2 and CDR3 are provided herein as FIGS. 17H (SEQ ID NO:356), 171 (SEQ ID NO:357) and 17J (SEQ ID NO:358), respectively. The amino acid sequence for scFv-Fc (vL-vH) is provided as FIG. 17K (SEQ ID NO:359), the amino acid sequence for scFv-Fc (vH-vL) is provided as FIG. 17L (SEQ ID NO:360), and the amino acid sequence for the scFv-HLA-A02:01-Fc (vL-vH) is provided herein as FIG. 17M (SEQ ID NO:361).
[0215] In some cases, an anti-IL5R antibody includes a variable region of a light chain comprising an amino sequence having at least 90%, at least 95%, at least 98%, at least 99%, or 100% amino acid sequence identity to the amino acid sequence of SEQ ID NO:349.
[0216] In some cases, an anti-IL5R antibody includes a variable region of a heavy chain comprising an amino sequence having at least 90%, at least 95%, at least 98%, at least 99%, or 100% amino acid sequence identity to tire amino acid sequence of SEQ ID NO:351.
[0217] In some cases, an anti-IL5R antibody is a scFv. For example, in some cases, an anti-IL5R scFv comprises an amino acid sequence having at least 90%, at least 95%, at least 98%, at least 99%, or 100%, amino acid sequence identity to either or both the VL or VH amino acid sequences of SEQ ID NOS: 349 and 351, wherein the sequences may be joined by a peptide linker, optionally a (GGGGS)n linker, where n=l-10, e.g., n=2, n=3 or n=4, e.g., where n=3.
[0218] In some cases, an anti-IL5R antibody is a scFv. For example, in some cases, an anti-IL5R scFv comprises an amino acid sequence having at least 90%, at least 95%, at least 98%, at least 99%, or 100%, amino acid sequence identity to the amino acid sequence of SEQ ID NO: 359 OR 360.
[0219] In some cases, an anti-IL5R antibody (e.g., an anti-IL5R scFv) comprises (i) one, two or all three heavy chain variable region CDRs set forth in SEQ ID NOS: 353-355, and / or (ii) one, two or all three light chain variable region CDRs set forth in SEQ ID NOS: 356-358.B. Other TCs that bind to IL5R
[0220] As noted above, a targeting component need not be an antibody but can also be any protein or peptide that binds to IL5R. For example, numerous peptides having a length of 14-50 amino acids, preferably 14-20 amino acids, have been disclosed as binding to IL5R. See, e.g., US Patent No.7,109,299. One such peptide is AF17121 described in US Patent No. 7,109,299, which has been reported to bind to IU5Ra. See, e.g., Shheide-Noeth, et al., Structural Basis of Interleukin-5 Inhibition by the Small Cyclic Peptide AF17121, J Mol Biol. 2019 Feb 15;431(4): 714-731. AF17121 has the amino acid sequence VDECWRIIASHTWFCAEE (SEQ ID NO:362). AF17121 can be provided as a TC of a TEP, e.g., by linking the C-terminus of AF17121 to the N-terminus of an MHC heavy chain-IgGl Fc polypeptide as illustrated in FIG. 170 (SEQ ID NO:363).
[0221] Other such peptides or proteins that bind IL5R will be known to persons of skill in the art.C. Antibodies to Other Targets
[0222] As discussed above, dual -targeting TEPs can include a TC that does not bind to IL5R. Such dual-targeting TEPs can include, for example, TCs directed to other proteins that are expressed (i) on IL5R-ECs, or (ii) in an IL5R-associated disorder or in primary disorder that can lead to secondary IL5R-associated disorder. See, e.g., the discussion below regarding several primary disorders that can lead to IL5R-associated eosinophil proliferation, differentiation and activation, and inflammatory conditions. MULTIMERS OF A TEP
[0223] As discussed above, a TEP can be a dimer of two TEPs. That is, the present disclosure provides a TEP comprising a dimer of two TEPs, which two TEPs can be the same or different. Because dimeric TEPs present two pMHCs to T-cells, they can effect crosslinking upon engaging with the TCRs of a T-cell, which can trigger intracellular signaling events within the T-cell and lead to T-cell activation. The covalent linkage of the dimer can be one or more (typically two) disulfide bonds between an Ig Fc polypeptide in the first TEP and an Ig Fc polypeptide in the second TEP. When the TEP comprises an Ig Fc polypeptide, e.g., an IgGl Fc polypeptide, the TEP typically will self-assemble into a dimer by spontaneously forming one or more (typically two) disulfide bonds with the Ig Fc polypeptide of another TEP. In many cases, the two TEPs will be identical to one another in amino acid sequence and comprise Ig Fc polypeptides that spontaneously form two disulfide bonds, thereby forming a TEP that is a homodimer. Alternatively, the dimeric TEP may comprise two different TEPs. In such case, the Ig Fc polypeptides of each TEP can comprise interspecific dimerization sequences, e.g., ‘‘Knob-in-Hole” (“KiH”) sequences that permit the two different TEPs to selectively dimerize. Such interspecific dimerization sequences are disclosed in WO 2022 / 197970 (Cue Biopharma, Inc.), the disclosure of which as it pertains to interspecific dimerization sequences (including but not limited to paragraphs
[0212] -
[0213] ) is expressly incorporated herein by reference. Interspecific dimerization sequences alsomay be employed to enable TEPs to be linked to non-TEP molecules that can provide additional functionality to the TEP.
[0224] Where the dimeric TEP comprises two different TEPs, the two TEPS may be of any configuration, e.g., one TEP can comprise a single-chain pMEIC and the other can comprise a heterodimeric pMHC. As another example, a dimeric TEP can comprise a first TEP that comprises a single-chain pMHC that has a single intrachain disulfide bond (e.g., a body disulfide) and a second TEP that comprises a single-chain pMHC that has two intrachain disulfide bonds (e.g., both a body disulfide and a linker disulfide). As another example, a dimeric TEP can comprise a first TEP that comprises a heterodimeric or single-chain pMHC that has a linker disulfide bond that joins a Cys-containing linker to a Y84C amino acid in the MHC heavy chain polypeptide and a second TEP that comprises a heterodimeric or single-chain pMHC that has a linker disulfide bond that joins a Cys-containing linker to an A139C amino acid in the MHC heavy chain polypeptide. As another example, the two TEPs can comprise two different IL5R binders, or on TC that is an IL5R binder and one TC that is not an IL5R binder. As another example, the first TEP can comprise one peptide epitope (e.g., a CMV epitope), and the second TEP can comprise a different peptide epitope (e.g., a SARS-CoV-2 epitope). As another example, the first TEP can comprise one TC and peptide epitope, and the second TEP can comprise a different TC and a different peptide epitope.
[0225] It should be understood that references to TEPs in the sections that follow expressly include dimeric TEPs.NUCLEIC ACIDS
[0226] Tire present disclosure provides nucleic acids comprising nucleotide sequences encoding a TEP. In some cases, e.g., where the TEP is heterodimeric or a dimeric TEP comprising two different TEPs, the individual polypeptide chains of a TEP may be encoded in separate nucleic acids. In some cases, all polypeptide chains of a TEP are encoded in a single nucleic acid. In some cases, a first nucleic acid comprises a nucleotide sequence encoding a first polypeptide of a TEP; and a second nucleic acid comprises a nucleotide sequence encoding a second polypeptide of a TEP. In some cases, single nucleic acid comprises a nucleotide sequence encoding a first polypeptide of a TEP and a second polypeptide of a TEP.A. Separate nucleic acids encoding individual polypeptides of a TEP
[0227] As noted above, in some cases, the individual polypeptide chains of a TEP, e.g., a heterodimeric TEP or a dimeric TEP comprising two different TEPs, are encoded in separate nucleic acids. In some cases, nucleotide sequences encoding the separate polypeptide chains of a TEP are operably linked to transcriptional control elements, e.g., promoters, such as promoters that are functional in a eukaryotic cell, where the promoter can be a constitutive promoter or an inducible promoter.
[0228] For example, the present disclosure provides a first nucleic acid and a second nucleic acid, where the first nucleic acid comprises a nucleotide sequence encoding a first polypeptide of a heterodimeric TEP, and where the second nucleic acid comprises a nucleotide sequence encoding a second polypeptide of a TEP. In some cases, the nucleotide sequences encoding the first and the second polypeptides are operably linked to transcriptional control elements. In some cases, the transcriptional control element is a promoter that is functional in a eukaryotic cell. In some cases, the nucleic acids are present in separate expression vectors. Constructs and methods for formulating separate nucleic acids and recombinant expression vectors comprising separate nucleic acids encoding multiple polypeptides are well known to persons skilled in the art.B. Nucleic acid encoding two or more polypeptides present in a TEP
[0229] Tire present disclosure also provides a nucleic acid comprising nucleotide sequences encoding multiple polypeptides of a TEP. For example, the nucleotide sequences encoding the first and second polypeptides of a heterodimeric TEP can include a proteolytically cleavable linker interposed between the nucleotide sequences. In some cases, the nucleotide sequences encoding the first and second polypeptides of a heterodimeric TEP can include an internal ribosome entry site (IRES) interposed between the nucleotide sequence encoding the first polypeptide and the nucleotide sequence encoding the second polypeptide. In some cases, the nucleotide sequences encoding the first polypeptide and the second polypeptide of a heterodimeric TEP includes a ribosome skipping signal (or c / .s -acting hydrolase element, CHYSEL) interposed between the nucleotide sequence encoding the first polypeptide and the nucleotide sequence encoding the second polypeptide.
[0230] In some cases, a first nucleic acid (e.g., a recombinant expression vector, an mRNA, a viral RNA. etc.) comprises a nucleotide sequence encoding a first polypeptide chain of a TEP; and a second nucleic acid (e.g., a recombinant expression vector, an mRNA, a viral RNA, etc.) comprises a nucleotide sequence encoding a second polypeptide chain of a TEP. In some cases, the nucleotide sequence encoding the first polypeptide, and the second nucleotide sequence encoding the second polypeptide, are each operably linked to transcriptional control elements, e.g., promoters, such as promoters that are functional in a eukaryotic cell, where the promoter can be a constitutive promoter or an inducible promoter. Constructs and methods for formulating nucleic acids and recombinant expression vectors encoding multiple polypeptides are well known to persons skilled in the art.C. Recombinant expression vectors
[0231] The present disclosure provides recombinant expression vectors comprising the nucleic acids described above. Numerous suitable expression vectors are known to those of skill in the art, and many are commercially available. See, e.g., published PCT Application WO 2020 / 243315 (Cue Biopharma, Inc.).GENETICALLY MODIFIED HOST CELLS
[0232] The present disclosure provides a genetically modified host cell and compositions of such genetically modified host cells, where the host cell is genetically modified with a nucleic acid or recombinant expression vector as described above.
[0233] Suitable host cells include eukaryotic cells, such as yeasT-cells, insecT-cells, and mammalian cells. In some cases, the host cell is a cell of a mammalian cell line. Suitable mammalian cell lines include human cell lines, non-human primate cell lines, rodent (e.g., mouse, rat) cell lines, and the like. Suitable mammalian cell lines include, but are not limited to, HeLa cells (e.g., American Type Culture Collection (ATCC) No. CCL-2), CHO cells (e.g., ATCC Nos. CRL9618, CCL61, CRL9096), 293 cells (e.g., ATCC No. CRL-1573). Vero cells, NIH 3T3 cells (e.g.. ATCC No. CRL-1658), Huh-7 cells, BHK cells (e.g., ATCC No. CCL10), PC12 cells (ATCC No. CRL1721), COS cells, COS-7 cells (ATCC No. CRL1651), RATI cells, mouse L cells (ATCC No. CCLI.3), human embryonic kidney (HEK) cells (ATCC No. CRL1573), HLHepG2 cells, and the like.
[0234] In some cases, the host cell is a mammalian cell that has been genetically modified such that it does not synthesize endogenous MHC P2-M.
[0235] In some cases, the host cell is a mammalian cell that has been genetically modified such that it does not synthesize endogenous MHC Class I heavy chain. In some cases, the host cell is a mammalian cell that has been genetically modified such that it does not synthesize endogenous MHC P2-M and such that it does not synthesize endogenous MHC Class I heavy chain.METHODS OF PRODUCING A TEP
[0236] The present disclosure provides methods of producing a TEP. The methods generally involve culturing, in a culture medium, a host cell that is genetically modified with one or more nucleic acids or one or more recombinant expression vectors as described above comprising nucleotide sequences encoding the TEP, and isolating the TEP from the genetically modified host cell and / or the culture medium. A host cell that is genetically modified with one or more nucleic acids (e.g.. one or more recombinant expression vectors) comprising nucleotide sequences encoding the TEP is also referred to as an “expression host.” As noted above, in some cases, the individual polypeptide chains of a TEP are encoded in separate nucleic acids (e.g., in separate recombinant expression vectors). In some cases, all polypeptide chains of a TEP are encoded in a single nucleic acid, e.g., in a single recombinant expression vector.
[0237] Isolation of the TEP from the expression host cell (e.g., from a lysate of the expression host cell) and / or the culture medium in which the host cell is cultured, can be carried out using standard methods of protein purification.
[0238] For example, a lysate may be prepared of the expression host and tire lysate purified using high performance liquid chromatography (HPLC), exclusion chromatography, gel electrophoresis, affinity chromatography, or other purification technique. Alternatively, where the TEP is secreted from the expression host cell into the culture medium, the TEP can be purified from the culture medium using HPLC, exclusion chromatography, gel electrophoresis, affinity chromatography, or other purification technique. In some cases, the compositions which are used will comprise at least 80% by weight of the desired product (TEP), at least about 85% by weight, at least about 95% by weight, or at least about 99.5% by weight, in relation to contaminants related to the method of preparation of the product and its purification. The percentages can be based upon total protein.
[0239] In some cases, e.g., where the TEP comprises an affinity tag, the TEP can be purified using an immobilized binding partner of the affinity tag.COMPOSITIONS, DOSAGES, A D ROUTES OF ADMINISTRATION OF THE TEP
[0240] The present disclosure provides compositions, including pharmaceutical compositions, comprising a TEP.
[0241] A pharmaceutical composition can comprise, in addition to a TEP, one or more pharmaceutically acceptable additives, a variety of which are known in the art and need not be discussed in detail herein. See, for example, the ninth (or latest) edition of Sheskey et al., ’‘Handbook of Pharmaceutical Excipients” (2020), and / or the 23rd(or latest) edition of “Remington: The Science and Practice of Pharmacy”, 23rd Ed. (2020).
[0242] Where a TEP is administered as an injectable (e.g. subcutaneously, intraperitoneally, intramuscularly, and / or intravenously) directly into a tissue or vessel, a formulation can be provided as a ready-to-use dosage form that may be directly injected or infused into the patient or admixed with a saline solution for infusion, or possibly as anon-aqueous form (e.g., a reconstitutable storage-stable powder) or aqueous form, such as liquid composed of pharmaceutically acceptable carriers and excipients. Formulations may also be provided so as to enhance serum half-life of the TEP following administration. For example, the TEP may be provided in a liposome formulation, prepared as a colloid, or other conventional techniques for extending serum half-life. The preparations may also be provided in controlled release or slow-release forms.
[0243] The concentration of a TEP in a liquid composition formulation can vary widely (e.g., from less than about 0.1% to at least about 2% to as much as 20% to 50% or more by weight). Included within this range is a concentration of from about 5 to about 15 mg / mL. from about 8 to about 12 mg / mL. from about 9 to about 11 mg / mL, including about 5 mg / mL, about 6 mg / mL. about 7 mg / mL, about 8 mg / mL, about 9 mg / mL, about 10 mg / mL, about 11 mg / mL, about 12 mg / mL, about 13 mg / mL,about 14 mg / mL and about 15 mg / mL. The concentration may depend on numerous factors, including the stability of the TEP in the liquid composition.
[0244] In some cases, a TEP is present in a liquid composition. In some cases, a composition comprises: a) a TEP; and b) saline (e.g.. 0.9% NaCl). In some cases, the composition is sterile and suitable for administration to a human subject.
[0245] In some cases, mRNA, DNA, or a recombinant expression vector comprising one or more nucleic acids encoding a TEP (or a cell, e.g., an IL5R-EC or other blood cell such as a red blood cell comprising such nucleic acids or recombinant expression vector) may be administered to induce in vivo expression of the TEP instead of directly administering the TEP itself to a patient. When nucleic acids are employed (e.g., mRNA or DNA), they may be formulated for delivery using known methods. For example, mRNA can be delivered using known lipid nanoparticle technology. DNA can be delivered using known viral and non-viral methods.
[0246] A suitable dose of a TEP can be determined by an attending physician or other qualified medical personnel, based on various clinical factors. As is well known in the medical arts, dosages for any one patient depend upon many factors, including the patient's size, body surface area, age, the particular TEP or nucleic acid to be administered (including the number and type of MOD(s), if present in the TEP), sex of the patient, time, and route of administration, general health, and other drugs being administered concurrently. A pharmacal composition comprising a TEP may be administered in amounts between 0.01 mg / kg body weight and 20 mg / kg body weight per dose, e.g. between 0.1 mg / kg body weight to 10 mg / kg body weight, e.g.. from 0.5 mg / kg to 1 mg / kg, from 0.5 mg / kg body weight to 5 mg / kg body weight, from 1 mg / kg body weight to 5 mg / kg body weight; from 5 mg / kg body weight to 10 mg / kg body weight; from 10 mg / kg body weight to 15 mg / kg body weight: from 15 mg / kg body weight to 20 mg / kg body weight, however, doses above this exemplary range are envisioned, especially considering the aforementioned factors. If the regimen is a continuous infusion, it can also be in the range of 1 pg to 10 mg per kilogram of body weight per minute.
[0247] Alternatively, a patient may simply be administered a flat amount of a TEP, e.g., in an amount of from 1 mg to 1500 mg, including from 50 to 1000 mg, from 100 to 800 mg, from 200 mg to 600 mg or more, including from 250 mg to 450 mg, from 250 mg to 350 mg, from 450 mg to 600 mg, including specific amounts of 250 mg, 300 mg, 350 mg, 400 mg, 500 mg, or 600 mg or more.
[0248] Persons of ordinary skill in the art can readily estimate repetition rates for dosing based on measured residence times and concentrations of the administered agent in bodily fluids or tissues. Following successful treatment, it may be desirable to have the patient undergo maintenance therapy to prevent the recurrence of the disease state, wherein a TEP or dimerized TEP is administered inmaintenance doses, wherein the maintenance dose level may be different from the dose level used during the treatment phase.
[0249] Those of skill will readily appreciate that dose levels can va as a function of the specific TEP, the severity of the symptoms and the susceptibility of the subject to side effects. Additionally, in some cases the desired level of depletion of IL5R-ECs may be less than a substantially complete depletion, e.g., in cases where depleting only a portion of IL5R-ECs (e.g., 30%, 40%, 50%, 60% or 70% of IL5R-ECs) may achieve a desired therapeutic effect. Appropriate dosages for a given compound are readily determinable by those of skill in the art by a variety of means.
[0250] In certain embodiments, one or multiple doses of a TEP, a nucleic acid (e.g., mRNA), or a recombinant expression vector (or a cell, e.g., an 1L5R-EC or other blood cell such as a red blood cell comprising a nucleic acid or recombinant expression vector) are administered. The frequency and duration of administration can vary depending on any of a variety of factors, e.g., severity of unwanted side effects, recurrence of symptoms. For some disorders, one or only a few treatments may be required to effect a therapeutically sufficient depletion of the patient’s IL5R-ECs, especially in the case of delivery of nucleic acids (mRNA or DNA) encoding the TEP, which can provide a prolonged, in vivo production of the TEP. Additional treatments will depend on recurrence of symptoms for the particular disorder being treated. Periodic treatments can be once per week (qw), once every two weeks, once every three weeks, or once every four weeks, once every month, every two months, every three months, and so on depending on the above factors.IL5R- ASSOCIATED DISORDERS SUITABLE FOR TREATMENT
[0251] As noted, IL5R-associated disorders that can be treated with a method or composition of this disclosure include several types of malignancies as well as disorders that may be characterized by eosinophilic proliferation and inflammation.
[0252] IL5R-associated cancers include hematologic cancers (including lymphoid cancers) and solid tumor cancers. Hematological cancers include, e.g., Chronic Eosinophilic Leukemia (CEL-NOS), Acute Myeloid Leukemia (AML) and its various subtypes, e.g., Acute Eosinophilic Leukemia (AEL), and AML with inv(16)(pl3q22) ort(16:16)(pl3;q22). l l M4Eo Myelodysplastic Syndromes (MDS) such as MDS with Single Lineage Dysplasia (MDS-SLD): MDS with Multilineage Dysplasia (MDS-MLD). MDS with Ring Sideroblasts (MDS-RS) and its subtypes: MDS with Ring Sideroblasts and Single Lineage Dysplasia (MDS-RS-SLD), and MDS with Ring Sideroblasts and Multilineage Dysplasia (MDS-RS-MLD), MDS with Excess Blasts (MDS-EB) and its subtypes: MDS with Excess Blasts-1 (MDS-EB-1) and MDS with Excess Blasts-2 (MDS-EB-2), MDS with Isolated del(5q), MDS (Unclassifiable) (MDS-U), Hypoplastic MDS, Myeloproliferative Neoplasms (MPNs) such as Hypereosinophilic Syndrome (HES), Myeoloid / Lymphoid Neoplasms with Eosinophilia and TyrosineKinase Gene Fusions, including PDGFRA-, PDGFRB-, and FGFR1 -Rearranged Neoplasms, and PCM1-JAK2 Fusion Neoplasms, and multiple myeloma (IgE variant).
[0253] Lymphoid malignancies include (i) Hodgkin Lymphoma and its subtypes: Nodular Sclerosis Hodgkin Lymphoma, Mixed Cellularity Hodgkin Lymphoma, Lymphocyte-Rich Hodgkin Lymphoma, Lymphocyte-Depleted Hodgkin Lymphoma, and Nodular Lymphocyte Predominant Hodgkin Lymphoma (NLPHL), (ii) T-cell lymphomas that exhibit eosinophilic infdtration such as Non-Hodgkin Lymphomas of T-cell origin such as T-cell Lymphoblastic Lymphoma / Leukemia (T-ALL), Mature Peripheral T-cell Lymphomas (PTCL), Peripheral T-cell Lymphoma, not otherwise specified (PTCL-NOS), Angioimmunoblastic T-cell Lymphoma (AITL), Anaplastic Large Cell Lymphoma (ALCL) including its subtypes, Extranodal NK / T-cell Lymphoma, nasal type, Adult T-cell Leukemia / Lymphoma (ATLL), Cutaneous T-cell Lymphomas (CTCL), Subcutaneous Panniculitis-Like T-cell Lymphoma (SPTCL), and Lymphocytic Variant of Hypereosinophilic Syndrome (L-HES), and (iii) B-cell lymphomas, e.g., Non-Hodgkin Lymphomas (NHL) of B-cell origin of which there are over 70 recognized subtypes, including Mixed Cellularity Classical Hodgkin Lymphoma (MCCHL), Nodular Sclerosis Classical Hodgkin Lymphoma (NSCHL), Lymphocyte-Rich Classical Hodgkin Lymphoma, Follicular Lymphoma (FL). Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), Burkitt Lymphoma, Lymphoplasmacytic Lymphoma (LPL), Small Lymphocytic Lymphoma / Chronic Lymphocytic Leukemia (SLL / CLL), Primary Cutaneous Marginal Zone Lymphoma, Primary7Cutaneous Follicle center Lymphoma, Diffuse Large B-cell lymphoma (DLBCL), including the T-Cell / Histiocytc-Rich Large B-Cell Lymphoma (THRLBCL), Unclassifiable B-Cell Lymphoma with Features Intermediate between DLBCL and Classical Hodgkin Lymphoma (HL), Lymphoma Acute Lymphoblastic Leukemia (ALL), Primary Central Nervous System Lymphoma, and Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue Lymphoma (MALT).
[0254] Solid tumor cancers include, e.g., respiratory7tumors such as lung adenocarcinoma and nonsmall cell lung cancer (NSCLC), pancreatic cancers, e.g., conventional pancreatic ductal adenocarcinomas (cPDAC). colloid carcinoma (mucinous or papillary-cystic carcinoma), adenosquamous carcinoma (ASqC), signet ring cell carcinoma (poorly cohesive carcinoma), undifferentiated carcinoma (UC), undifferentiated carcinoma with osteoclast-like gianT-cells (UCOGC), hepatoid carcinoma (HC), medullary carcinoma (MC), pancreatic undifferentiated carcinoma with rhabdoid phenotype (PUCR), head and neck squamous cell carcinomas (HNSCC) such as tumors of the oral cavity, phar nx and lary nx, papillary thyroid carcinoma, salivary gland tumors nasophary ngeal carcinoma, gastrointestinal, hepatic and biliary cancers such as colorectal cancer, gastric and esophageal adenocarcinomas, hepatocellular carcinoma, cholangiocarcinoma, urothelial (bladder) carcinoma, prostate adenocarcinoma, renal cell carcinoma, ovarian and cervical carcinomas, skin carcinomas including cutaneous squamous cell carcinoma (SCC), basal cell Carcinoma (BCC), and melanoma, softtissue sarcomas and other rare solid tumors. In addition Tumor-Associated Tissue Eosinophilia (TATE) may be observed in solid tumors.
[0255] IL5R-associated disorders include primary eosinophilic disorders such as idiopathic hypereosinophilic syndrome (HES). chronic eosinophilic leukemia (CEL / CEL-NOS). and myeloproliferative neoplasms with eosinophilia. They also include allergic and atopic disorders such as eosinophilic asthma, allergic rhinitis, and chronic sinusitis, chronic rhinosinusitis, chronic rhinosinusitis with nasal polyps, atopic dermatitis, eosinophilic esophagitis (EoE), eosinophilic gastroenteritis, colitis and enteritis, pulmonary’ vasculitis, and allergic bronchopulmonary aspergillosis (ABPA). Certain parasitic infections can trigger an eosinophilic response, including schistosomiasis, ascariasis, strongyloidiasis, hookworm infections, toxocariasis and trichinellosis. Drug -induced reactions include those with eosinophilia and systemic symptoms (DRESS) syndrome and drug-induced eosinophilic pneumonia. Autoimmune and vasculitic diseases include eosinophilic granulomatosis with polyangiitis (EGPA, f / k / a Churg-Strauss Syndrome), eosinophilic fasciitis (Shulman Syndrome), and acute and chronic eosinophilic pneumonia, autoimmune disorders such as rheumatoid arthritis, systemic lupus erythematosus (SLE), psoriasis and psoriatic arthritis, inflammatory bowel diseases including ulcerative colitis and Crohn’s Disease, and autoimmune thyroiditis (Hashimoto’s Thyroiditis). Chronic infections and related inflammatory conditions include: chronic hepatitis (B&C), Heliobacter pylori infection, chronic periodontitis and tuberculosis. Metabolic and cardiovascular diseases include obesity and metabolic syndrome, type 2 diabetes mellitus, and atherosclerosis, Pulmonary’ and other disorders include chronic obstructive pulmonary disease (COPD), eosinophilic asthma, paraneoplastic eosinophilia, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), chronic kidney disease and chronic skin conditions such as eczema.METHODS OF TREATMENT
[0256] Methods of treatment comprise administering to a patient having an above-described IL5R-associated disorder a therapeutically effective amount of a pharmaceutical composition comprising (i) a TEP or (ii) a nucleic acid (e.g., DNA or mRNA), recombinant expression vector or other composition that causes in vivo production of the TEP to cause a reduction of, or a substantially complete elimination of, the patient’s IL5R-ECs or a reduction in both tire activation of IL5R-ECs and their survival. For disorders such as those discussed above that can lead to IL5R-associated eosinophilic proliferation, the TEP can be prophylactically administered or administered with the onset of symptoms to reduce or substantially prevent the onset of eosinophilic proliferation and inflammation.
[0257] As mentioned above, methods of treating can include vaccination prior to administration of tire TEP. Hie vaccination will be to elicit / expand the patient's repertoire of T-cells having TCRs specific for the pMHC of the TEP, thereby ensuring that the patient will have an available repertoire of T-cells forIL5R-EC depletion. A vaccine typically can be administered from one to four weeks prior to administration of the TEP. In instances where a patient has previously received a vaccine that elicits T-cells having TCRs specific for the pMHC of the TEP, it may be desirable to give the patient a booster of the vaccine to ensure a higher titer of T-cells that will recognize and bind to the pMHC of the TEP. In tire event that the duration of treatment is prolonged, it may be advantageous to re-administer the vaccine to increase the patient’s T-cells specific for the TEP.Combination Treatments
[0258] TEPs may be administered in combination with any therapeutic that treats a patient’s IL5R-associated disorder. As noted above, peptides such as AF17121 have been found to bind to IL5Ra, and thus may be administered in provided in combination with the TEPs described herein. Additionally, antibodies that bind to IL5Ra, e.g. Mepolizumab (Nucala®) and Reslizumab (Cinqair®), also may be useful when administered in combination with the TEPs described herein.EXAMPLES OF NON-LIMITING ASPECTS OF THE DISCLOSURE
[0259] Aspects, including embodiments, of the present subject matter described above may be beneficial alone or in combination, with one or more other aspects or embodiments. Without limiting the foregoing description, certain non-limiting aspects of the disclosure are provided below. As will be apparent to those of skill in the art upon reading this disclosure, each of the individually numbered aspects may be used or combined with any of the preceding or following individually numbered aspects. This is intended to provide support for all such combinations of aspects and is not limited to combinations of aspects explicitly provided below.
[0260] 1. A T-cell engaging protein (“TEP"’). wherein the TEP comprises:i) a peptide-major histocompatibility complex (“pMHC”) comprising a peptide epitope, a P2-microglobulin (“P2M”) polypeptide, and an MHC class I heavy chain polypeptide;ii) a scaffold component;iii) at least one targeting component (“TC”) that binds to IL5R;iv) optionally one or more activating immunomodulatory polypeptides; andv) optionally one or more independently selected peptide linkers between any two of the components of the TEP, and wherein when the TEP comprises more than one activating immunomodulatory polypeptide, the activating immunomodulatory polypeptides optionally may be connected by one or more independently selected peptide linkers.
[0261] 2 The TEP of aspect 1, wherein the TC is an antibody or antigen-binding portion of an antibody that binds to IL5R, e.g., a fragment of an antibody that retains specific binding to IL5R, including, but not limited to. Fab, Fv, scFv, and Fd fragment, chimeric antibody, humanized antibody,single-chain antibody (scAb), single domain antibody (dAb), single domain heavy chain antibody, single domain light chain antibody, or nanobody.
[0262] 3. The TEP of aspect 1 or 2, wherein the scaffold component is(i) an Ig Fc polypeptide selected from an IgGl Fc polypeptide, IgG2 Fc polypeptide, IgG3 Fc polypeptide, or IgG4 polypeptide, or(ii) a non-Ig scaffold selected from albumin, an XTEN (extended recombinant) polypeptide, transferrin, an Fc receptor polypeptide, an elastin-like polypeptide, an albumin-binding polypeptide, a silk-like polypeptide, and a silk-elastin-like polypeptide (SELP).
[0263] 4 The TEP of aspect 3, wherein the Ig Fc polypeptide is a variant having one or more substitutions that reduce or substantially eliminate effector function.
[0264] 5. The TEP of aspect 4, wherein the Ig Fc polypeptide is an IgGl Fc polypeptide having one or more substitutions that reduce or substantially eliminate effector function, optionally wherein the Ig Fc polypeptide does not include a C-terminal Lys present in a wild-type Ig Fc polypeptide variant.
[0265] 6. The TEP of any one of aspects 1-5, wherein the pMHC presents an epitope of a pathogen-infected cell, optionally wherein the pMHC presents an epitope of a virus-infected cell or a bacteria-infected cell.
[0266] 7 The TEP of aspect 6, wherein the pMHC presents an epitope of a cell infected with a virus selected from CMV, influenza (flu), SARS-CoV2, EBV, HPV, or yellow fever virus.
[0267] 8 The TEP of any one of aspects 1-7, wherein the MHC class I heavy chain is an HLA-A allele heavy chain polypeptide, optionally wherein the HLA-A allele heavy chain polypeptide comprises an amino acid sequence having at least 90%, at least 95%, at least 98%, or at least 99%, amino acid sequence identity to the HLA-A amino acid sequence depicted in any one of FIGS. 7A-7E, 8A-8E, 9A-9E, 10A-10E. HA-llE and 12A-12D.
[0268] 9 The TEP of any one of aspects 1-7, wherein the MHC class I heavy chain is an HLA-B allele heavy chain polypeptide, optionally wherein the HLA-B allele heavy chain polypeptide comprises an amino acid sequence having at least 90%, at least 95%, at least 98%. or at least 99%, amino acid sequence identity to the HLA-B amino acid sequence depicted in FIGS. 13A-13D.
[0269] 10. Hie TEP of any one of aspects 1-7, wherein the MHC class I heavy chain is an HLA-C allele heavy chain polypeptide, optionally wherein the HLA-C allele heavy chain polypeptide comprisesan amino acid sequence having at least 90%, at least 95%, at least 98%, or at least 99%, amino acid sequence identity to tire HLA-C amino acid sequence depicted in FIGS. 14A-14D.
[0270] 11. The TEP of any one of aspects 1-7, wherein the MHC class I heavy chain is an HLA-E allele heavy chain polypeptide, optionally wherein the HLA-E allele heavy chain polypeptide comprises an amino acid sequence having at least 90%, at least 95%, at least 98%, or at least 99%, amino acid sequence identity to tire HLA-E amino acid sequence depicted in FIGS 15A-15E.
[0271] 12. The TEP of any one of aspects 1-11, wherein the 02M polypeptide, wherein the 02M polypeptide comprises an amino acid sequence having at least 95% amino acid sequence identity to 21-119 of any one of the amino acid sequences set forth in SEQ ID NOs: 1-3.
[0272] 13. The TEP of any one of aspects 1-12, wherein each of the optional one or more activating immunomodulatory polypeptides, if present, are independently selected from a cytokine, a 4-1BBL polypeptide, an ICOS-L polypeptide, an OX-40L polypeptide, a CD80 polypeptide, a CD86 polypeptide, a CD40 polypeptide, a CD70 polypeptide, and combinations thereof.
[0273] 14. The TEP of aspect 13, wherein the cytokine is an IL-2 polypeptide, and wherein the IL-2 polypeptide is a variant IL-2 polypeptide that exhibits reduced affinity to an IL-2 receptor compared to the affinity of a wild-type IL-2 polypeptide for the IL-2 receptor, optionally wherein the variant IL-2 polypeptide exhibits substantially no binding to IL-2Ra, and also exhibits decreased binding to IL-2R0.
[0274] 15. The TEP of aspect 14, wherein the variant IL-2 polypeptide has at least 90%, at least 95%, at least 97%, at least 98%, at least 99%, or 100% amino acid sequence identity to the wild-type IL-2 amino acid sequence, and wherein amino acid 16 of the variant IL-2 polypeptide is other than histidine and amino acid 42 is other than pheny lalanine, optionally wherein amino acid 16 is Ala, Thr, Asp or Glu and wherein amino acid 42 is Ala, and optionally wherein amino acid 16 is Ala and wherein amino acid 42 is Ala.
[0275] 16. The TEP of any one of aspects 13-15, wherein the TEP comprises two variant IL-2 polypeptides in tandem, optionally connected by a linker.
[0276] 17. Tire TEP of any one of aspects 1-16, wherein the TEP comprises a heterodimer, wherein the heterodimer comprises:a) a first polypeptide comprising:i) the peptide; andii) the 02-microglobulin (02M) polypeptide; andb) a second polypeptide comprising:i) the MHC class I heavy chain polypeptide; andii) the immunoglobulin (Ig) Fc polypeptide;iii) the at least one TC; andiv) optionally, one or more activating immunomodulatory polypeptides, optionally wherein the TEP comprises one or more independently selected peptide linkers between any two of the components, and wherein when the TEP comprises more than one activating immunomodulatory polypeptide, the activating immunomodulatory polypeptides optionally may be connected by one or more independently selected peptide linkers.
[0277] 18. The TEP of aspect 17, wherein each heterodimeric TEP comprises a disulfide bond formed between a Cys residue in the [12M polypeptide and a Cys residue in the MHC class I heavy chain polypeptide.
[0278] 19. The TEP of aspect 17 or 18, wherein the heterodimeric TEP comprises a disulfide bond formed between (i) a Cys residue in a Cys-containing linker interposed between the peptide and the P2M polypeptide, and (ii) a Cys residue in the MHC class I heavy chain polypeptide.
[0279] 20. The TEP of aspect 19, wherein the first polypeptide and the second polypeptide are covalently linked to one another by at least a first and second disulfide bond,wherein the first disulfide bond formed between (i) a Cys residue in a Cys-containing linker between the peptide epitope and the P2M polypeptide, and (ii) a Cys residue in the MHC class I heavy chain polypeptide; andwherein tire second disulfide bond is formed between a Cys residue in the P2M polypeptide and a Cys residue in the MHC class I heavy chain polypeptide.
[0280] 21. The TEP of any one of aspects 17-20, whereina) the first polypeptide of the heterodimeric TEP comprises, in order from N-terminus to C-terminus:i) the peptide, optionally wherein the peptide epitope has a length of 8-12 amino acids; ii) a peptide linker; andiii) the P2M polypeptide;b) the second polypeptide of each heterodimeric TEP comprises, in order from N-terminus to C-terminus:i) optionally, one or more activating immunomodulatory polypeptides;ii) the MHC class I heavy chain polypeptide;iii) the Ig Fc polypeptide; andiv) the at least one TC, andwherein the second polypeptide optionally comprises independently selected peptide linkers between one or more components of the second polypeptide.
[0281] 22. The TEP of any one of aspects 17-20, whereina) tire first polypeptide of tire heterodimeric TEP comprises, in order from N-terminus to C-terminus:i) the peptide, optionally wherein the peptide epitope has a length of 8-12 amino acids; ii) a peptide linker; andiii) the P2M polypeptide;b) the second polypeptide of each heterodimeric TEP comprises, in order from N-terminus to C-temiinus:i) the at least one TC:ii) the MHC class I heavy chain polypeptide;iii) the Ig Fc polypeptide; andiv) optionally, one or more activating immunomodulatory polypeptides, wherein the second polypeptide optionally comprises independently selected peptide linkers between one or more components of the second polypeptide.
[0282] 23. The TEP of any one of aspects 17-22, wherein:i) the P2M polypeptide comprises a Cys at amino acid 12 based on the amino acid numbering of SEQ ID NO: 1; andii) the MHC class I polypeptide comprises a Cys at residue 236 based on the amino acid numbering of FIG. 7A, andwherein the heterodimeric TEP comprises a disulfide bond linking the first polypeptide to the second polypeptide, and wherein the disulfide bond joins the Cys at amino acid 12 of the P2M polypeptide to the Cys at amino acid 236 of the MHC heavy chain polypeptide, optionally wherein the heterodimer comprises a second disulfide bond fomied between (i) a Cys residue in a Cys-containing linker between the peptide and the P2M polypeptide, and (ii) a Cys residue in the MHC class I heavy chain polypeptide.
[0283] 24. A dimeric TEP comprising two heterodimeric TEPs according to any one of aspects 17-23, wherein the first polypeptides of each heterodimeric TEP have the same amino acid sequence, and the second polypeptide of each heterodimeric TEP have the same amino acid sequences, and wherein the two heterodimeric TEPs are joined together by one or more disulfide bonds formed between the Ig Fcpolypeptides of each heterodimeric TEP, optionally wherein the two heterodimeric TEPs are joined together by two disulfide bonds formed between the Ig Fc polypeptides of each heterodimeric TEP.
[0284] 25. A dimeric TEP comprising two heterodimeric TEPs according to any one of aspects 17-23, wherein the first and / or second polypeptides of each heterodimeric TEP have a different amino acid sequence, and wherein the Ig Fc polypeptides of the first and second heterodimeric TEPs comprise interspecific dimerization sequences, optionally wherein the interspecific dimerization sequences are “Knob-in-Hole" sequences that permit the two heterodimeric TEPs to selectively dimerize, optionally wherein (i) each TEP of the dimeric TEP comprises a different antibody TC (e.g.. a different scFv). and / or (ii) each TEP of the dimeric TEP comprises a different peptide epitope.
[0285] 26. The TEP of any one of aspects 1-16, wherein the TEP is a single-chain TEP comprising:i) the peptide:ii) the P2M polypeptide;iii) the class I HLA heavy chain polypeptide;iv) the immunoglobulin (Ig) Fc polypeptide;v) the at least one TC; andvi) optionally, one or more activating immunomodulatory polypeptides,optionally wherein the TEP comprises one or more independently selected peptide linkers between any two of the components, and wherein when the TEP comprises more than one activating immunomodulatory polypeptide, the activating immunomodulatory polypeptides optionally may be connected by one or more independently selected peptide linkers.
[0286] 27. The TEP of aspect 26, wherein the single-chain TEP comprises a Cys-containing peptide linker between the peptide and the 02M polypeptide, and wherein the single-chain TEP comprises an intrachain disulfide bond between the Cys in the Cys-containing peptide linker and a Cys in the class I HLA heavy chain polypeptide.
[0287] 28. The TEP of aspect 27, wherein the class I HLA heavy chain polypeptide comprises a Cys at any one of amino acids 135-143 (e.g., amino acid 139), based on the numbering of the class I HLA heavy chain polypeptide depicted in FIG 7A, and wherein amino acid 84, based on the numbering of the class I HLA heavy chain polypeptide depicted in FIG. 7A is other than Cys; andwherein the TEP comprises an intrachain disulfide bond between the Cys present in the Cys-containing peptide linker and the Cys at any one of amino acids 135-143 of the class I HLA heavy chain polypeptide.
[0288] 29. The TEP of aspect 28, wherein the class I HLA heavy chain polypeptide comprises a Cys at amino acid 138, 139, or 140 based on the numbering of the class I HLA heavy chain polypeptide depicted in FIG. 7A.
[0289] 30. The TEP of aspect 28, wherein the class I HLA heavy chain polypeptide comprises a Cys at amino acid 139 based on the numbering of the class I HLA heavy chain polypeptide depicted in FIG. 7A.
[0290] 31. The TEP of aspect 27, wherein the single-chain TEP comprises an intrachain disulfide bond between the Cys present in the Cys-containing peptide linker and the Cys at amino acid 84 of the class I HLA polypeptide.
[0291] 32. The TEP of any one of aspects 27-31, wherein the peptide linker between the peptide and the P2M polypeptide in the single-chain TEP comprises the sequence CGGGS(GGGGS)n (SEQ ID NO:93), GCGGS(GGGGS)n (SEQ ID NO:90), or GGCGS(GGGGS)n (SEQ ID NO:95), wherein n is an integer from 1-10, optionally wherein n is an integer from 1-3.
[0292] 33. The TEP of any one of aspects 26-32, wherein the |32M polypeptide comprises a Cys at amino acid 12 based on the numbering of the P2M polypeptide depicted in SEQ ID NO: 1, wherein the class I HLA heavy chain polypeptide comprises a Cys at amino acid 236 based on the numbering of the class 1 HLA heavy chain polypeptide depicted in FIG. 7A, and wherein the single-chain TEP comprises a disulfide bond formed between the Cys at amino acid 12 of the P2M polypeptide and the Cys at amino acid 236 of the class I HLA heavy chain polypeptide.
[0293] 34. A dimeric TEP comprising two single-chain TEPs according to any one of aspects 26-33, wherein the two single-chain TEPs have the same amino acid sequence, and wherein the two singlechain TEPs are joined together by one or more disulfide bonds formed between the Ig Fc polypeptides of each single-chain TEP, optionally wherein the two single-chain TEPs are joined together by two disulfide bonds fomied between the Ig Fc polypeptides of each single-chain TEP.
[0294] 35. A dimeric TEP comprising two single-chain TEPs according to any one of aspects 26-33, wherein each single-chain TEP has a different amino acid sequence, and wherein the Ig Fc polypeptides of the first and second single-chain TEPs comprise interspecific dimerization sequences, optionally "Knob-in-Holc” sequences that permit the two single-chain TEPs to selectively dimerize, optionally wherein (i) each TEP of the dimeric TEP comprises a different antibody TC (e.g., a different scFv), and / or (ii) each TEP of the dimeric TEP comprises a different peptide epitope.
[0295] 36. The TEP of any one of aspects 1-16, wherein the TEP comprises a chemical conjugation site, wherein the peptide of the pMHC of the TEP is chemically conjugated to the constituent TEP through the chemical conjugation site, and wherein the peptide is positioned in the pMEIC of the constituent TEP for presentation to a cell bearing a T-cell receptor specific for the epitope presented by the pMHC.
[0296] 37. Hie TEP of aspect 36, wherein the chemical conjugation site is present in the [32 M polypeptide or MHC class I heavy chain polypeptide.
[0297] 38. The TEP of aspects 37, wherein the chemical conjugation site is present in the P2M polypeptide.
[0298] 39. The TEP of aspect 38, wherein the chemical conjugation site is a cysteine present in the P2M polypeptide.
[0299] 40. The TEP of aspect 39, wherein the peptide is conjugated to the TEP by the reaction of a maleimide group and the cysteine of the chemical conjugation site.
[0300] 41. A TEP according to any one of aspects 36-40, wherein the TEP comprises:a) a first polypeptide comprising the P2M polypeptide;b) a second polypeptide comprising,(i) the MHC class I heavy chain polypeptide;(ii) the Ig Fc polypeptide;(iii) at least one TC; and(iv) optionally, one or more activating immunomodulatory polypeptides.
[0301] 42. A dimeric TEP comprising two heterodimeric TEPs according to aspect 41, wherein:(i) the first polypeptides of the heterodimeric TEPs have the same amino acid sequence, and the second polypeptides of the heterodimeric TEPs have the same amino acid sequences, and wherein the two heterodimeric TEPs are joined together by one or more disulfide bonds formed between the Ig Fc polypeptides of each heterodimeric TEP, optionally wherein the two heterodimeric TEPs are joined together by two disulfide bonds formed between the Ig Fc polypeptides of each heterodimeric TEP; or(ii) the first or second polypeptide of one heterodimeric TEP has a different amino acid sequence from the second polypeptide of the other heterodimeric TEP, and wherein the Ig Fc polypeptides of the two heterodimeric TEPs comprise interspecific dimerization sequences, e g., Knobin-Hole” sequences that permit the two heterodimeric TEPs to selectively dimerize, optionally wherein(i) each TEP of the dimeric TEP comprises a different antibody TC (e.g., a different scFv), and / or (ii) each TEP of the dimeric TEP comprises a different peptide epitope.
[0302] 43. The TEP of any one of aspects 36-40, wherein the TEP is a single-chain TEP comprising:a) the P2M polypeptide;b) the MHC class I heavy chain polypeptide;c) the Ig Fc polypeptide;d) at least one TC; ande) optionally, one or more activating immunomodulatory polypeptides.
[0303] 44. A dimeric TEP comprising two single-chain TEPs according to aspect 43, wherein:(i) the single-chain TEPs have the same amino acid sequence, and wherein the two singlechain TEPs are joined together by one or more disulfide bonds formed between the Ig Fc polypeptides of each TEP, optionally wherein the two TEPs are joined together by two disulfide bonds formed between the Ig Fc polypeptides of each TEP; or(ii) each single-chain TEP has a different amino acid sequence, and wherein the Ig Fc polypeptides of the first and second single-chain TEPs comprise interspecific dimerization sequences, e.g., '’Kiiob-m-Holc" sequences that permit the two heterodimers to selectively dimerize, optionally wherein (i) each TEP of the dimeric TEP comprises a different antibody TC (e.g., a different scFv), and / or (ii) each TEP of the dimeric TEP comprises a different peptide epitope.
[0304] 45. The TEP of any one of aspects 1-16, wherein the TEP comprises a MAPP, wherein the MAPP comprises:(i) a framework polypeptide comprising a dimerization sequence and a multimerization sequence;(ii) a dimerization polypeptide comprising a counterpart dimerization sequence complementary to the dimerization sequence of the framework polypeptide, the dimerization sequence and counterpart dimerization sequence dimerizing through covalent and / or non-covalent interactions to form a heterodimer;(iii) the pMHC, wherein the pMHC comprises at least one presenting sequence and / or presenting complex;(iv) at least one TC;(v) optionally, one or more activating immunomodulatory polypeptides.
[0305] 46. The TEP of aspect 45, wherein the pMHC comprises a heterodimeric presenting complex or a single-chain presenting sequence.
[0306] 47. A dimeric TEP comprising two TEP MAPPs according to aspect 45 or 46, wherein the first and second TEP MAPPs are covalently attached through the binding of non-interspecific multimcrization sequences in the MAPPs.
[0307] 48. A dimeric TEP comprising two TEP MAPPs according to aspect 45 or 46, wherein the first and second TEP MAPPs are not identical and are covalently attached through the binding of interspecific multimerization sequences in the MAPPs, optionally wherein (i) each TEP MAPP comprises a TC ( e.g. different scFvs), and / or (ii) each TEP MAP comprises a different presenting sequence and / or presenting complex.
[0308] 49. A dimeric TEP according to any one of aspects 25, 35, 42, 44, and 48 wherein the dimeric TEP comprises first and second TEPs, wherein(i) the first TEP and second TEP comprise different anti-IL5R antibodies, optionally where the anti-IL5R antibodies target different 1L5R epitopes, and / or(ii) the first TEP comprises a pMHC that presents an epitope to T-cells, and the second TEP comprises a different pMEIC that presents a different epitope to T-cells, optionally wherein the pMHCs of the first and second TEPs present viral epitopes to anti-viral T-cells.
[0309] 50. The TEP or dimeric TEP of any one of aspects 1-49, wherein the TEP or dimeric presents a one or more viral epitopes.
[0310] 51. The TEP or dimeric TEP of aspect 50, wherein the pMHC presents an epitope selected from influenza (flu), CMV (e.g., wherein the peptide epitope is NLVPMVATV, SEQ ID NO: 141), EBV, SARS-Cov-2 (e.g., wherein the peptide epitope comprises YLQPRTFLL, SEQ ID NO: 166), yellow fever (e.g., wherein the peptide epitope comprises LLWNGPMAV, SEQ ID NO:420), HPV, or Varicella Zoster Virus (VZV) (e.g., where the peptide epitope is ILIEGIFFV, SEQ ID NO:418).
[0311] 52. The TEP or dimeric TEP of any one of aspects 1-51, wherein the TEP comprises a TC that is an anti-IL5R antibody (e.g., an scFv) that comprises:(i) a variable region of a light chain comprising an amino sequence having at least 90%, at least 95%, at least 98%, at least 99%, or 100%, amino acid sequence identity to the amino acid sequence of SEQ ID NO:349; and / or.(ii) a variable region of a heavy chain comprising an amino sequence having at least 90%, at least 95%, at least 98%, at least 99%, or 100%, amino acid sequence identity to the amino acid sequence of SEQ ID NO:351.
[0312] 53. The TEP or dimeric TEP of any one of aspects 1- 1, wherein the TEP comprises a TC that is an anti-IL5R scFv comprising at least 90%, at least 95%, at least 98%, at least 99%, or 100%, amino acid sequence identity to either or both the VL or VH amino acid sequences of SEQ ID NOS: 349 and 351, wherein the sequences may be joined by a peptide linker, optionally a (GGGGS)n linker, where n=l-10. e.g., n=2. n=3 or n=4, e.g., where n=3.
[0313] 54. The TEP or dimeric TEP of any one of aspects 1-51, wherein the TEP comprises a TC that is an anti-IL5R scFv comprising at least 90%, at least 95%. at least 98%, at least 99%, or 100%, amino acid sequence identity to the amino acid sequences set forth in SEQ ID NOS: 359 or 360.
[0314] 55. The TEP or dimeric TEP of any one of aspects 1-51, wherein the TEP comprises a TC that is an anti-IL5R antibody that comprises:(i) one, two or all three heavy chain variable region CDRs set forth in SEQ ID NOS: 353-355; and / or(ii) one, two or all three light chain variable region CDRs set forth in SEQ ID NOS: 356-358.
[0315] 56. Tire TEP or dimeric TEP of any one of aspects 1-55, wherein the TEP does not comprise an activating immunomodulatory polypeptide.
[0316] 57. The TEP or dimeric TEP of any one of aspects 1-55, wherein the TEP comprises at least one activating immunomodulatory polypeptide.
[0317] 58. A pharmaceutical composition comprising the TEP or dimeric TEP of any one of aspects 1-57.
[0318] 59. One or more nucleic acids encoding the polypeptide or polypeptides of a TEP or dimeric TEP according to any one of aspects 1-57.
[0319] 60. One or more recombinant expression vectors comprising one or more nucleic acids encoding the polypeptide or polypeptides of a TEP or dimeric TEP according to any one of aspects 1-57.
[0320] 61. An in vitro composition of host cells modified with the one or more nucleic acids of aspect 59 or the one or more recombinant expression vectors of aspect 60.
[0321] 62. A method of making a TEP or dimeric TEP of any one of aspects 1 -57, comprising culturing in vitro a composition of host cells according to claim 61 under conditions in which the TEP or dimeric TEP is produced.
[0322] 63. A method of treating an individual to deplete IL5R-expressing cells, the method comprising administering to the individual a therapeutic amount of a pharmaceutical composition according to aspect 58.
[0323] 64. A TEP or dimeric TEP according to any one of aspects 1-57 for use in a method of treating an individual to deplete IL5R-expressing cells, the method comprising administering to the individual a therapeutic amount of the TEP or dimeric TEP.
[0324] 65. Use of a TEP or dimeric TEP according to any one of aspects 1-57 in a method of treating an individual to deplete IL5R-expressing cells, the method comprising administering to the individual a therapeutic amount of the TEP or dimeric TEP.
[0325] 66. Use of a TEP or dimeric TEP according to any one of aspects 1-57 for the preparation of a medicament for use in a method of treating an individual to deplete IL5R-expressing cells, the method comprising administering to the individual a therapeutic amount of the TEP or dimeric TEP.
[0326] 67. The method, TEP or dimeric TEP, or use of any one of aspects 63-66, wherein the individual has an IL5R-associated disorder.
[0327] 68. The method, TEP or dimeric TEP, or use of aspect 67, wherein the IL5R-associated disorder is an IL5R-associated cancer, optionally wherein the IL5R-associated cancer is a hematological cancer (e.g., chronic eosinophilic leukemia, acute myeloid leukemia, acute eosinophilic leukemia, or myelodysplastic syndrome), lymphoid cancer (e.g., a B-cell carcinoma, T-cell carcinoma, or Hodgkin Lymphoma), or solid tumor cancer.
[0328] 69. The method, TEP or dimeric TEP, or use of aspect 67, wherein the IL5R-associated disorder is a primary' eosinophilic disorder (e.g., idiopathic hypereosinophilic syndrome (HES), chronic eosinophilic leukemia, and myeloproliferative neoplasms with eosinophilia), an allergic or atopic disorder (e.g.. eosinophilic asthma, allergic rhinitis, chronic sinusitis, chronic rhinosinusitis, chronic rhinosinusitis with nasal polyps, atopic dermatitis, eosinophilic esophagitis, eosinophilic gastroenteritis,colitis, enteritis, pulmonary vasculitis, and allergic bronchopulmonary aspergillosis), an autoimmune or vasculitic disorder (e.g., eosinophilic granulomatosis with polyangiitis or Churg-Strauss Syndrome, eosinophilic fasciitis (Shulman Syndrome), acute and chronic eosinophilic pneumonia, as rheumatoid arthritis, systemic lupus erythematosus, psoriasis and psoriatic arthritis, inflammatory bowel diseases including ulcerative colitis and Crohn's Disease, and autoimmune thyroiditis (Hashimoto's Thyroiditis)), a chronic infection or related inflammatory condition (e.g., chronic hepatitis, Heliobacter pylori infection, chronic periodontitis and tuberculosis), a metabolic or cardiovascular disease (e.g., obesity and metabolic syndrome, type 2 diabetes mellitus, and atherosclerosis), pulmonary or other disorder (e.g., chronic obstructive pulmonary disease, eosinophilic asthma, paraneoplastic eosinophilia, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), chronic kidney disease), or a chronic skin condition (e.g.. eczema).
[0329] 70. A method of treating an individual having an IL5R-associated disorder, the method comprising administering to the individual a therapeutic amount of a pharmacal composition of aspect 58.
[0330] 71. A TEP or dimeric TEP according to any one of aspects 1-57 for use in a method of treating an individual having an IL5R-associated disorder, the method comprising administering to the individual a therapeutic amount of the TEP or dimeric TEP.
[0331] 72. Use of a TEP or dimeric TEP according to any one of aspects 1-57 in a method of treating an individual having an IL5R-associated disorder, the method comprising administering to the individual a therapeutic amount of the TEP or dimeric TEP.
[0332] 73. Use of a TEP or dimeric TEP according to any one of aspects 1-57 for the preparation of a medicament for use in a method of treating an IL5R-associated disorder, the method comprising administering to the individual a therapeutic amount of the TEP or dimeric TEP.
[0333] 74. The method, TEP or dimeric TEP, or use of any one of aspects 70-73, wherein the IL5R-associated disorder is an IL5R-associated cancer, wherein the IL5R-associated disorder is an IL5R-associated cancer, optionally wherein the IL5R-associated cancer is a hematological cancer (e.g., chronic eosinophilic leukemia, acute myeloid leukemia, acute eosinophilic leukemia, or myelodysplastic syndrome), lymphoid cancer (e.g., a B-cell carcinoma, T-cell carcinoma, or Hodgkin Lymphoma), or solid tumor cancer.
[0334] 75. The method, TEP or dimeric TEP, or use of any one of aspects 70-73, wherein the RAR-associated disorder is characterized by proliferation of eosinophils and inflammation.
[0335] 76. The method, TEP or dimeric TEP, or use of any one of aspects 70-73, wherein the IL5R-associatcd disorder is a primary eosinophilic disorder (c.g., idiopathic hypcrcosinophilic syndrome (EIES), chronic eosinophilic leukemia, and myeloproliferative neoplasms with eosinophilia), an allergic or atopic disorder (e.g., eosinophilic asthma, allergic rhinitis, chronic sinusitis, chronic rhinosinusitis, chronic rhinosinusitis with nasal polyps, atopic dermatitis, eosinophilic esophagitis, eosinophilic gastroenteritis, colitis, enteritis, pulmonary vasculitis, and allergic bronchopulmonary aspergillosis), an autoimmune or vasculitic disorder (e.g., eosinophilic granulomatosis with polyangiitis or Churg-Strauss Syndrome, eosinophilic fasciitis (Shulman Syndrome), acute and chronic eosinophilic pneumonia, as rheumatoid arthritis, systemic lupus erythematosus, psoriasis and psoriatic arthritis, inflammatory bowel diseases including ulcerative colitis and Crohn’s Disease, and autoimmune thyroiditis (Hashimoto’s Thyroiditis)), a chronic infection or related inflammatory condition (e.g., chronic hepatitis, Heliobacter pylori infection, chronic periodontitis and tuberculosis), a metabolic or cardiovascular disorder (e.g., obesity and metabolic syndrome, type 2 diabetes mellitus, and atherosclerosis), pulmonary or other disorder (e.g., chronic obstructive pulmonary disease, eosinophilic asthma, paraneoplastic eosinophilia, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), chronic kidney disease), or a chronic skin condition (e.g.. eczema).EXAMPLES
[0336] The following prophetic examples (Examples 1-3) and actual experiment (Example 4) are put forth so as to provide those of ordinary skill with additional disclosure and description of how to make and use the present disclosure and are not intended to limit the scope of the disclosure in any way.EXAMPLE 1 : Production of TEP Comprising a Benralizumab TC
[0337] Plasmids containing nucleic acids for two TEPs of interest (see Table 3) are transfected into ExpiCHO cells and cultured for product expression. Upon harvest and media clarification, TEPs are purified through a standard two-step chromatography process and dialyzed into final product buffer prior to use. Tire first TEP comprises two heterodimeric TEPS, each comprising heavy chain 513A (FIG.17M, SEQ ID NO: 361) and light chain 1717 (FIG. 17P, SEQ ID NO: 364), and the second TEP comprises two heterodimeric TEPS, each comprising heavy chain 513A and light chain 4700 (FIG. 17Q, SEQ ID NO:365). Each heterodimeric TEP includes: a heterodimeric pMHC, a body disulfide and linker disulfide, a scaffold component (an IgGl Fc polypeptide), a benralizumab anti-IL5R scFv as the TC, and either a CMV peptide (pp65495.503) or a SARS-CoV-2 (“SCV2”) peptide (YLQPRTFLL; SEQ ID NO: 166) as the peptide epitope.Table 3Engineering DesignA^^ bbConstruct 2X (513A-1717) 2X (513A-4700) Peptide CMV SCV2TC Benralizuma 3 scFvEXAMPLE 2: Production of TEP Comprising a AF17121 TC
[0338] Plasmids containing nucleic acids for two TEPs of interest (see Table 3) are transfected into ExpiCHO cells and cultured for product expression. Upon harvest and media clarification, TEPs are purified through a standard two-step chromatography process and dialyzed into final product buffer prior to use. The first TEP comprises two heterodimeric TEPS, each comprising heavy chain 513B (FIG. 170, SEQ ID NO:36e) and light chain 1717 (FIG. 17P, SEQ ID NO:364), and the second TEP comprises two heterodimeric TEPS, each comprising heavy chain 513B and light chain 4700 (FIG. 17Q, SEQ ID NO:365). Each heterodimeric TEP includes: a heterodimeric pMHC, a body disulfide and linker disulfide, a scaffold component (an IgGl Fc polypeptide), a benralizumab anti-IL5R scFv as the TC, and either a CMV peptide (pp65495-503) or a SARS-CoV-2 (“SCV2”) peptide (YLQPRTFLL; SEQ ID NO: 166) as the peptide epitope.Table 4Engineering DesignConstruct 2X (513B-1717) 2X (513B-4700) Peptide CMV SCV2TC AF17121EXAMPLE 3: Production of a Dual-Targeting TEP Comprising a Benralizumab scFv TC and a AF17121 TC
[0339] Using athree-chain transfection, a TEP having a benralizumab scFv TC and AF17121 TC is prepared in ExpiCHO cells and cultured for product expression. Upon harvest and media clarification, TEPs are purified through a standard two-step chromatography process and dialyzed into final product buffer prior to use . See Table5. The TEP comprises a heterodimer of two different heterodimeric TEPs, i.e.. TEP 513C-1717 and TEP 513D-1717, which are joined together through “Knob-in-Hole” interspecific dimerization sequences (discussed above). The amino acid sequence of the heavy chain 513C is provided as FIG. 17R (SEQ ID NO:366) and the amino acid sequence of the heavy chain 513D is provided as FIG. 17S (SEQ ID NO:367). Each heterodimeric TEP includes: a heterodimeric pMHC, a body disulfide and linker disulfide, a scaffold component (an IgGl Fc polypeptide), a Benralizumab scFv TC (in TEP 513C-1717) or an AF17121 TC (in TEP 513D-1717), and a CMV peptide (pp65495-5o3) as the peptide epitope.Table 5Engineering DesignConstruct 513C-513D-1717Peptide CMVTCs Benralizumab scFv and AF17121EXAMPLE 4: Dimeric TEPs deplete IL-5Ra-positive B cells via antigen-specific CD8+ T cells
[0340] Two dimeric TEPs were prepared following the general procedure discussed in Example 1 above. The first dimeric TEP comprised two heterodimeric TEPS, each comprising heavychain construct 5105 shown as Sequence 513A (FIG. 17M) and light chain construct 1717 (FIG. 17P). as discussed above. Each heterodimeric TEP comprised a heterodimeric pMHC with an HLA-A*02 allele MHC Class I heavy chain, a body disulfide and a linker disulfide, a scaffold component (an IgGlFc polypeptide), a human anti-IL-5Ra TC, and a CMV peptide epitope. The first dimeric TEP did not include a MOD. The second dimeric TEP comprised two heterodimeric TEPS, each comprising heavy chain construct 5105 shown as Sequence 513A (FIG. 17M) and light chain construct 3598 (SEQ ID NO:421) (FIG. 17T), as discussed above. Each heterodimeric TEP in the second dimeric TEP comprised a heterodimeric pMHC with an HLA-A*02 allele MHC Class I heavy chain, a body disulfide and a linker disulfide, a scaffold component (an IgGl Fc polypeptide), a human anti-IL-5Ra TC, and an HIV peptide epitope. The second dimeric TEP also did not include a MOD.
[0341] HLA-A*02:01-rcstrictcd Cytomegalovirus (CMV) pp65 95-503_spccific CD8+T cells were expanded using pp65495.503 peptide NLVPMVATV (SEQ ID NO: 141) (Elim Biopharma) from the Human peripheral blood mononuclear cells (PBMCs) of HLA-A*02:01+CMV-seropositive and HIV-seronegative healthy donors for 10 days in the presence of recombinant Interleukin-2 (IL-2) (STEMCELL Technologies), and purified by EasySep™ Human CD8+T Cell Isolation Kit (STEMCELL Technologies). After purification, the percentage of CMV-specific CD8+T cells among total CD8+T cells is 18%. IL-5Ra transgene was synthesized and cloned into pLVX-EFlalpha-IRES-Puro vector (Takara Bio) by Genewiz. Lentiviruses were generated via Lenti-X 293T cells (Takara Bio) and used to transduce both the TF-1 cell line and the K562 cell line (ATCC). The IL-5Ra-transduced TF-1 cells and IL-5Ra-transduced K562 cells were labeled by CellTrace™ Violet (Thermo Fisher), respectively.
[0342] Purified CD8+T cells containing CMV-specific cells were mixed with labeled IL-5Ra-transduced TF-1 cells and IL-5Ra-transduced K562 cells, respectively, at a ratio of 10: 1 and incubated for 24 hours in the presence of the two dimeric TEPs at indicated concentrations. After 24 hours, cells were harvested, stained and analyzed by flow cytometry. Dimeric anti-IL-5Ra TEPs with CMV peptide-MHC (shown in filled circles in FIGS. 20A-B) exhibited effective killings of both the IL-5Ra-transduced TF-1 cells and IL-5Ra-transduced K562 cells. Dimeric anti-IL-5Ra TEPs with HIV peptide-MHC (shown in filled squares in FIGS. 20A-B) demonstrated no killing at all concentrations tested. These experiments indicate that dimeric TEPs can mediate substantial depletion of IL-5Ra-positive B cells via killing by antigen-specific CD8 T cells.
Claims
CLAIMS1. A T-cell engaging protein (“TEP' ). wherein the TEP comprises:i) a peptide-major histocompatibility complex (“pMHC”) comprising a peptide epitope, a P2- microglobulin (“P2M”) polypeptide, and an MHC class I heavy chain polypeptide;ii) a scaffold component;iii) at least one targeting component (“TC”) that binds to IL5R;iv) optionally one or more activating immunomodulatory polypeptides; andv) optionally one or more independently selected peptide linkers between any two of the components of the TEP, and wherein when the TEP comprises more than one activating immunomodulatory polypeptide, the activating immunomodulatory7polypeptides optionally may be connected by one or more independently selected peptide linkers.
2. Tire TEP of claim 1, wherein the TC is an antibody or antigen-binding portion of an antibody that binds to IL5R, e.g., a fragment of an antibody that retains specific binding to IL5R, including, but not limited to. Fab, Fv, scFv, and Fd fragment, chimeric antibody, humanized antibody, single-chain antibody (scAb), single domain antibody (dAb), single domain heavy chain antibody, single domain light chain antibody, or nanobody .
3. The TEP of claim 1 or 2, wherein the scaffold component is(i) an Ig Fc polypeptide selected from an IgGl Fc polypeptide, IgG2 Fc polypeptide, IgG3 Fc polypeptide, or IgG4 polypeptide, or(ii) a non-Ig scaffold selected from albumin, an XTEN (extended recombinant) polypeptide, transferrin, an Fc receptor polypeptide, an elastin-like polypeptide, an albumin-binding polypeptide, a silk-like polypeptide, and a silk-elastin-like polypeptide (SELP).
4. The TEP of claim 3, wherein the Ig Fc polypeptide is a variant having one or more substitutions that reduce or substantially eliminate effector function.
5. The TEP of claim 4, wherein the Ig Fc polypeptide is an IgGl Fc polypeptide having one or more substitutions that reduce or substantially eliminate effector function, optionally wherein the Ig Fc polypeptide docs not include a C -terminal Lys present in a wild-type Ig Fc polypeptide variant.
6. The TEP of any one of claims 1-5, wherein the pMHC presents an epitope of a pathogen-infected cell, optionally wherein the pMHC presents an epitope of a virus-infected cell or a bacteria-infected cell.
7. The TEP of claim 6, wherein the pMHC presents an epitope of a cell infected with a virus selected from CMV, influenza (flu), SARS-CoV2, EBV, HPV, or yellow fever virus.
8. The TEP of any one of claims 1-7, wherein the MHC class I heavy chain is an HLA-A allele heavy chain polypeptide, optionally wherein the HLA-A allele heavy chain polypeptide comprises an amino acid sequence having at least 90%, at least 95%, at least 98%, or at least 99%, amino acid sequence identity to the HLA-A amino acid sequence depicted in any one of FIGS. 7A-7E, 8A-8E, 9A-9E, 10A-10E, HA-HE and 12A-12D.
9. The TEP of any one of claims 1 -7, wherein the MHC class I heavy chain is an HLA-B allele heavy chain polypeptide, optionally wherein the HLA-B allele heavy chain polypeptide comprises an amino acid sequence having at least 90%, at least 95%, at least 98%, or at least 99%, amino acid sequence identity to the HLA-B amino acid sequence depicted in FIGS. 13A-13D.
10. The TEP of any one of claims 1-7, wherein the MHC class I heavy chain is an HLA-C allele heavy chain polypeptide, optionally wherein the HLA-C allele heavy chain polypeptide comprises an amino acid sequence having at least 90%, at least 95%, at least 98%, or at least 99%, amino acid sequence identity to the HLA-C amino acid sequence depicted in FIGS. 14A-14D.
11. The TEP of any one of claims 1-7, wherein the MHC class I heavy chain is an HLA-E allele heavy chain polypeptide, optionally wherein the HLA-E allele heavy chain polypeptide comprises an amino acid sequence having at least 90%, at least 95%, at least 98%, or at least 99%, amino acid sequence identity to the HLA-E amino acid sequence depicted in FIGS 15A-15E.
12. The TEP of any one of claims 1-11, wherein the |32M polypeptide, wherein the P2M polypeptide comprises an amino acid sequence having at least 95% amino acid sequence identity to 21-119 of any one of the amino acid sequences set forth in SEQ ID NOs: 1-3.
13. The TEP of any one of claims 1-12, wherein each of the optional one or more activating immunomodulatory polypeptides, if present, are independently selected from a cytokine, a 4-1BBL polypeptide, an ICOS-L polypeptide, an OX-40L polypeptide, a CD80 polypeptide, a CD86 polypeptide, a CD40 polypeptide, a CD70 polypeptide, and combinations thereof.
14. The TEP of claim 13, wherein the cytokine is an IL-2 polypeptide, and wherein the IL-2 polypeptide is a variant IL-2 polypeptide that exhibits reduced affinity to an IL-2 receptor compared to the affinity of a wild-type IL-2 polypeptide for the IL-2 receptor, optionally wherein the variant IL-2 polypeptide exhibits substantially no binding to IL-2Ra, and also exhibits decreased binding to IL-2Rp.
15. The TEP of claim 14, wherein the variant IL-2 polypeptide has at least 90%, at least 95%, at least 97%, at least 98%, at least 99%, or 100% amino acid sequence identity to the wild-type IL-2 amino acid sequence, and wherein amino acid 16 of the variant IL -2 polypeptide is other than histidine and amino acid 42 is other than phenylalanine, optionally wherein amino acid 16 is Ala, Thr, Asp or Glu and wherein amino acid 42 is Ala, and optionally wherein amino acid 16 is Ala and wherein amino acid 42 is Ala.
16. Hie TEP of any one of claims 13-15, wherein the TEP comprises two variant IL-2 polypeptides in tandem, optionally connected by a linker.
17. The TEP of any one of claims 1-16, wherein the TEP comprises a heterodimer, wherein the heterodimer comprises:a) a first polypeptide comprising:i) the peptide; andii) the p2-microglobulin (|32M) polypeptide; andb) a second polypeptide comprising:i) the MHC class I heavy chain polypeptide; andii) the immunoglobulin (Ig) Fc polypeptide;iii) the at least one TC; andiv) optionally, one or more activating immunomodulatory polypeptides, optionally wherein the TEP comprises one or more independently selected peptide linkers between any two of the components, and wherein when the TEP comprises more than one activating immunomodulatory polypeptide, the activating immunomodulatory polypeptides optionally may be connected by one or more independently selected peptide linkers.
18. The TEP of claim 17, wherein each heterodimeric TEP comprises a disulfide bond formed between a Cys residue in the 02M polypeptide and a Cys residue in the MHC class I heavy chain polypeptide.
19. The TEP of claim 17 or 18, wherein the heterodimeric TEP comprises a disulfide bond formed between (i) a Cys residue in a Cys-containing linker interposed between the peptide and the [32 M polypeptide, and (ii) a Cys residue in the MHC class I heavy chain polypeptide.
20. Tire TEP of claim 19. wherein the first polypeptide and the second polypeptide are covalently linked to one another by at least a first and second disulfide bond,wherein the first disulfide bond formed between (i) a Cys residue in a Cys-containing linker between the peptide epitope and the p2M polypeptide, and (ii) a Cys residue in the MHC class I heavy chain polypeptide; andwherein the second disulfide bond is formed between a Cys residue in the 02M polypeptide and a Cys residue in tire MHC class I heavy chain polypeptide.
21. The TEP of any one of claims 17-20, whereina) the first polypeptide of the heterodimeric TEP comprises, in order from N-terminus to C- terminus:i) the peptide, optionally wherein the peptide epitope has a length of 8-12 amino acids: ii) a peptide linker; andiii) the 02 M polypeptide;b) the second polypeptide of each heterodimeric TEP comprises, in order from N-terminus to C- terminus:i) optionally, one or more activating immunomodulatory polypeptides;ii) the MHC class I heavy chain polypeptide;iii) the Ig Fc polypeptide; andiv) the at least one TC, andwherein the second polypeptide optionally comprises independently selected peptide linkers between one or more components of the second polypeptide.
22. The TEP of any one of claims 17-20, whereina) tire first polypeptide of the heterodimeric TEP comprises, in order from N-terminus to C- tenninus:i) the peptide, optionally wherein the peptide epitope has a length of 8-12 amino acids; ii) a peptide linker; andiii) the 02 M polypeptide;b) the second polypeptide of each heterodimeric TEP comprises, in order from N-terminus to C- terminus:i) the at least one TC;ii) the MHC class I heavy chain polypeptide;iii) the Ig Fc polypeptide: andiv) optionally, one or more activating immunomodulatory polypeptides, wherein the second polypeptide optionally comprises independently selected peptide linkers between one or more components of the second polypeptide.
23. The TEP of any one of claims 17-22, wherein:i) the P2M polypeptide comprises a Cys at amino acid 12 based on the amino acid numbering of SEQ ID NO: 1; andii) the MHC class I polypeptide comprises a Cys at residue 236 based on the amino acid numbering of FIG. 7A, andwherein the heterodimeric TEP comprises a disulfide bond linking the first polypeptide to the second polypeptide, and wherein the disulfide bond joins the Cys at amino acid 12 of the P2M polypeptide to the Cys at amino acid 236 of the MHC heavy chain polypeptide, optionally wherein the heterodimer comprises a second disulfide bond formed between (i) a Cys residue in a Cys-containing linker between the peptide and the P2M polypeptide, and (ii) a Cys residue in the MHC class I heavy chain polypeptide.
24. A dimeric TEP comprising two heterodimeric TEPs according to any one of claims 17-23, wherein the first polypeptides of each heterodimeric TEP have tire same amino acid sequence, and the second polypeptide of each heterodimeric TEP have the same amino acid sequences, and wherein the two heterodimeric TEPs are joined together by one or more disulfide bonds formed between the Ig Fc polypeptides of each heterodimeric TEP, optionally? wherein the two heterodimeric TEPs are joined together by two disulfide bonds formed between the Ig Fc polypeptides of each heterodimeric TEP.
25. A dimeric TEP comprising two heterodimeric TEPs according to any one of claims 17-23, wherein the first and / or second polypeptides of each heterodimeric TEP have a different amino acid sequence, and wherein the Ig Fc polypeptides of the first and second heterodimeric TEPs comprise interspecific dimerization sequences, optionally wherein the interspecific dimerization sequences are “Knob-in-Hole” sequences that permit the two heterodimeric TEPs to selectively dimerize, optionally wherein (i) each TEP of the dimeric TEP comprises a different antibody TC (e.g.. a different scFv), and / or (ii) each TEP of the dimeric TEP comprises a different peptide epitope.
26. The TEP of any one of claims 1-16, wherein the TEP is a single-chain TEP comprising:i) the peptide;ii) the P2M polypeptide;iii) the class I HLA heavy chain polypeptide;iv) the immunoglobulin (Ig) Fc polypeptide:v) the at least one TC; andvi) optionally, one or more activating immunomodulatory' polypeptides,optionally wherein the TEP comprises one or more independently selected peptide linkers between any two of the components, and wherein when the TEP comprises more than oneactivating immunomodulatory polypeptide, the activating immunomodulatory polypeptides optionally may be connected by one or more independently selected peptide linkers.
27. The TEP of claim 26. wherein the single-chain TEP comprises a Cys-containing peptide linker between the peptide and the 02M polypeptide, and wherein the single-chain TEP comprises an intrachain disulfide bond between the Cys in the Cys-containing peptide linker and a Cys in the class I HLA heavy chain polypeptide.
28. The TEP of claim 27. wherein the class 1 HLA heavy chain polypeptide comprises a Cys at any one of amino acids 135-143 (e.g., amino acid 139), based on the numbering of the class I HLA heavy chain polypeptide depicted in FIG 7A, and wherein amino acid 84, based on the numbering of the class I HLA heavy chain polypeptide depicted in FIG. 7A is other than Cys; andwherein tire TEP comprises an intrachain disulfide bond between the Cys present in the Cys- containing peptide linker and the Cys at any one of amino acids 135-143 of the class I HLA heavy chain polypeptide.
29. The TEP of claim 28, wherein the class I HLA heavy chain polypeptide comprises a Cys at amino acid 138, 139, or 140 based on the numbering of the class I HLA heavy chain polypeptide depicted in FIG. 7A.
30. The TEP of claim 28, wherein the class I HLA heavy chain polypeptide comprises a Cys at amino acid 139 based on the numbering of the class I HLA heavy chain polypeptide depicted in FIG.7A.
31. The TEP of claim 27, wherein the single-chain TEP comprises an intrachain disulfide bond between the Cys present in the Cys-containing peptide linker and the Cys at amino acid 84 of the class I HLA polypeptide.
32. The TEP of any one of claims 27-31, wherein the peptide linker between the peptide and the 02 M polypeptide in the single-chain TEP comprises the sequence CGGGS(GGGGS)n (SEQ ID NO:93), GCGGS(GGGGS)n (SEQ ID NO:90), or GGCGS(GGGGS)n (SEQ ID NO:95), wherein n is an integer from 1-10, optionally wherein n is an integer from 1-3.
33. The TEP of any one of claims 26-32, wherein the 02M polypeptide comprises a Cys at amino acid 12 based on the numbering of the 02M polypeptide depicted in SEQ ID NO: 1, wherein the class I HLA heavy chain polypeptide comprises a Cys at amino acid 236 based on the numbering of the class I HLA heavy chain polypeptide depicted in FIG. 7A, and wherein the single-chain TEP comprises adisulfide bond formed between the Cys at amino acid 12 of the 02M polypeptide and the Cys at amino acid 236 of the class I HLA heavy chain polypeptide.
34. A dimeric TEP comprising two single-chain TEPs according to any one of claims 26-33. wherein the two single-chain TEPs have the same amino acid sequence, and wherein the two singlechain TEPs are joined together by one or more disulfide bonds formed between the Ig Fc polypeptides of each single-chain TEP, optionally wherein the two single-chain TEPs are joined together by two disulfide bonds fomied betw een the Ig Fc polypeptides of each single-chain TEP.
35. A dimeric TEP comprising two single-chain TEPs according to any one of claims 26-33, wherein each single-chain TEP has a different amino acid sequence, and wherein the Ig Fc polypeptides of the first and second single-chain TEPs comprise interspecific dimerization sequences, optionally “Knob-in-Hole" sequences that permit tire two single-chain TEPs to selectively dimerize, optionally wherein (i) each TEP of the dimeric TEP comprises a different antibody TC (e.g.. a different scFv). and / or (ii) each TEP of the dimeric TEP comprises a different peptide epitope.
36. The TEP of any one of claims 1-16, wherein the TEP comprises a chemical conjugation site, wherein the peptide of the pMHC of the TEP is chemically conjugated to the constituent TEP through the chemical conjugation site, and wherein the peptide is positioned in the pMHC of the constituent TEP for presentation to a cell bearing a T-cell receptor specific for the epitope presented by the pMHC.
37. Tire TEP of claim 36. wherein the chemical conjugation site is present in the 02M polypeptide or MHC class I heavy chain polypeptide.
38. The TEP of claims 37, wherein the chemical conjugation site is present in the 02M polypeptide.
39. The TEP of claim 38, wherein the chemical conjugation site is a cysteine present in the 02M polypeptide.
40. The TEP of claim 39. wherein the peptide is conjugated to the TEP by the reaction of a maleimide group and the cysteine of the chemical conjugation site.
41. A TEP according to any one of claims 36-40, wherein the TEP comprises:a) a first polypeptide comprising the 02M polypeptide;b) a second polypeptide comprising,(i) the MHC class I heavy chain polypeptide;(ii) the Ig Fc polypeptide;(iii) at least one TC: and(iv) optionally, one or more activating immunomodulatory polypeptides.
42. A dimeric TEP comprising two heterodimeric TEPs according to claim 41, wherein:(i) the first polypeptides of the heterodimeric TEPs have tire same amino acid sequence, and the second polypeptides of the heterodimeric TEPs have the same amino acid sequences, and wherein the two heterodimeric TEPs are joined together by one or more disulfide bonds formed between the Ig Fc polypeptides of each heterodimeric TEP, optionally wherein the two heterodimeric TEPs are joined together by two disulfide bonds formed between the Ig Fc polypeptides of each heterodimeric TEP; or(ii) the first or second polypeptide of one heterodimeric TEP has a different amino acid sequence from the second polypeptide of the other heterodimeric TEP, and wherein the Ig Fc polypeptides of the two heterodimeric TEPs comprise interspecific dimerization sequences, e.g., Knob-in-Holc” sequences that pemrit the two heterodimeric TEPs to selectively dimerize, optionally wherein (i) each TEP of the dimeric TEP comprises a different antibody TC (e g., a different scFv), and / or (ii) each TEP of the dimeric TEP comprises a different peptide epitope.
43. The TEP of any one of claims 36-40, wherein the TEP is a single-chain TEP comprising:a) the P2M polypeptide;b) the MHC class I heavy chain polypeptide;c) the Ig Fc polypeptide;d) at least one TC; ande) optionally, one or more activating immunomodulatory polypeptides.
44. A dimeric TEP comprising two single-chain TEPs according to claim 43. wherein:(i) the single-chain TEPs have the same amino acid sequence, and wherein the two singlechain TEPs are joined together by one or more disulfide bonds formed between the Ig Fc polypeptides of each TEP, optionally wherein the two TEPs are joined together by two disulfide bonds formed between the Ig Fc polypeptides of each TEP; or(ii) each single-chain TEP has a different amino acid sequence, and wherein the Ig Fc polypeptides of the first and second single-chain TEPs comprise interspecific dimerizationsequences, e.g., “Knob-in-Hole” sequences that permit the two heterodimers to selectively dimerize, optionally wherein (i) each TEP of the dimeric TEP comprises a different antibody TC (e.g., a different scFv), and / or (ii) each TEP of the dimeric TEP comprises a different peptide epitope.
45. The TEP of any one of claims 1-16, wherein the TEP comprises a MAPP, wherein the MAPP comprises:(i) a framework polypeptide comprising a dimerization sequence and a multimerization sequence:(ii) a dimerization polypeptide comprising a counterpart dimerization sequence complementary to the dimerization sequence of the framework polypeptide, the dimerization sequence and counterpart dimerization sequence dimerizing through covalent and / or non- covalent interactions to form a heterodimer;(iii) the pMHC, wherein the pMHC comprises at least one presenting sequence and / or presenting complex;(iv) at least one TC;(v) optionally, one or more activating immunomodulatory polypeptides.
46. Tire TEP of claim 45. wherein the pMHC comprises a heterodimeric presenting complex or a single-chain presenting sequence.
47. A dimeric TEP comprising two TEP MAPPs according to claim 45 or 46, wherein the first and second TEP MAPPs are covalently attached through the binding of non-interspecific multimerization sequences in the MAPPs.
48. A dimeric TEP comprising two TEP MAPPs according to claim 45 or 46, wherein the first and second TEP MAPPs are not identical and are covalently attached through the binding of interspecific multimerization sequences in the MAPPs, optionally wherein (i) each TEP MAPP comprises a TC ( e.g. different scFvs), and / or (ii) each TEP MAP comprises a different presenting sequence and / or presenting complex.
49. A dimeric TEP according to any one of claims 25, 35, 42, 44, and 48 wherein the dimeric TEP comprises first and second TEPs, wherein(i) the first TEP and second TEP comprise different anti-IL5R antibodies, optionally where the anti-IL5R antibodies target different IL5R epitopes, and / or(ii) the first TEP comprises a pMHC that presents an epitope to T-cells, and the second TEP comprises a different pMHC that presents a different epitope to T-cells, optionally wherein the pMHCs of the first and second TEPs present viral epitopes to anti-viral T-cells.
50. Tire TEP or dimeric TEP of any one of claims 1-49, wherein the TEP or dimeric presents a one or more viral epitopes.
51. The TEP or dimeric TEP of claim 50, wherein the pMHC presents an epitope selected from influenza (flu), CMV (e.g., wherein the peptide epitope is NLVPMVATV, SEQ ID NO: 141), EBV, SARS-Cov-2 (e.g., wherein the peptide epitope comprises YLQPRTFLL. SEQ ID NO: 166), yellow fever (e.g., wherein the peptide epitope comprises LLWNGPMAV, SEQ ID NO:420), HPV, or Varicella Zoster Virus (VZV) (e g., where the peptide epitope is ILIEGIFFV, SEQ ID NO:418).
52. Hie TEP or dimeric TEP of any one of claims 1-51, wherein the TEP comprises a TC that is an anti-IL5R antibody (e.g., an scFv) that comprises:(i) a variable region of a light chain comprising an amino sequence having at least 90%, at least 95%, at least 98%, at least 99%, or 100%, amino acid sequence identity to the amino acid sequence of SEQ ID NO:349: and / or.(ii) a variable region of a heavy chain comprising an amino sequence having at least 90%, at least 95%, at least 98%, at least 99%, or 100%, amino acid sequence identity to the amino acid sequence of SEQ ID NO:351.
53. The TEP or dimeric TEP of any one of claims 1-51, wherein the TEP comprises a TC that is an anti-IL5R scFv comprising at least 90%, at least 95%, at least 98%, at least 99%, or 100%, amino acid sequence identity to either or both the VL or VH amino acid sequences of SEQ ID NOS: 349 and 351, wherein the sequences may be joined by a peptide linker, optionally a (GGGGS)n linker, where n=l-10. e.g., n=2. n=3 or n=4, e.g., where n=3.
54. The TEP or dimeric TEP of any one of claims 1-51, wherein the TEP comprises a TC that is an anti-IL5R scFv comprising at least 90%, at least 95%, at least 98%, at least 99%, or 100%, amino acid sequence identity to the amino acid sequences set forth in SEQ ID NOS:359 or 360.
55. The TEP or dimeric TEP of any one of claims 1-51, wherein the TEP comprises a TC that is an anti-IL5R antibody that comprises:(i) one, two or all three heavy chain variable region CDRs set forth in SEQ ID NOS: 353-355; and / or(ii) one, two or all three light chain variable region CDRs set forth in SEQ ID NOS: 356-358.
56. The TEP or dimeric TEP of any one of claims 1-55, wherein the TEP does not comprise an activating immunomodulatory polypeptide.
57. The TEP or dimeric TEP of any one of claims 1-55, wherein the TEP comprises at least one activating immunomodulatory polypeptide.
58. A pharmaceutical composition comprising the TEP or dimeric TEP of any one of claims 1-57.
59. One or more nucleic acids encoding the polypeptide or polypeptides of a TEP or dimeric TEP according to any one of claims 1-57.
60. One or more recombinant expression vectors comprising one or more nucleic acids encoding the polypeptide or polypeptides of a TEP or dimeric TEP according to any one of claims 1-57.
61. An in vitro composition of host cells modified with the one or more nucleic acids of claim 59 or the one or more recombinant expression vectors of claim 60.
62. A method of making a TEP or dimeric TEP of any one of claims 1-57, comprising culturing in vitro a composition of host cells according to claim 61 under conditions in which the TEP or dimeric TEP is produced.
63. A method of treating an individual to deplete IL5R-expressing cells, the method comprising administering to the individual a therapeutic amount of a pharmacal composition according to claim 58.
64. A TEP or dimeric TEP according to any one of claims 1-57 for use in a method of treating an individual to deplete IL5R-expressing cells, the method comprising administering to the individual a therapeutic amount of tire TEP or dimeric TEP.
65. Use of a TEP or dimeric TEP according to any one of claims 1-57 in a method of treating an individual to deplete IL5R-expressing cells, the method comprising administering to the individual a therapeutic amount of the TEP or dimeric TEP.
66. Use of a TEP or dimeric TEP according to any one of claims 1-57 for the preparation of a medicament for use in a method of treating an individual to deplete IL5R-expressing cells, the method comprising administering to the individual a therapeutic amount of the TEP or dimeric TEP.
67. The method, TEP or dimeric TEP, or use of any one of claims 63-66, wherein the individual has an IL5R-associated disorder.
68. Tire method, TEP or dimeric TEP, or use of claim 67, wherein the IL5R-associated disorder is an IL5R-associated cancer, optionally wherein the IL5R-associated cancer is a hematological cancer (e.g., chronic eosinophilic leukemia, acute myeloid leukemia, acute eosinophilic leukemia, or myelodysplastic syndrome), lymphoid cancer (e g., a B-cell carcinoma, T-cell carcinoma, or Elodgkin Lymphoma), or solid tumor cancer.
69. The method, TEP or dimeric TEP, or use of claim 67, wherein the IL5R-associated disorder is a primary eosinophilic disorder (e.g., idiopathic hypereosinophilic syndrome (HES), chronic eosinophilic leukemia, and myeloproliferative neoplasms with eosinophilia), an allergic or atopic disorder (e.g., eosinophilic asthma, allergic rhinitis, chronic sinusitis, chronic rhinosinusitis, chronic rhinosinusitis with nasal polyps, atopic dermatitis, eosinophilic esophagitis, eosinophilic gastroenteritis, colitis, enteritis, pulmonary vasculitis, and allergic bronchopulmonary aspergillosis), an autoimmune or vasculitic disorder (e.g., eosinophilic granulomatosis with polyangiitis or Churg-Strauss Syndrome, eosinophilic fasciitis (Shulman Syndrome), acute and chronic eosinophilic pneumonia, as rheumatoid arthritis, systemic lupus erythematosus, psoriasis and psoriatic arthritis, inflammatory bowel diseases including ulcerative colitis and Crohn’s Disease, and autoimmune thyroiditis (Hashimoto’s Thyroiditis)), a chronic infection or related inflammatory condition (e.g., chronic hepatitis, Heliobacter pylori infection, chronic periodontitis and tuberculosis), a metabolic or cardiovascular disease (e.g., obesity and metabolic syndrome, type 2 diabetes mellitus. and atherosclerosis), pulmonary or other disorder (e.g., chronic obstructive pulmonary disease, eosinophilic asthma, paraneoplastic eosinophilia, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), chronic kidney disease), or a chronic skin condition (e.g., eczema).
70. A method of treating an individual having an IL5R-associated disorder, the method comprising administering to the individual a therapeutic amount of a pharmaceutical composition of claim 58.
71. A TEP or dimeric TEP according to any one of claims 1-57 for use in a method of treating an individual having an IL5R-associated disorder, the method comprising administering to the individual a therapeutic amount of the TEP or dimeric TEP.
72. Use of a TEP or dimeric TEP according to any one of claims 1-57 in a method of treating an individual having an IL5R-associated disorder, the method comprising administering to the individual a therapeutic amount of the TEP or dimeric TEP.
73. Use of a TEP or dimeric TEP according to any one of claims 1-57 for the preparation of a medicament for use in a method of treating an IL5R-associated disorder, the method comprising administering to the individual a therapeutic amount of the TEP or dimeric TEP.
74. The method, TEP or dimeric TEP, or use of any one of claims 70-73. wherein the IL5R-associated disorder is an IL5R-associated cancer, wherein the IL5R-associated disorder is an IL5R-associated cancer, optionally wherein the IL5R-associated cancer is a hematological cancer (e.g., chronic eosinophilic leukemia, acute myeloid leukemia, acute eosinophilic leukemia, or myelodysplastic syndrome), lymphoid cancer (e.g., a B-cell carcinoma, T-cell carcinoma, or Hodgkin Lymphoma), or solid tumor cancer.
75. The method, TEP or dimeric TEP, or use of any one of claims 70-73, wherein the IL5R-associated disorder is characterized by proliferation of eosinophils and inflammation.
76. The method, TEP or dimeric TEP, or use of any one of claims 70-73, wherein the 1L5R-associated disorder is a primary eosinophilic disorder (e.g., idiopathic hypereosinophilic syndrome (HES), chronic eosinophilic leukemia, and myeloproliferative neoplasms with eosinophilia), an allergic or atopic disorder (e.g., eosinophilic asthma, allergic rhinitis, chronic sinusitis, chronic rhinosinusitis, chronic rhinosinusitis with nasal polyps, atopic demiatitis, eosinophilic esophagitis, eosinophilic gastroenteritis, colitis, enteritis, pulmonary vasculitis, and allergic bronchopulmonary aspergillosis), an autoimmune or vasculitic disorder (e.g., eosinophilic granulomatosis with polyangiitis or Churg-Strauss Syndrome, eosinophilic fasciitis (Shulman Syndrome), acute and chronic eosinophilic pneumonia, as rheumatoid arthritis, systemic lupus erythematosus, psoriasis and psoriatic arthritis, inflammatory bowel diseases including ulcerative colitis and Crohn’s Disease, and autoimmune thyroiditis (Hashimoto’s Thyroiditis)), a chronic infection or related inflammatory condition (e.g., chronic hepatitis, Heliobacter pylori infection, chronic periodontitis and tuberculosis), a metabolic or cardiovascular disorder (e.g., obesity and metabolic syndrome, type 2 diabetes mellitus, and atherosclerosis), pulmonary or other disorder (e g., chronic obstructive pulmonary disease, eosinophilic asthma, paraneoplastic eosinophilia,non-alcoholic faty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), chronic kidney disease), or a chronic skin condition (e.g., eczema).
